WO2000063153A1 - New compounds, their preparation and use - Google Patents

New compounds, their preparation and use Download PDF

Info

Publication number
WO2000063153A1
WO2000063153A1 PCT/DK2000/000190 DK0000190W WO0063153A1 WO 2000063153 A1 WO2000063153 A1 WO 2000063153A1 DK 0000190 W DK0000190 W DK 0000190W WO 0063153 A1 WO0063153 A1 WO 0063153A1
Authority
WO
WIPO (PCT)
Prior art keywords
phenyl
alkyl
ethoxy
propionic acid
allyloxy
Prior art date
Application number
PCT/DK2000/000190
Other languages
French (fr)
Inventor
Anthony Murray
Per Sauerberg
Lone Jeppesen
Ingrid Pettersson
Paul Stanley Bury
Original Assignee
Novo Nordisk A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk A/S filed Critical Novo Nordisk A/S
Priority to KR1020017013417A priority Critical patent/KR20020005703A/en
Priority to JP2000612250A priority patent/JP2002542218A/en
Priority to AU39580/00A priority patent/AU3958000A/en
Priority to IL14578900A priority patent/IL145789A0/en
Priority to PL00351312A priority patent/PL351312A1/en
Priority to CA002367356A priority patent/CA2367356A1/en
Priority to EP00918725A priority patent/EP1171414A1/en
Priority to BR0009864-7A priority patent/BR0009864A/en
Priority to TW089108460A priority patent/TW553931B/en
Publication of WO2000063153A1 publication Critical patent/WO2000063153A1/en
Priority to NO20015113A priority patent/NO20015113L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
    • C07C59/64—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
    • C07C59/66—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings
    • C07C59/68—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings the oxygen atom of the ether group being bound to a non-condensed six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/734—Ethers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/40—Radicals substituted by oxygen atoms
    • C07D307/42—Singly bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/16—Radicals substituted by singly bound hetero atoms other than halogen by oxygen atoms

Definitions

  • the present invention relates to novel compounds, pharmaceutical compositions containing them, methods for preparing the compounds and their use as medicaments. More specifically, compounds of the invention can be utilised in the treatment and/or prevention of conditions mediated by nuclear receptors, in particular the Peroxisome Proliferator-Activated Re- ceptors (PPAR).
  • PPAR Peroxisome Proliferator-Activated Re- ceptors
  • Coronary artery disease is the major cause of death in Type 2 diabetic and metabolic syndrome patients (i.e. patients that fall within the 'deadly quartet' category of impaired glucose tolerance, insulin resistance, hypertriglyceridaemia and/or obesity).
  • hypolipidaemic fibrates and antidiabetic thiazolidinediones separately display moderately effective triglyce de-lowering activities although they are neither potent nor efficacious enough to be a single therapy of choice for the dyslipidaemia often observed in Type 2 diabetic or metabolic syndrome patients.
  • the thiazolidinediones also potently lower circulating glucose levels of Type 2 diabetic animal models and humans.
  • the fibrate class of compounds are without beneficial effects on glycaemia.
  • thiazolidinediones and fibrates exert their action by activating distinct transcription factors of the peroxisome proliferator activated receptor (PPAR) family, resulting in increased and decreased expression of specific enzymes and apolipoproteins respectively, both key-players in regulation of plasma triglyceride content.
  • Fibrates on the one hand, are PPAR ⁇ activators, acting primarily in the liver.
  • Thiazolidinediones on the other hand, are high affinity ligands for PPAR ⁇ acting primarily on adipose tissue.
  • Adipose tissue plays a central role in lipid homeostasis and the maintenance of energy balance in vertebrates.
  • Adipocytes store energy in the form of triglycerides during periods of nutritional affluence and release it in the form of free fatty acids at times of nutritional deprivation.
  • white adipose tissue is the result of a continuous differentiation process throughout life.
  • Much evidence points to the central role of PPAR ⁇ activation in initiating and regulating this cell differentiation.
  • Several highly specialised proteins are induced during adipocyte differentiation, most of them being involved in lipid storage and metabolism. The exact link from activation of PPAR ⁇ to changes in glucose metabolism, most notably a decrease in insulin resistance in muscle, has not yet been clarified.
  • a possible link is via free fatty acids such that activation of PPAR ⁇ induces Lipoprotein Lipase (LPL), Fatty Acid Transport Protein (FATP) and Acyl-CoA Synthetase (ACS) in adipose tissue but not in muscle tissue.
  • LPL Lipoprotein Lipase
  • FATP Fatty Acid Transport Protein
  • ACS Acyl-CoA Synthetase
  • PPAR ⁇ is involved in stimulating ⁇ -oxidation of fatty acids.
  • a PPAR ⁇ -mediated change in the expression of genes involved in fatty acid metabolism lies at the basis of the phenomenon of peroxisome proliferation, a pleiotropic cellular response, mainly limited to liver and kidney and which can lead to hepatocarcinogenesis in rodents.
  • the phenomenon of peroxisome proliferation is not seen in man.
  • PPAR ⁇ is also involved in the control of HDL cholesterol levels in rodents and humans.
  • Glucose lowering as a single approach does not overcome the macrovascular complications associated with Type 2 diabetes and metabolic syndrome.
  • Novel treatments of Type 2 diabetes and metabolic syndrome must therefore aim at lowering both the overt hypertriglyceri- daemia associated with these syndromes as well as alleviation of hyperglycaemia.
  • a 1 and A 2 are independently of each other a 5-6 membered cyclic ring or a 9-10 membered bicyclic ring, optionally substituted with one or more halogen, perhalomethyl, hydroxy, nitro, cyano, formyl, or C 4 . 12 -alkenynyl, C 2 . 12 -alkenyl, C 2 . 12 -alkynyl, aryl, aryloxy, arylalkyl, arylalkoxy, heterocyclyl, heteroaryl, heteroarylalkyl, heteroaryloxy, heteroarylalkoxy, acyl, acyloxy, hydroxyC,.
  • Z is C, CR 3 , wherein R 3 is hydrogen, halogen, perhalomethyl, C, 12 -alkyl, C 4 . 12 - alkenynyl, C 2 _ 12 -alkenyl, C 2 . 12 -alkynyl, C, 12 -alkoxy, aryloxy, arylalkoxy, heteroaryloxy, heteroarylalkoxy, acyl, acyloxy, hydroxyC ⁇ -alkyl, C ⁇ -alkoxyC L ⁇ -alkyl, aryloxyC,.
  • R 4 and R 11 independently of each other are selected from hydroxy, halogen, perhalomethyl, C 6 -alkoxy or am o optionally substituted with one or more C ⁇ -alkyl, perhalomethyl or aryl optionally substituted with one or more halogen, perhalomethyl, hydroxy, nitro or cyano,
  • Q is O, S, NR 12 , wherein R 12 is hydrogen, perhalomethyl, C ⁇ -alkyl, C 4 . 12 -alkenynyl, C 2 12 -alkenyl, C 2 12 -alkynyl, aryl, arylalkyl, heterocyclyl, heteroaryl, heteroarylalkyl, acyl, hydroxyC.
  • R 13 and R 14 independently of each other are selected from hydroxy, perhalomethyl, C,. 6 -alkoxy or ammo optionally substituted with one or more C ⁇ -alkyl, perhalomethyl or aryl optionally substituted with one or more halogen, perhalomethyl, hydroxy, nitro or cyano;
  • Ar represents arylene, heteroarylene, or a divalent heterocyclic group each of which can optionally be substituted with one or more halogen, C,. 6 -alkyl, ammo, hydroxy, C ⁇ -alkoxy or aryl
  • R 5 represents hydrogen, hydroxy, halogen, C, 12 -alkoxy, C, 12 -alkyl, C 4 12 -alkenynyl, C 2 12 - alkenyl, C 2 12 -alkynyl or arylalkyl, optionally substituted with one or more halogen, perhalomethyl, hydroxy, nitro or cyano or R 5 forms a bond together with R 6 ,
  • R 6 represents hydrogen, hydroxy, halogen, C, 12 -alkoxy, C, 12 -alkyl, C 4 12 -alkenynyl, C 2 12 - alkenyl, C 2 12 -alkynyl, acyl or arylalkyl optionally substituted with one or more halogen, perhalomethyl, hydroxy, nitro or cyano or R 6 forms a bond together with R 5 ,
  • M represents OR 7 , where R 7 represents hydrogen, C, 12 -alkyl, C 4 12 -alkenynyl, C 2 12 -alkenyl, C 2 12 -alkynyl, aryl, arylalkyl, C, ⁇ -alkoxyC, 12 -alkyl, C, 12 -alkoxycarbonyl, aryloxycarbonyl, C, 12 -alkylam ⁇ nocarbonyl, arylammocarbonyl, acyl, heterocyclyl, heteroaryl or heteroarylalkyl groups optionally substituted with one or more halogen, perhalomethyl, hydroxy, nitro or cyano or M represents COYR 8 ,
  • R 8 represents hydrogen, C, 12 alkyl, C 4 12 -alkenynyl, C 2 12 -alkenyl, C 2 12 -alkynyl, aryl, arylalkyl, heterocyclyl, heteroaryl or heteroarylalkyl groups optionally substituted with one or more halogen, perhalomethyl, hydroxy, nitro or cyano,
  • Y represents oxygen, sulphur or NR 10 , where R 10 represents hydrogen, C ⁇ -alkyl, aryl, hy- droxyC, 12 -alkyl or arylalkyl groups or when Y is NR 10 , R 8 and R 10 may form a 5 or 6 membered nitrogen containing ring, optionally substituted with one or more C, 6 -alkyl,
  • k is an integer ranging from 1 to 2
  • n is an integer ranging from 0 to 3
  • m is an integer ranging from 0 to 1 ,
  • the present invention is concerned with compounds of formula I wherein A 1 and A 2 are independently of each other a 5-6 membered cyclic ring or a 9-10 membered bicyclic ring, optionally substituted with one or more halogen, perhalomethyl, hydroxy, C 1 6 -alkyl, (Ca-e-cycloalky C, 6 -alkyl, C 4 6 -alkenynyl, C 2 6 -alkenyl, C 2 6 -alkynyl, C ⁇ -alkoxy, aryl, aryloxy, arylalkyl, arylalkoxy, heterocyclyl, heteroaryl, heteroarylalkyl, heteroaryloxy, heteroarylalkoxy, acyl, hydroxyC-, 6 -alkyl, C, 6 -alkyl-am ⁇ no, C, 6 -d ⁇ alkylam ⁇ o, arylamino, arylalkylammo, aminoC,
  • the present invention is concerned with compounds of formula I wherein A 1 and A 2 are independently of each other a 5-6 membered cyclic ring or a 9-10 membered bicychc ring, optionally substituted with one or more halogen, perhalomethyl, hydroxy, C, 6 -alkyl, C 4 6 -alkenynyl, C 2 6 -alkenyl, C 2 6 -alkynyl, C 1 6 -alkoxy, aryl, aryloxy, arylalkyl, arylalkoxy, heterocyclyl, heteroaryl, heteroarylalkyl, heteroaryloxy, heteroarylalkoxy, acyl, hydroxyC, 6 -alkyl, C, 6 -alkyl-am ⁇ no, C, 6 -d ⁇ alkylam ⁇ no, arylamino, arylalkylammo, aminoC, 6 -alkyl, C, g-alkoxyC,
  • the present invention is concerned with compounds of formula I wherein A 1 and A 2 are independently of each other a 5-6 membered cyclic ring or a 9-10 membered bicychc ring, optionally substituted with one or more halogen, C, 6 -alkyl, C, 6 -alkoxy, or aryl
  • the present invention is concerned with compounds of formula I wherein A 1 and A 2 are independently of each other a 5-6 membered cyclic ring optionally substituted with one or more halogen, C, 6 -alkyl, C, 6 -alkoxy, or aryl
  • the present invention is concerned with compounds of formula I wherein Z is a carbon atom at the end of a double bond, or Z is CR 3 , wherein R 3 is hydrogen, halogen, perhalomethyl, C, 12 -alkyl, C ⁇ 2 - alkenynyl, C 2 12 -alkenyl, C 2 12 -alkynyl, C, 12 -alkoxy, aryloxy, arylalkoxy, heteroaryloxy, heteroarylalkoxy, acyl, acyloxy, hydroxyC L ⁇ -alkyl, C, , 2 -alkoxyC, 12 -alkyl, aryloxyC, , 2 -alkyl, arylalkoxyC, 12 -alkyl, thioC, 12 -alkyl, -COR 4 , or -SO 2 R 11 , wherein R 4 and R 11 independently of each other are selected from hydroxy, halogen, perhalomethyl,
  • 6 -alkyl C 4 . 6 -alkenynyl, C 2 6 -alkenyl, C 2 6 -alkynyl, C,. 6 -alkoxy, aryloxy, arylalkoxy, heteroaryloxy, heteroarylalkoxy, acyl, acyloxy, hydroxyC,. 6 -alkyl, C ⁇ -alkoxyC ⁇ -alkyl, aryloxyC, 6 - alkyl, arylalkoxyC,.
  • R 4 and R 1 independently of each other are selected from hydroxy, halogen, perhalomethyl, C,. 6 -alkoxy or ammo optionally substituted with one or more C,. 6 -alkyl, perhalomethyl or aryl optionally substituted with one or more halogen, perhalomethyl, hydroxy, nitro or cyano
  • the present invention is concerned with compounds of formula I wherein Z is a carbon atom at the end of a double bond, or Z is CR 3 , wherein R 3 is hydrogen, halogen, perhalomethyl, C,. 6 -alkyl, C 4 . 6 -alkenynyl, C 2 . 6 -alkenyl, C 2 . 6 -alkynyl, C,. 6 -alkoxy, aryloxy, arylalkoxy, heteroaryloxy, heteroarylalkoxy, C ⁇ -alkoxyC ⁇ -alkyl, aryloxyC,. 6 -alkyl, or arylalkoxyC,. 6 -alkyl
  • the present invention is concerned with compounds of formula I wherein Z is a carbon atom at the end of a double bond, or Z is CR 3 , wherein R 3 is hydrogen
  • the present invention is concerned with compounds of formula I wherein Q is O, S, or NR 12 , wherein R 12 is hydrogen, perhalomethyl, C,. 6 -alkyl, C 4 . 6 -alkenynyl, C 2 . 6 -alkenyl, C 2 . 6 -alkynyl, aryl, arylalkyl, heterocyclyl, heteroaryl, heteroarylalkyl, acyl, hydroxyC,. 6 -alkyl, am ⁇ noC,. 6 -alkyl, C,. 6 - alkoxycarbonyl, aryloxycarbonyl, arylalkoxycarbonyl, C,.
  • R 13 and R 14 independently of each other are selected from hydroxy, perhalomethyl, C,. 6 -alkoxy or ammo optionally substituted with one or more C,. 6 -alkyl, perhalomethyl or aryl optionally substituted with one or more halogen, or perhalomethyl.
  • the present invention is concerned with compounds of formula I wherein Q is O, S or NR 12 , wherein R 12 is hydrogen, perhalomethyl, C,. 6 -alkyl, aryl, arylalkyl, heteroarylalkyl, or acyl
  • the present invention is concerned with compounds of formula I wherein Q is O or S.
  • the present invention is concerned with compounds of formula I wherein Q is O.
  • the present invention is concerned with compounds of formula I wherein Ar represents arylene or heteroarylene, or a divalent heterocyclic group each of which can optionally be substituted with one or more halogen, C,. 6 -alkyl or C,. 6 -alkoxy.
  • the present invention is concerned with compounds of formula I wherein Ar represents arylene, or heteroarylene.
  • the present invention is concerned with compounds of formula I wherein Ar represents arylene.
  • the present invention is concerned with compounds of for- mula I wherein R 5 represents hydrogen, hydroxy, halogen, C,. 6 -alkoxy, C,- 6 -alkyl, C ⁇ - alkenynyl, C 2 . 6 -alkenyl, C 2 . 6 -alkynyl or arylalkyl optionally substituted with one or more halogen, or perhalomethyl or R 5 forms a bond together with R 6 .
  • the present invention is concerned with compounds of formula I wherein R 5 represents hydrogen, halogen, C,_ 6 -alkoxy, C,. 6 -alkyi, or perhalomethyl or R 5 forms a bond together with R 6 .
  • the present invention is concerned with compounds of formula I wherein R 5 represents hydrogen, halogen or R 5 forms a bond together with R 6 .
  • the present invention is concerned with compounds of formula I wherein R 5 represents hydrogen.
  • the present invention is concerned with compounds of formula I wherein R 6 represents hydrogen, C,. 6 -alkoxy, C,- 6 -alkyl, C 4 . 6 -alkenynyl, C 2 . 6 -alkenyl, C 2 . 6 -alkynyl, acyl or arylalkyl optionally substituted with one or more halogen or perhalomethyl or R 6 forms a bond together with R 5 .
  • the present invention is concerned with compounds of formula I wherein R 6 represents hydrogen, halogen, C,. 6 -alkoxy, or R 6 forms a bond together with R 5 .
  • the present invention is concerned with compounds of formula I wherein R 6 represents hydrogen, C,. 6 -alkoxy, or R 6 forms a bond together with R 5 .
  • the present invention is concerned with compounds of formula I wherein R 6 represents hydrogen.
  • the present invention is concerned with compounds of formula I wherein M represents OR 7 , where R 7 represents hydrogen, C,. 6 -alkyl, C 4 . 6 -alkenynyl, C 2 . 6 -alkenyl, C 2 . 6 -alkynyl, aryl, arylalkyl, Ci-e-alkoxyC L g-alkyl, C,. 6 -alkoxycarbonyl, aryloxycarbonyl, C,.
  • the present invention is concerned with compounds of formula I wherein M represents OR 7 , where R 7 represents hydrogen, C,. 6 -alkyl, C ⁇ - alkenynyl, C 2 . 6 -alkenyl, C 2 . 6 -alkynyl, aryl, arylalkyl, C,- 6 -alkoxyC,. 6 -alkyl, heterocyclyl, heteroaryl or heteroarylalkyl groups optionally substituted with one or more halogen, or perhalomethyl.
  • R 7 represents hydrogen, C,. 6 -alkyl, C ⁇ - alkenynyl, C 2 . 6 -alkenyl, C 2 . 6 -alkynyl, aryl, arylalkyl, C,- 6 -alkoxyC,. 6 -alkyl, heterocyclyl, heteroaryl or heteroarylalkyl groups optionally substituted with one or more halogen, or perhalomethyl.
  • the present invention is concerned with compounds of for- mula I wherein M represents OR 7 , where R 7 represents C,. 6 -alkyl, or M represents COYR 8 .
  • the present invention is concerned with compounds of formula I wherein M represents OR 7 , where R 7 represents ethyl, or M represents COYR 8 .
  • the present invention is concerned with compounds of formula I wherein R 8 represents hydrogen, C 1 6 alkyl, C 4 6 -alkenynyl, C 26 -alkenyl, C 2 6 -alkynyl, aryl, arylalkyl, heterocyclyl, heteroaryl or heteroarylalkyl groups optionally substituted with one or more halogen, perhalomethyl, hydroxy, nitro or cyano
  • the present invention is concerned with compounds of formula I wherein R 8 represents hydrogen, C, 6 alkyl, C 4 6 -aikenynyl, C 2 6 -alkenyl, C 2 6 -alkynyl, aryl, arylalkyl, heterocyclyl, heteroaryl or heteroarylalkyl groups optionally substituted with one or more halogen, or perhalomethyl
  • the present invention is concerned with compounds of formula I wherein R 8 represents hydrogen or C, 6 alkyl
  • the present invention is concerned with compounds of formula I wherein R 8 represents hydrogen, methyl or ethyl
  • the present invention is concerned with compounds of formula I wherein Y represents oxygen, sulphur or NR 10 , where R 10 represents hydrogen, C, 6 -alkyl, aryl, hydroxyC, 6 -alkyl or arylalkyl groups or when Y is NR 10 , R 8 and R 10 may form a 5 or 6 membered nitrogen containing ring, optionally substituted with one or more C 1 - 6 -alkyl
  • the present invention is concerned with compounds of formula I wherein Y represents oxygen, or NR 10 , where R 10 represents hydrogen, C, 6 -alkyl, aryl, or arylalkyl groups, or when Y is NR 10 , R 8 and R 10 may form a 5 or 6 membered nitrogen containing ring, optionally substituted with one or more C,. 6 -alkyl
  • the present invention is concerned with compounds of formula I wherein Y represents oxygen
  • the present invention is concerned with compounds of formula I wherein k is an integer ranging from 1 to 2
  • the present invention is concerned with compounds of formula I wherein n and m are 1
  • Preferred compounds of the invention are:
  • C,. n -alkyl wherein n' can be from 2 through 12, as used herein, represents a branched or straight or cyclic alkyl group having from one to the specified number of carbon atoms.
  • groups include, but are not limited to methyl, ethyl, n-propyl, iso- propyl, butyl, iso-butyl, sec-butyl, tert-butyl, pentyl, hexyl and the like and cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl and the like.
  • C 2 _ n -alkenyl wherein n' can be from 3 through 15, as used herein, represents an olefinically unsaturated branched or straight hydrocarbon group having from 2 to the specified number of carbon atoms and at least one double bond.
  • groups include, but are not limited to, vinyl, 1-propenyl, 2-propenyl, allyl, iso-proppenyl, 1 ,3-butadienyl, 1-butenyl, hexenyl, pentenyl and the like.
  • C 2 . n -alkynyl wherein n' can be from 3 through 15, as used herein, represents an unsaturated branched or straight hydrocarbon group having from 2 to the specified number of carbon atoms and at least one triple bond.
  • examples of such groups include, but are not limited to, 1-propynyl, 2-propynyl, 1-butynyl, 2-butynyl, 1-pentynyl, 2-pentynyl and the like.
  • C 4 . n -alkenynyl wherein n' can be from 5 through 15, as used herein, represent an unsaturated branched or straight hydrocarbon group having from 4 to the specified number of carbon atoms and both at least one double bond and at least one triple bond. Examples of such groups include, but are not limited to, 1-penten-4-yne, 3-penten-1-yne, 1 ,3- hexadiene-5-yne and the like.
  • C,., 2 -alkoxy as used herein, alone or in combination is intended to include those C,_ ⁇ 2 -alkyl groups of the designated length in either a linear or branched or cyclic configuration linked through an ether oxygen having its free valence bond from the ether oxygen.
  • linear alkoxy groups are methoxy, ethoxy, propoxy, butoxy, pentoxy, hexoxy and the like.
  • branched alkoxy are isopropoxy, sec-butoxy, tert-butoxy, isopentoxy, isohexoxy and the like.
  • cyclic alkoxy are cyclopropyloxy, cyclobutyloxy, cyclopentyloxy, cyclohexyloxy and the like.
  • C,., 2 -alkylthio refers to a straight or branched or cyclic monovalent substituent comprising a C,. 12 -alkyl group linked through a divalent sulfur atom having its free valence bond from the sulfur atom and having 1 to 12 carbon atoms e.g. methylthio, ethylthio, propylthio, butylthio, pentylthio and the like.
  • Examples of cyclic alkylthio are cyclopropylthio, cyclobutylthio, cyclopentylthio, cyclohexylthio and the like.
  • C,., 2 -alkylamino refers to a straight or branched or cyclic monovalent substituent comprising a C,., 2 -alkyl group linked through amino having a free valence bond from the nitrogen atom e.g. methylamino, ethylamino, propylamino, butylamino, pentylamino and the like.
  • cyclic alkylamino are cyclopropylamino, cyclobutylamino, cyclopentylamino, cyclohexylamino and the like.
  • hydroxyC ⁇ -alkyl refers to a C,., 2 -alkyl as defined herein whereto is attached a hydroxy group, e.g. hydroxyethyl, 1-hydroxypropyl, 2-hydroxypropyl and the like.
  • arylamino refers to an aryl as defined herein linked through amino having a free valence bond from the nitrogen atom e.g. phenylamino, naphthylamino and the like.
  • arylalkylamino refers to an arylalkyl as defined herein linked through amino having a free valence bond from the nitrogen atom e.g. benzylamino, phenethylamino, 3-phenylpropylamino, 1-naphthylmethylamino, 2-(1- naphthyl)ethylamino and the like.
  • aminoC,., 2 -alkyl refers to a C,. 12 -alkyl as defined herein whereto is attached an amino group, e.g. aminoethyl, 1-aminopropyl, 2- aminopropyl and the like.
  • aryloxycarbonyl refers to an aryloxy as defined herein linked through a carbonyl having a free valence bond from the carbon atom, e.g. phenoxycarbonyl, 1-naphthyloxycarbonyl or 2-naphthyloxycarbonyl and the like.
  • arylalkoxycarbonyl refers to an arylalkoxy as defined herein linked through a carbonyl having a free valence bond from the carbon atom, e.g. benzyloxycarbonyl, phenethoxycarbonyl, 3-phenylpropoxycarbonyl, 1- naphthylmethoxycarbonyl, 2-(1-naphthyl)ethoxycarbonyl and the like.
  • C,- ⁇ 2 -alkoxyC,. ⁇ 2 -alkyl refers to a C,., 2 - alkyl as defined herein whereto is attached a C,., 2 -alkoxy as defined herein, e.g. methoxymethyl, ethoxymethyl, methoxyethyl, ethoxyethyl and the like.
  • aryloxyC,., 2 -alkyl refers to a C,., 2 -alkyl as defined herein whereto is attached an aryloxy as defined herein, e.g. phenoxymethyl, phenoxydodecyl, 1-naphthyloxyethyl, 2-naphthyloxypropyi and the like.
  • arylalkoxyC,. 12 -alkyl refers to a C,-, 2 -alkyl as defined herein whereto is attached an arylalkoxy as defined herein, e.g. benzyloxymethyl, phenethoxydodecyl, 3-phenylpropoxyethyl, 1-naphthylmethoxypropyl, 2-(1- naphthyl)ethoxymethyl and the like.
  • thioC,. 12 -alkyl refers to a C,., 2 -alkyl as defined herein whereto is attached a group of formula -SR'" wherein R'" is hydrogen, C,. 6 - alkyl or aryl, e.g. thiomethyl, methylthiomethyl, phenylthioethyl and the like.
  • C,., 2 -alkoxycarbonylamino refers to a C,_ i 2 -alkoxycarbonyl as defined herein linked through amino having a free valence bond from the nitrogen atom e g methoxycarbonylamino, carbethoxyamino, propoxycarbonylamino, isopropoxycarbonylammo, n-butoxycarbonylammo, tert-butoxycarbonylammo and the like
  • aryloxycarbonylamino refers to an aryloxycarbonyl as defined herein linked through ammo having a free valence bond from the nitrogen atom e g phenoxycarbonylamino, 1-naphthyloxycarbonylam ⁇ no or 2- naphthyloxycarbonylamino and the like
  • arylalkoxycarbonylamino refers to an arylalkoxycarbonyl as defined herein linked through ammo having a free valence bond from the nitrogen atom e g benzyloxycarbonylamino, phenethoxycarbonylamino, 3- phenylpropoxycarbonylamino, 1 -naphthylmethoxycarbonylamino, 2-(1 - naphthyl)ethoxycarbonylam ⁇ no and the like
  • aryl is intended to include aromatic rings, such as carboxylic aromatic rings selected from the group consisting of phenyl, naphthyl, (1-naphthyl or 2-naphthyl) and the like optionally substituted with halogen, ammo, hydroxy, C, 6 -alkyl or C, 6 -alkoxy and the like
  • arylene is intended to include divalent aromatic rings, such as carboxylic aromatic rings selected from the group consisting of phenylene, naphthylene and the like optionally substituted with halogen, am o, hydroxy, C, 6 -alkyl or C, 6 -alkoxy and the like
  • halogen means fluorine, chlorine, bromine or iodine
  • perhalomethyl means t ⁇ fluoromethyl, t ⁇ chloromethyl, t ⁇ bromomethyl or triiodomethyl
  • C, 6 -d ⁇ alkylam ⁇ no refers to an ammo group wherein the two hydrogen atoms independently are substituted with a straight or branched, saturated hydrocarbon chain having the indicated number of carbon atoms, such as dimethylammo, N- ethyl-N-methylamino, diethylammo, dipropylamino, N-(n-butyl)-N-methylam ⁇ no, d ⁇ (n- pentyl)am ⁇ no and the like
  • acyl refers to a monovalent substituent comprising a C,. 6 -alkyl group linked through a carbonyl group; such as e.g. acetyl, propionyl, butyryl, isobutyryl, pivaloyl, valeryl and the like.
  • acyloxy refers to acyl as defined herein linked to an oxygen atom having its free valence bond from the oxygen atom e.g. acetyloxy, propionyloxy, butyryloxy, isobutyryloxy, pivaloyloxy, valeryloxy and the like.
  • C,. 12 -alkoxycarbonyl refers to a monovalent substituent comprising a C ⁇ -alkoxy group linked through a carbonyl group; such as e.g. methoxycarbonyl, carbethoxy, propoxycarbonyl, isopropoxycarbonyl, n-butoxycarbonyl, sec- butoxycarbonyl, tert-butoxycarbonyl, 3-methylbutoxycarbonyl, n-hexoxycarbonyl and the like.
  • heteroaryl refers to a monovalent substituent comprising a 5-6 membered monocyclic aromatic system or a 9-10 membered bicyclic aromatic system containing one or more heteroatoms selected from nitrogen, oxygen and sulfur, e.g.
  • heteroarylene refers to a divalent group comprising a 5-6 membered monocyclic aromatic system or a 9-10 membered bicyclic aromatic system containing one or more heteroatoms selected from nitrogen, oxygen and sulfur, e.g.
  • heteroaryloxy refers to a heteroaryl as defined herein linked to an oxygen atom having its free valence bond from the oxygen atom e.g. pyrrole, imidazole, pyrazole, triazole, pyridine, pyrazine, pyrimidine, pyridazine, isothiazole, isoxazole, oxazole, oxadiazole, thiadiazole, quinoline, isoquinoline, quinazoiine, quinoxaline, indole, benzimidazole, benzofuran, pteridine and purine linked to oxygen, and the like.
  • oxygen atom e.g. pyrrole, imidazole, pyrazole, triazole, pyridine, pyrazine, pyrimidine, pyridazine, isothiazole, isoxazole, oxazole, oxadiazole, thiadiazole, quinoline, isoquino
  • arylalkyl refers to a straight or branched saturated carbon chain containing from 1 to 6 carbons substituted with an aromatic carbohydride; such as benzyl, phenethyl, 3-phenylpropyl, 1-naphthylmethyl, 2-(1-naphthyl)ethyl and the like.
  • aryloxy refers to phenoxy, 1-naphthyloxy, 2-naphthyloxy and the like.
  • arylalkoxy refers to a C,. 6 -alkoxy group substituted with an aromatic carbohydride, such as benzyloxy, phenethoxy, 3-phenylpropoxy, 1- naphthylmethoxy, 2-(1-naphthyl)ethoxy and the like.
  • heteroarylalkyl refers to a straight or branched saturated carbon chain containing from 1 to 6 carbons substituted with a heteroaryl group; such as (2- furyl)methyl, (3-furyl)methyl, (2-thienyl)methyl, (3-thienyl)methyl, (2-pyridyl)methyl, 1-methyl- 1-(2-pyrimidyl)ethyl and the like.
  • heteroarylalkoxy refers to a heteroarylalkyl as defined herein linked to an oxygen atom having its free valence bond from the oxygen atom, e.g. (2- furyl)methyl, (3-furyl)methyl, (2-thienyl)methyl, (3-thienyl)methyl, (2-pyridyl)methyl, 1-methyl- 1-(2-pyrimidyl)ethyl linked to oxygen, and the like.
  • acylamino refers to an amino group wherein one of the hydrogen atoms is substituted with an acyl group, such as e.g. acetamido, propionamido, isopropylcar- bonylamino and the like.
  • (C 3 - 6 -cycloalkyl)C,. 6 -alkyl refers to a straight or branched, saturated hydrocarbon chain having 1 to 6 carbon atoms and being monosubsti- tuted with a C 3 - 6 -cycloalkyl group, the cycloalkyl group optionally being mono- or polysubsti- tuted with C,. 6 -alkyl, halogen, hydroxy or C,. 6 -alkoxy; such as e.g.
  • arylthio refers to an aryl group linked through a divalent sulfur atom having its free valence bond from the sulfur atom, the aryl group optionally being mono- or polysubstituted with C,. 6 -alkyl, halogen, hydroxy or C,. 6 -alkoxy; e.g. phenylthio, (4-methylphenyl)- thio, (2-chlorophenyl)thio and the like.
  • C,. 6 -alkylaminocarbonyl refers to a monovalent substituent comprising a C,_ 6 -monoalkylamino group linked through a carbonyl group such as e.g.
  • methylamino- carbonyl ethylaminocarbonyl, n-propylaminocarbonyl, isopropylaminocarbonyl, n- butylaminocarbonyl, sec-butylaminocarbonyl, isobutylaminocarbonyl, tert-butylaminocarbonyl, n-pentylaminocarbonyl, 2-methylbutylaminocarbonyl, 3-methylbutylaminocarbonyl, n- hexylaminocarbonyl, 4-methylpentylaminocarbonyl, neopentylaminocarbonyl, n- hexylaminocarbonyl and 2-2-dimethylpropylaminocarbonyl and the like.
  • heterocyclyl means a monovalent saturated or unsaturated non aromatic group being monocyclic and containing one or more, such as from one to four carbon atom(s), and from one to four N, O or S atom(s) or a combination thereof.
  • heterocyclyl includes, but is not limited to, 5-membered heterocycles having one hetero atom (e.g. pyrrolidine, pyrroline and the like); 5-membered heterocycles having two heteroa- toms in 1 ,2 or 1 ,3 positions (e.g.
  • pyrazoline pyrazolidine, 1 ,2-oxathiolane, imidazolidine, imi- dazoline, 4-oxazolone and the like
  • 5-membered heterocycles having three heteroatoms e.g. tetrahydrofurazan and the like
  • 5-membered heterocycles having four heteroatoms 6- membered heterocycles with one heteroatom (e.g. piperidine and the like); 6-membered heterocycles with two heteroatoms (e.g. piperazine, morpholine and the like); 6-membered het- erocycles with three heteroatoms; and 6-membered heterocycles with four heteroatoms, and the like.
  • a divalent heterocyclic group means a divalent saturated or unsaturated system being monocyclic and containing one or more, such as from one to four carbon atom(s), and one to four N, O or S atom(s) or a combination thereof.
  • the phrase a divalent heterocyclic group includes, but is not limited to, 5-membered heterocycles having one hetero atom (e.g. pyrrolidine, pyrroline and the like); 5-membered heterocycles having two heteroatoms in 1 ,2 or 1 ,3 positions (e.g.
  • pyrazoline pyrazolidine, 1 ,2-oxathiolane, imidazolidine, imidazoline, 4-oxazolone and the like
  • 5-membered heterocycles having three het- eroatoms e.g. tetrahydrofurazan and the like
  • 5-membered heterocycles having four heteroatoms 6-membered heterocycles with one heteroatom (e.g. piperidine and the like); 6- membered heterocycles with two heteroatoms (e.g. piperazine, morphoiine and the like); 6- membered heterocycles with three heteroatoms; and 6-membered heterocycles with four heteroatoms, and the like.
  • a 5-6 membered cyclic ring means an unsaturated or saturated or aromatic system containing one or more carbon atoms and optionally from one to four N, O or S atom(s) or a combination thereof.
  • the phrase “a 5-6 membered cyclic ring” includes, but is not limited to, e.g.
  • cyclopentyl cyclohexyl, phenyl, cyclohexenyl, pyrrolidinyl, pyrrolinyl, imidazolidinyl, pyrazolidinyl, pyrazolinyl, piperidyl, piperazinyl, pyrrolyl, 2H-pyrrolyl, imidazolyl, pyrazolyl, triazolyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, morpholinyl, thiomorpholinyl, isothiazolyl, isoxazolyl, oxazolyl, oxadiazolyl, thiadiazolyl, 1 ,3-dioxolanyl, 1 ,4-dioxolanyl and the like, 5-membered heterocycles having one hetero atom (e.g.
  • 5-membered heterocycles having two heteroatoms in 1 ,2 or 1 ,3 positions (e.g. oxazoles, pyrazoles, imidazoles, thiazoles, purines and the like); 5-membered heterocycles having three heteroatoms (e.g. thazoles, thiadiazoles and the like); 5-membered heterocycles having four heteroatoms; 6-membered heterocycles with one heteroatom (e.g. pyridine, quinoline, isoquinoline, phenanthridine, cyclohepta[b]pyridine and the like); 6-membered heterocycles with two heteroatoms (e.g.
  • pyridazines cinnolines, phthalazines, pyrazines, pyrimidines, quinazolines, morpholines and the like
  • 6-membered heterocycles with three heteroatoms e.g. 1 ,3,5-triazine and the like
  • 6-membered heterocycles with four heteroatoms and the like e.g. 1 ,3,5-triazine and the like.
  • a 9-10 membered bicyclic ring means an unsaturated or saturated or aromatic system containing one or more carbon atoms and optionally from one to four N, O or S atom(s) or a combination thereof.
  • the phrase “a 9-10 membered bicyclic ring” includes but is not limited to napthalene, quinoline, isoquinoline, indole, benzothiophene, benzofuran and the like.
  • the present invention also encompasses pharmaceutically acceptable salts of the present compounds.
  • Such salts include pharmaceutically acceptable acid addition salts, pharmaceutically acceptable base addition salts, pharmaceutically acceptable metal salts, ammonium and alkylated ammonium salts.
  • Acid addition salts include salts of inorganic acids as well as organic acids. Representative examples of suitable inorganic acids include hydrochloric, hy- drobromic, hydroiodic, phosphoric, sulfuric, nitric acids and the like.
  • suitable organic acids include formic, acetic, trichloroacetic, trifluoroacetic, propionic, benzoic, cinnamic, citric, fumaric, glycolic, lactic, maleic, malic, malonic, mandelic, oxalic, picric, pyruvic, salicylic, succinic, methanesulfonic, ethanesulfonic, tartaric, ascorbic, pamoic, bismethylene salicylic, ethanedisulfonic, gluconic, citraconic, aspartic, stearic, palmitic, EDTA, glycolic, p-aminobenzoic, glutamic, benzenesulfonic, p-toluenesulfonic acids, sulphates, nitrates, phosphates, perchlorates, borates, acetates, benzoates, hydroxynaphtho- ates, glycero
  • compositions include the pharmaceutically acceptable salts listed in J. Pharm. Sci. 1977, 66, 2, which is incorporated herein by reference.
  • metal salts include lithium, sodium, potassium, magnesium salts and the like.
  • ammonium and alkylated ammonium salts include ammonium, methylammonium, dimethylammonium, trimethylammonium, ethylammonium, hydroxyethylammonium, diethyl- ammonium, butylammonium, tetramethylammonium salts and the like.
  • organic bases include lysine, arginine, guanidine, diethanolamine, choline and the like.
  • the pharmaceutically acceptable salts are prepared by reacting the compound of formula I with 1 to 4 equivalents of a base such as sodium hydroxide, sodium methoxide, sodium hydride, potassium t-butoxide, calcium hydroxide, magnesium hydroxide and the like, in sol- vents like ether, THF, methanol, t-butanol, dioxane, isopropanol, ethanol etc. Mixture of solvents may be used. Organic bases like lysine, arginine, diethanolamine, choline, guandine and their derivatives etc. may also be used.
  • acid addition salts wherever applicable are prepared by treatment with acids such as hydrochloric acid, hydrobromic acid, nitric acid, sulfuric acid, phosphoric acid, p-toluenesulphonic acid, methanesulfonic acid, ace- tic acid, citric acid, maleic acid salicylic acid, hydroxynaphthoic acid, ascorbic acid, palmitic acid, succinic acid, benzoic acid, benzenesulfonic acid, tartaric acid and the like in solvents like ethyl acetate, ether, alcohols, acetone, THF, dioxane etc. Mixture of solvents may also be used.
  • acids such as hydrochloric acid, hydrobromic acid, nitric acid, sulfuric acid, phosphoric acid, p-toluenesulphonic acid, methanesulfonic acid, ace- tic acid, citric acid, maleic acid salicylic acid, hydroxynaphthoic acid
  • stereoisomers of the compounds forming part of this invention may be prepared by using reactants in their single enantiomeric form in the process wherever possible or by conducting the reaction in the presence of reagents or catalysts in their single enantiomer form or by resolving the mixture of stereoisomers by conventional methods.
  • Some of the pre- ferred methods include use of microbial resolution, resolving the diastereomeric salts formed with chiral acids such as mandelic acid, camphorsulfonic acid, tartaric acid, lactic acid, and the like wherever applicable or chiral bases such as brucine, cinchona alkaloids and their derivatives and the like.
  • the com- pound of formula I may be converted to a 1 :1 mixture of diastereomeric amides by treating with chiral amines, aminoacids, aminoalcohols derived from aminoacids; conventional reaction conditions may be employed to convert acid into an amide; the dia-stereomers may be separated either by fractional crystallization or chromatography and the stereoisomers of compound of formula I may be prepared by hydrolysing the pure diastereomeric amide.
  • polymorphs of compound of general formula I forming part of this invention may be prepared by crystallization of compound of formula I under different conditions. For example, using different solvents commonly used or their mixtures for recrystallization; crystallizations at different temperatures; various modes of cooling, ranging from very fast to very slow cooling during crystallizations. Polymorphs may also be obtained by heating or melting the compound followed by gradual or fast cooling. The presence of polymorphs may be determined by solid probe nmr spectroscopy, ir spectroscopy, differential scanning calorimetry, powder X-ray diffraction or such other techniques.
  • the invention also encompasses prodrugs of the present compounds, which on administration undergo chemical conversion by metabolic processes before becoming active pharmacological substances.
  • prodrugs will be functional derivatives of the present compounds, which are readily convertible in vivo into the required compound of the formula (I).
  • Conventional procedures for the selection and preparation of suitable prodrug derivatives are described, for example, in "Design of Prodrugs", ed. H. Bundgaard, Elsevier, 1985.
  • the invention also encompasses active metabolites of the present compounds.
  • the present compounds of formula I can be utilised in the treatment and/or prevention of conditions mediated by nuclear receptors, in particular the Peroxisome Prolif- erator-Activated Receptors (PPAR).
  • PPAR Peroxisome Prolif- erator-Activated Receptors
  • the present invention relates to a method of treating and/or preventing Type I or Type II diabetes.
  • the present invention relates to the use of one or more compounds of the general formula I or pharmaceutically acceptable salts thereof for the preparation of a medicament for the treatment and/or prevention of Type I or Type II diabetes.
  • the present compounds are useful for the treatment and/or prevention of IGT.
  • the present compounds are useful for the treatment and/or prevention of Type 2 diabetes.
  • the present compounds are useful for the delaying or prevention of the progression from IGT to Type 2 diabetes.
  • the present compounds are useful for the delaying or prevention of the progression from non-insulin requiring Type 2 diabetes to insulin requiring Type 2 diabetes.
  • the present compounds reduce blood glucose and triglycehde levels and are accordingly useful for the treatment and/or prevention of ailments and disorders such as diabetes and/or obesity.
  • the present compounds are useful for the treatment and/or prophy- laxis of insulin resistance (Type 2 diabetes), impaired glucose tolerance, dyslipidemia, disorders related to Syndrome X such as hypertension, obesity, insulin resistance, hyperglycae- mia, atherosclerosis, hyperlipidemia, coronary artery disease, myocardial ischemia and other cardiovascular disorders.
  • the present compounds are effective in decreasing apoptosis in mammalian cells such as beta cells of Islets of Langerhans.
  • the present compounds are useful for the treatment of certain renal diseases including glomerulonephritis, glomerulosclerosis, nephrotic syndrome, hypertensive nephrosclerosis.
  • the present compounds may also be useful for improving cognitive functions in dementia, treating diabetic complications, psoriasis, polycystic ovarian syndrome (PCOS) and prevention and treatment of bone loss, e.g. osteoporosis.
  • PCOS polycystic ovarian syndrome
  • the invention also relates to pharmaceutical compositions comprising, as an active ingredient, at least one compound of the formula I or any optical or geometric isomer or tautomeric form thereof including mixtures of these or a pharmaceutically acceptable salt thereof to- gether with one or more pharmaceutically acceptable carriers or diluents.
  • the invention relates to the use of compounds of the general formula I or their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts or pharmaceutically acceptable solvates thereof for the preparation of a pharmaceutical composition for the treatment and/or prevention of conditions mediated by nuclear receptors, in particular the Peroxisome Proliferator-Activated Receptors (PPAR) such as the conditions mentioned above.
  • PPAR Peroxisome Proliferator-Activated Receptors
  • the present invention also relates to a process for the preparation of the above said novel compounds, their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts or pharmaceutically acceptable solvates.
  • the method comprises:
  • a compound of formula III can be reduced with diisobutyl aluminium hydride to give a compound of formula IV where A 1 and A 2 and n are as defined previously.
  • a compound of formula IV can be prepared via reaction of a compound of formula II with (Ph 3 P) 3 PCH 2 (CH 2 ) n CH 2 OH.Br and BuLi in a Wittig reaction
  • the alcohol group in a compound of formula IV can undergo a Mitsunobo reaction with a compound of formula V, alternatively it can be converted to a suitable leaving group (mesy- loxy, halide) and react under alkylating conditions with a compound of formula V, wherein Q is OH, SH or amino, Ar, M, Y and R 5 -R 8 are as defined previously.
  • the PPAR gene transcription activation assays were based on transient transfection into human HEK293 cells of two plasmids encoding a chime ⁇ c test protein and a reporter protein respectively
  • the chime ⁇ c test protein was a fusion of the DNA binding domain (DBD) from the yeast GAL4 transcription factor to the ligand binding domain (LBD) of the human PPAR proteins
  • the GAL4 DBD will force the fusion protein to bind only to Gal4 enhancers (of which none existed in HEK293 cells)
  • the reporter plasmid contained a Gal4 enhancer driving the expression of the firefly luciferase protein After transfection, HEK293 cells expressed the GAL4-DBD-PPAR-LBD fusion protein The fusion
  • Plasmids Human PPAR ⁇ and ⁇ was obtained by PCR amplification using cDNA templates from liver, intestine and adipose tissue respectively Amplified cDNAs were cloned into pCR2 1 and sequenced
  • the LBD from each isoform PPAR was generated by PCR (PPAR ⁇ aa 167 - C-term, PPAR ⁇ aa 165 - C-term) and fused to GAL4-DBD by subclonmg fragments in frame into the vector pM1 generating the plasmids pMl ⁇ LBD and pMl ⁇ LBD Ensuing fusions were verified by sequencing
  • the reporter was constructed by inserting an ohgonucleotide encoding five repeats of the Gal4 recognition sequence into the pGL2 vector (Promega) Compounds: All compounds were dissolved in DMSO and diluted 1 :1000 upon addition to the cells. Cells were treated with compound (1 :1000 in 200 ⁇
  • Luciferase assay Medium including test compound was aspirated and 100 ⁇ l PBS incl. 1mM Mg++ and Ca++ was added to each well. The luciferase assay was performed using the Lu- cLite kit according to the manufacturers instructions (Packard Instruments). Light emission was quantified by counting SPC mode on a Packard Instruments top-counter.
  • the present invention includes within its scope pharmaceutical compositions comprising, as an active ingredient, at least one of the compounds of the general formula I or a pharmaceutically acceptable salt thereof together with a pharmaceutically acceptable carrier or diluent.
  • the present compounds may also be administered in combination with one or more further pharmacologically active substances eg., selected from antiobesity agents, antidiabetics, an- tihypertensive agents, agents for the treatment and/or prevention of complications resulting from or associated with diabetes and agents for the treatment and/or prevention of complications and disorders resulting from or associated with obesity.
  • further pharmacologically active substances eg., selected from antiobesity agents, antidiabetics, an- tihypertensive agents, agents for the treatment and/or prevention of complications resulting from or associated with diabetes and agents for the treatment and/or prevention of complications and disorders resulting from or associated with obesity.
  • the present compounds may be administered in combination with one or more antiobesity agents or appetite regulating agents.
  • Such agents may be selected from the group consisting of CART (cocaine amphetamine regulated transcript) agonists, NPY (neuropeptide Y) antagonists, MC4 (melanocortin 4) agonists, orexin antagonists, TNF (tumor necrosis factor) agonists, CRF (corticotropin releasing factor) agonists, CRF BP (corticotropin releasing factor binding protein) antagonists, urocortin agonists, ⁇ 3 agonists, MSH (melanocyte-stimulating hormone) agonists, MCH (melanocyte-concentrating hormone) antagonists, CCK (cholecystokinin) agonists, serotonin re-uptake inhibitors, serotonin and noradrenaline re-uptake inhibitors, mixed serotonin and noradrenergic compounds, 5HT (serotonin) agonists, bombesm agonists, galanm antagonists, growth hormone, growth hormone releasing compounds
  • Suitable antidiabetics comprise insulin, GLP-1 (glucagon like pept ⁇ de-1) derivatives such as those disclosed in WO 98/08871 to Novo Nordisk A/S, which is incorporated herein by reference as well as orally active hypoglycaemic agents
  • the orally active hypoglycaemic agents preferably comprise sulphonylureas, biguanides, meghtinides, glucosidase inhibitors, glucagon antagonists such as those disclosed in WO 99/01423 to Novo Nordisk A/S and Agouron Pharmaceuticals, Inc , GLP-1 agonists, potassium channel openers such as those disclosed in WO 97/26265 and WO 99/03861 to Novo Nordisk A/S which are incorporated herein by reference, DPP-IV (dipeptidyl peptidase-IV) inhibitors, inhibitors of hepatic enzymes involved in stimulation of gluconeogenesis and/or glycogenolysis, glucose uptake modulators, compounds modifying the lipid metabolism such as antihyperlipidemic agents and antilipidemic agents as HMG CoA inhibitors (statins), compounds lowering food intake, RXR agonists and agents acting on the ATP-dependent potassium channel of the ⁇ -cells
  • the present compounds are administered in combination with a sul- phonylurea eg. tolbutamide, glibenclamide, glipizide or glicazide.
  • a sul- phonylurea eg. tolbutamide, glibenclamide, glipizide or glicazide.
  • the present compounds are administered in combination with a bi- guanide eg. metformin.
  • the present compounds are administered in combination with a meglitinide eg. repaglinide.
  • the present compounds are administered in combination with an ⁇ -glucosidase inhibitor eg. miglitol or acarbose.
  • an ⁇ -glucosidase inhibitor eg. miglitol or acarbose.
  • the present compounds are administered in combination with an agent acting on the ATP-dependent potassium channel of the ⁇ -cells eg. tolbutamide, glibenclamide, glipizide, glicazide or repaglinide.
  • an agent acting on the ATP-dependent potassium channel of the ⁇ -cells eg. tolbutamide, glibenclamide, glipizide, glicazide or repaglinide.
  • the present compounds may be administered in combination with nateglinide.
  • the present compounds are administered in combination with an antihyperlipidemic agent or antilipidemic agent eg. cholestyramine, colestipol, clofibrate, gemfibrozil, lovastatin, pravastatin, simvastatin, probucol or dextrothyroxine.
  • an antihyperlipidemic agent or antilipidemic agent eg. cholestyramine, colestipol, clofibrate, gemfibrozil, lovastatin, pravastatin, simvastatin, probucol or dextrothyroxine.
  • the present compounds are administered in combination with more than one of the above-mentioned compounds eg. in combination with a sulphonylurea and metformin, a sulphonylurea and acarbose, repaglinide and metformin, insulin and a sulphonylurea, insulin and metformin, insulin, insulin and lovastatin, etc.
  • the present compounds may be administered in combination with one or more antihypertensive agents.
  • antihypertensive agents are ⁇ -blockers such as aipre- nolol, atenolol, timolol, pindolol, propranolol and metoprolol, ACE (angiotensin converting enzyme) inhibitors such as benazepril, captopril, enalapril, fosinopril, lisinopril, quinap l and ramipril, calcium channel blockers such as nifedipine, felodipine, nicardipine, isradipine, ni- modipine, diltiazem and verapamil, and ⁇ -blockers such as doxazosin, urapidil, prazosin and terazosin. Further reference can be made to Remington: The Science and Practice of Pharmacy, 19 th Edition, Gennaro,
  • compositions containing a compound of the present invention may be prepared by conventional techniques, e.g. as described in Remington: The Science and Practise of Pharmacy, 19 th Ed., 1995.
  • the compositions may appear in conventional forms, for example capsules, tablets, aerosols, solutions, suspensions or topical applications.
  • compositions include a compound of formula I or a pharmaceutically acceptable acid addition salt thereof, associated with a pharmaceutically acceptable excipient which may be a carrier or a diluent or be diluted by a carrier, or enclosed within a carrier which can be in the form of a capsule, sachet, paper or other container.
  • a pharmaceutically acceptable excipient which may be a carrier or a diluent or be diluted by a carrier, or enclosed within a carrier which can be in the form of a capsule, sachet, paper or other container.
  • the active compound will usually be mixed with a carrier, or diluted by a carrier, or enclosed within a carrier which may be in the form of a ampoule, capsule, sachet, paper, or other container.
  • the carrier When the carrier serves as a diluent, it may be solid, semi-solid, or liquid material which acts as a vehicle, excipient, or medium for the active compound.
  • the active compound can be adsorbed on a granular solid container for example in a sachet.
  • suitable carriers are water, salt solutions, alcohols, polyethylene glycols, polyhydroxyethoxylated castor oil, peanut oil, olive oil, gelatine, lactose, terra alba, sucrose, cyclodextrin, amylose, magnesium stearate, talc, gelatin, agar, pectin, acacia, stearic acid or lower alkyl ethers of cellulose, silicic acid, fatty acids, fatty acid amines, fatty acid monoglycerides and diglycerides, pentaerythritol fatty acid esters, poiyoxyethylene, hydroxymethylcelluiose and polyvinylpyrrolidone.
  • the carrier or diluent may include any sustained release material known in the art, such as glyceryl monostearate or giyceryl distearate, alone or mixed with a wax.
  • the formulations may also include wetting agents, emulsifying and suspending agents, preserving agents, sweetening agents or flavouring agents.
  • the formulations of the invention may be formulated so as to provide quick, sustained, or delayed release of the active ingredient after administration to the patient by employing procedures well known in the art.
  • compositions can be sterilized and mixed, if desired, with auxiliary agents, emulsifiers, salt for influencing osmotic pressure, buffers and/or colouring substances and the like, which do not deleteriously react with the active compounds.
  • the route of administration may be any route, which effectively transports the active com- pound to the appropriate or desired site of action, such as oral, nasal, pulmonary, transder- mal or parenteral e.g. rectal, depot, subcutaneous, intravenous, intraurethral, intramuscular, intranasal, ophthalmic solution or an ointment, the oral route being preferred.
  • the preparation may be tabletted, placed in a hard gelatin capsule in powder or pellet form or it can be in the form of a troche or lozenge. If a liquid carrier is used, the preparation may be in the form of a syrup, emulsion, soft gelatin capsule or sterile injectable liquid such as an aqueous or non-aqueous liquid suspension or solution.
  • the preparation may contain a compound of formula I dissolved or suspended in a liquid carrier, in particular an aqueous carrier, for aerosol application.
  • a liquid carrier in particular an aqueous carrier
  • the carrier may contain additives such as solubilizing agents, e.g. propylene glycol, surfactants, absorption enhancers such as lecithin (phosphatidylcholine) or cyclodextrin, or preservatives such as parabenes.
  • injectable solutions or suspensions preferably aqueous solutions with the active compound dissolved in polyhydroxylated castor oil.
  • Tablets, dragees, or capsules having talc and/or a carbohydrate carrier or binder or the like are particularly suitable for oral application.
  • Preferable carriers for tablets, dragees, or capsules include lactose, corn starch, and/or potato starch.
  • a syrup or elixir can be used in cases where a sweetened vehicle can be employed.
  • a typical tablet which may be prepared by conventional tabletting techniques may contain: Core:
  • the compounds of the invention may be administered to a mammal, especially a human in need of such treatment, prevention, elimination, alleviation or amelioration of diseases related to the regulation of blood sugar.
  • Such mammals include also animals, both domestic animals, e.g. household pets, and non- domestic animals such as wildlife.
  • the compounds of the invention are effective over a wide dosage range.
  • dosages from about 0.05 to about 100 mg, preferably from about 0.1 to about 100 mg, per day may be used.
  • a most preferable dosage is about 0.1 mg to about 70 mg per day.
  • the exact dosage will depend upon the mode of administration, on the therapy desired, form in which administered, the subject to be treated and the body weight of the subject to be treated, and the preference and experience of the physician or veterinarian in charge.
  • the compounds of the present invention are dispensed in unit dosage form comprising from about 0.1 to about 100 mg of active ingredient together with a pharmaceutically acceptable carrier per unit dosage.
  • dosage forms suitable for oral, nasal, pulmonary or transdermal administration comprise from about 0.001 mg to about 100 mg, preferably from about 0.01 mg to about 50 mg of the compounds of formula I admixed with a pharmaceutically acceptable carrier or diluent.
  • NMR nuclear magnetic resonance
  • MS mass spectrometry
  • Potassium carbonate (0.25 g, 1.81 mmol) was added to a stirred solution of 4-(3-bromo-1- phenyl-prop-1-enyl)-biphenyl (0.35 g, 1.00 mmol) and (2R)-2-ethoxy-3-(4-hydroxy-phenyl)- propionic acid ethyl ester (0.215 g, 0.90 mmol) in dry acetone (20 ml), and the mixture heated to 60°C under reflux for 18 h.

Abstract

The present invention relates to compounds of general formula (I) The compounds are useful in the treatment and/or prevention of conditions mediated by nuclear receptors, in particular the Peroxisome Proliferator-Activated Receptors (PPAR).

Description

New Compounds, their Preparation and Use
FIELD OF INVENTION
The present invention relates to novel compounds, pharmaceutical compositions containing them, methods for preparing the compounds and their use as medicaments. More specifically, compounds of the invention can be utilised in the treatment and/or prevention of conditions mediated by nuclear receptors, in particular the Peroxisome Proliferator-Activated Re- ceptors (PPAR).
BACKGROUND OF THE INVENTION
Coronary artery disease (CAD) is the major cause of death in Type 2 diabetic and metabolic syndrome patients (i.e. patients that fall within the 'deadly quartet' category of impaired glucose tolerance, insulin resistance, hypertriglyceridaemia and/or obesity).
The hypolipidaemic fibrates and antidiabetic thiazolidinediones separately display moderately effective triglyce de-lowering activities although they are neither potent nor efficacious enough to be a single therapy of choice for the dyslipidaemia often observed in Type 2 diabetic or metabolic syndrome patients. The thiazolidinediones also potently lower circulating glucose levels of Type 2 diabetic animal models and humans. However, the fibrate class of compounds are without beneficial effects on glycaemia. Studies on the molecular actions of these compounds indicate that thiazolidinediones and fibrates exert their action by activating distinct transcription factors of the peroxisome proliferator activated receptor (PPAR) family, resulting in increased and decreased expression of specific enzymes and apolipoproteins respectively, both key-players in regulation of plasma triglyceride content. Fibrates, on the one hand, are PPARα activators, acting primarily in the liver. Thiazolidinediones, on the other hand, are high affinity ligands for PPARγ acting primarily on adipose tissue.
Adipose tissue plays a central role in lipid homeostasis and the maintenance of energy balance in vertebrates. Adipocytes store energy in the form of triglycerides during periods of nutritional affluence and release it in the form of free fatty acids at times of nutritional deprivation. The development of white adipose tissue is the result of a continuous differentiation process throughout life. Much evidence points to the central role of PPARγ activation in initiating and regulating this cell differentiation. Several highly specialised proteins are induced during adipocyte differentiation, most of them being involved in lipid storage and metabolism. The exact link from activation of PPARγ to changes in glucose metabolism, most notably a decrease in insulin resistance in muscle, has not yet been clarified. A possible link is via free fatty acids such that activation of PPARγ induces Lipoprotein Lipase (LPL), Fatty Acid Transport Protein (FATP) and Acyl-CoA Synthetase (ACS) in adipose tissue but not in muscle tissue. This, in turn, reduces the concentration of free fatty acids in plasma dramatically, and due to substrate competition at the cellular level, skeletal muscle and other tissues with high metabolic rates eventually switch from fatty acid oxidation to glucose oxidation with decreased insulin resistance as a consequence.
PPARα is involved in stimulating β-oxidation of fatty acids. In rodents, a PPARα-mediated change in the expression of genes involved in fatty acid metabolism lies at the basis of the phenomenon of peroxisome proliferation, a pleiotropic cellular response, mainly limited to liver and kidney and which can lead to hepatocarcinogenesis in rodents. The phenomenon of peroxisome proliferation is not seen in man. In addition to its role in peroxisome proliferation in rodents, PPARα is also involved in the control of HDL cholesterol levels in rodents and humans. This effect is, at least partially, based on a PPARα-mediated transcrip- tional regulation of the major HDL apolipoproteins, apo A-l and apo A-ll. The hypotriglyceridemic action of fibrates and fatty acids also involves PPARα and can be summarised as follows: (I) an increased lipolysis and clearance of remnant particles, due to changes in lipoprotein lipase and apo C-lll levels, (II) a stimulation of cellular fatty acid uptake and their subsequent conversion to acyl-CoA derivatives by the induction of fatty acid binding protein and acyl-CoA synthase, (III) an induction of fatty acid -oxidation pathways, (IV) a reduction in fatty acid and triglyceride synthesis, and finally (V) a decrease in VLDL production. Hence, both enhanced catabolism of t glyceride-rich particles as well as reduced secretion of VLDL particles constitutes mechanisms that contribute to the hypolipidemic effect of fibrates.
A number of compounds have been reported to be useful in the treatment of hyperglycemia, hyperiipidemia and hypercholesterolemia (U.S. Pat. 5,306,726, PCT Publications nos. W091/19702, WO 95/03038, WO 96/04260, WO 94/13650, WO 94/01420, WO 97/36579, WO 97/25042, WO 95/17394, WO 99/08501 , WO 99/19313 and WO 99/16758). SUMMARY OF THE INVENTION
Glucose lowering as a single approach does not overcome the macrovascular complications associated with Type 2 diabetes and metabolic syndrome. Novel treatments of Type 2 diabetes and metabolic syndrome must therefore aim at lowering both the overt hypertriglyceri- daemia associated with these syndromes as well as alleviation of hyperglycaemia.
The clinical activity of fibrates and thiazolidinediones indicates that research for compounds displaying combined PPARα and PPARγ activation should lead to the discovery of efficacious glucose and triglyceride lowering drugs that have great potential in the treatment of Type 2 diabetes and the metabolic syndrome (i.e. impaired glucose tolerance, insulin resistance, hypertriglyceridaemia and/or obesity).
DETAILED DESCRIPTION OF THE INVENTION
Accordingly, the present invention relates to compounds of the general formula (I):
Figure imgf000005_0001
wherein A1 and A2 are independently of each other a 5-6 membered cyclic ring or a 9-10 membered bicyclic ring, optionally substituted with one or more halogen, perhalomethyl, hydroxy, nitro, cyano, formyl, or
Figure imgf000005_0002
C4.12-alkenynyl, C2.12-alkenyl, C2.12-alkynyl,
Figure imgf000005_0003
aryl, aryloxy, arylalkyl, arylalkoxy, heterocyclyl, heteroaryl, heteroarylalkyl, heteroaryloxy, heteroarylalkoxy, acyl, acyloxy, hydroxyC,.12-alkyl, ammo, acylamino, CL^-alkyl-ammo, C^- dialkylammo, arylamino, arylalkylammo, amιnoC1-12-alkyl, C^^-alkoxycarbonyl, alkylaminocarbonyl, aryloxycarbonyl, arylalkoxycarbonyl,
Figure imgf000006_0001
aryloxyC, 12-alkyl,
Figure imgf000006_0002
alkoxycarbonylam o, aryloxycarbonylammo, arylalkoxycarbonylamino, -COR1, or - SO2R2, wherein R1 and R2 independently of each other are selected from hydroxy, halogen, perhalomethyl, C^-alkoxy or ammo optionally substituted with one or more C, 6-alkyl, perhalomethyl or aryl, optionally substituted with one or more halogen, perhalomethyl, hydroxy, nitro or cyano,
Z is C, CR3, wherein R3 is hydrogen, halogen, perhalomethyl, C, 12-alkyl, C4.12- alkenynyl, C2_12-alkenyl, C2.12-alkynyl, C, 12-alkoxy, aryloxy, arylalkoxy, heteroaryloxy, heteroarylalkoxy, acyl, acyloxy, hydroxyC^^-alkyl, C^^-alkoxyCL^-alkyl, aryloxyC,. 12-alkyl,
Figure imgf000006_0003
-COR4, or -SO2R11, wherein R4 and R11 independently of each other are selected from hydroxy, halogen, perhalomethyl, C 6-alkoxy or am o optionally substituted with one or more C^-alkyl, perhalomethyl or aryl optionally substituted with one or more halogen, perhalomethyl, hydroxy, nitro or cyano,
Q is O, S, NR12, wherein R12 is hydrogen, perhalomethyl, C^^-alkyl, C4.12-alkenynyl, C2 12-alkenyl, C2 12-alkynyl, aryl, arylalkyl, heterocyclyl, heteroaryl, heteroarylalkyl, acyl, hydroxyC.|.12-alkyl,
Figure imgf000006_0004
aryloxycarbonyl, arylalkoxycarbonyl, C^^-alkoxyC^^-alkyl, aryloxyC^^-alkyl, arylalkoxyC^ralkyl, thioCMz-alkyl, -COR13, or -SO2R14, wherein R13 and R14 independently of each other are selected from hydroxy, perhalomethyl, C,.6-alkoxy or ammo optionally substituted with one or more C^-alkyl, perhalomethyl or aryl optionally substituted with one or more halogen, perhalomethyl, hydroxy, nitro or cyano;
represents a single bond or a double bond,
Ar represents arylene, heteroarylene, or a divalent heterocyclic group each of which can optionally be substituted with one or more halogen, C,.6-alkyl, ammo, hydroxy, C^-alkoxy or aryl, R5 represents hydrogen, hydroxy, halogen, C, 12-alkoxy, C, 12-alkyl, C4 12-alkenynyl, C2 12- alkenyl, C2 12-alkynyl or arylalkyl, optionally substituted with one or more halogen, perhalomethyl, hydroxy, nitro or cyano or R5 forms a bond together with R6,
R6 represents hydrogen, hydroxy, halogen, C, 12-alkoxy, C, 12-alkyl, C4 12-alkenynyl, C2 12- alkenyl, C2 12-alkynyl, acyl or arylalkyl optionally substituted with one or more halogen, perhalomethyl, hydroxy, nitro or cyano or R6 forms a bond together with R5,
M represents OR7, where R7 represents hydrogen, C, 12-alkyl, C4 12-alkenynyl, C2 12-alkenyl, C2 12-alkynyl, aryl, arylalkyl, C, ^-alkoxyC, 12-alkyl, C, 12-alkoxycarbonyl, aryloxycarbonyl, C, 12-alkylamιnocarbonyl, arylammocarbonyl, acyl, heterocyclyl, heteroaryl or heteroarylalkyl groups optionally substituted with one or more halogen, perhalomethyl, hydroxy, nitro or cyano or M represents COYR8,
R8 represents hydrogen, C, 12alkyl, C4 12-alkenynyl, C2 12-alkenyl, C2 12-alkynyl, aryl, arylalkyl, heterocyclyl, heteroaryl or heteroarylalkyl groups optionally substituted with one or more halogen, perhalomethyl, hydroxy, nitro or cyano,
Y represents oxygen, sulphur or NR10, where R10 represents hydrogen, C^^-alkyl, aryl, hy- droxyC, 12-alkyl or arylalkyl groups or when Y is NR10, R8 and R10 may form a 5 or 6 membered nitrogen containing ring, optionally substituted with one or more C, 6-alkyl,
k is an integer ranging from 1 to 2, n is an integer ranging from 0 to 3 and m is an integer ranging from 0 to 1 ,
or a salt thereof with a pharmaceutically acceptable acid or base, or any optical isomer or mixture of optical isomers, including a racemic mixture, or any tautomeπc forms
In a preferred embodiment, the present invention is concerned with compounds of formula I wherein A1 and A2 are independently of each other a 5-6 membered cyclic ring or a 9-10 membered bicyclic ring, optionally substituted with one or more halogen, perhalomethyl, hydroxy, C1 6-alkyl, (Ca-e-cycloalky C, 6-alkyl, C4 6-alkenynyl, C2 6-alkenyl, C2 6-alkynyl, C^-alkoxy, aryl, aryloxy, arylalkyl, arylalkoxy, heterocyclyl, heteroaryl, heteroarylalkyl, heteroaryloxy, heteroarylalkoxy, acyl, hydroxyC-, 6-alkyl, C, 6-alkyl-amιno, C, 6-dιalkylamιπo, arylamino, arylalkylammo, aminoC, 6-alkyl, C, 6- alkoxycarbonyl, alkylammocarbonyl, aryloxycarbonyl, arylalkoxycarbonyl C, 6- alkoxyC, 6-alkyl aryloxyC, 6-alkyl, or arylalkoxyC, 6-alkyl
In another preferred embodiment, the present invention is concerned with compounds of formula I wherein A1 and A2 are independently of each other a 5-6 membered cyclic ring or a 9-10 membered bicychc ring, optionally substituted with one or more halogen, perhalomethyl, hydroxy, C, 6-alkyl,
Figure imgf000008_0001
C4 6-alkenynyl, C2 6-alkenyl, C2 6-alkynyl, C1 6-alkoxy, aryl, aryloxy, arylalkyl, arylalkoxy, heterocyclyl, heteroaryl, heteroarylalkyl, heteroaryloxy, heteroarylalkoxy, acyl, hydroxyC, 6-alkyl, C, 6-alkyl-amιno, C, 6-dιalkylamιno, arylamino, arylalkylammo, aminoC, 6-alkyl, C, g-alkoxyC, 6-alkyl, aryloxyC, 6-alkyl, or arylalkoxyC, 6-alkyl
In another preferred embodiment, the present invention is concerned with compounds of formula I wherein A1 and A2 are independently of each other a 5-6 membered cyclic ring or a 9-10 membered bicychc ring, optionally substituted with one or more halogen, C, 6-alkyl, C, 6-alkoxy, or aryl
In another preferred embodiment, the present invention is concerned with compounds of formula I wherein A1 and A2 are independently of each other a 5-6 membered cyclic ring optionally substituted with one or more halogen, C, 6-alkyl, C, 6-alkoxy, or aryl
In another preferred embodiment, the present invention is concerned with compounds of formula I wherein Z is a carbon atom at the end of a double bond, or Z is CR3, wherein R3 is hydrogen, halogen, perhalomethyl, C, 12-alkyl, C^2- alkenynyl, C2 12-alkenyl, C2 12-alkynyl, C, 12-alkoxy, aryloxy, arylalkoxy, heteroaryloxy, heteroarylalkoxy, acyl, acyloxy, hydroxyCL^-alkyl, C, ,2-alkoxyC, 12-alkyl, aryloxyC, ,2-alkyl, arylalkoxyC, 12-alkyl, thioC, 12-alkyl, -COR4, or -SO2R11, wherein R4 and R11 independently of each other are selected from hydroxy, halogen, perhalomethyl, C, 6-alkoxy or ammo optionally substituted with one or more C, 6-alkyl, perhalomethyl or aryl optionally substituted with one or more halogen, perhalomethyl, hydroxy, nitro or cyano In another preferred embodiment the present invention is concerned with compounds of formula I wherein Z is a carbon atom at the end of a double bond, or Z is CR3, wherein R3 is hydrogen, halogen, perhalomethyl, C,.6-alkyl, C4.6-alkenynyl, C2 6-alkenyl, C2 6-alkynyl, C,.6-alkoxy, aryloxy, arylalkoxy, heteroaryloxy, heteroarylalkoxy, acyl, acyloxy, hydroxyC,.6-alkyl, C^-alkoxyC^-alkyl, aryloxyC, 6- alkyl, arylalkoxyC,.6-alkyl, thioC, 6-alkyl, -COR4, or -SO2R11, wherein R4 and R1 independently of each other are selected from hydroxy, halogen, perhalomethyl, C,. 6-alkoxy or ammo optionally substituted with one or more C,.6-alkyl, perhalomethyl or aryl optionally substituted with one or more halogen, perhalomethyl, hydroxy, nitro or cyano
In another preferred embodiment, the present invention is concerned with compounds of formula I wherein Z is a carbon atom at the end of a double bond, or Z is CR3, wherein R3 is hydrogen, halogen, perhalomethyl, C,.6-alkyl, C4.6-alkenynyl, C2.6-alkenyl, C2.6-alkynyl, C,.6-alkoxy, aryloxy, arylalkoxy, heteroaryloxy, heteroarylalkoxy, C^-alkoxyC^-alkyl, aryloxyC,.6-alkyl, or arylalkoxyC,.6-alkyl
In another preferred embodiment, the present invention is concerned with compounds of formula I wherein Z is a carbon atom at the end of a double bond, or Z is CR3, wherein R3 is hydrogen
In another preferred embodiment, the present invention is concerned with compounds of formula I wherein Q is O, S, or NR12, wherein R12 is hydrogen, perhalomethyl, C,.6-alkyl, C4.6-alkenynyl, C2.6-alkenyl, C2.6-alkynyl, aryl, arylalkyl, heterocyclyl, heteroaryl, heteroarylalkyl, acyl, hydroxyC,.6-alkyl, amιnoC,.6-alkyl, C,.6- alkoxycarbonyl, aryloxycarbonyl, arylalkoxycarbonyl, C,.6-alkoxyCι_6-alkyl, aryloxyC,, 6-alkyl, arylalkoxyC,.6-alkyl, thioC,.6-alkyl, -COR13, or -SO2R14, wherein R13 and R14 independently of each other are selected from hydroxy, perhalomethyl, C,.6-alkoxy or ammo optionally substituted with one or more C,.6-alkyl, perhalomethyl or aryl optionally substituted with one or more halogen, or perhalomethyl.
In another preferred embodiment, the present invention is concerned with compounds of formula I wherein Q is O, S or NR12, wherein R12 is hydrogen, perhalomethyl, C,.6-alkyl, aryl, arylalkyl, heteroarylalkyl, or acyl In another preferred embodiment, the present invention is concerned with compounds of formula I wherein Q is O or S.
In another preferred embodiment, the present invention is concerned with compounds of formula I wherein Q is O.
In another preferred embodiment, the present invention is concerned with compounds of formula I wherein Ar represents arylene or heteroarylene, or a divalent heterocyclic group each of which can optionally be substituted with one or more halogen, C,.6-alkyl or C,.6-alkoxy.
In another preferred embodiment, the present invention is concerned with compounds of formula I wherein Ar represents arylene, or heteroarylene.
In another preferred embodiment, the present invention is concerned with compounds of formula I wherein Ar represents arylene.
In another preferred embodiment, the present invention is concerned with compounds of for- mula I wherein R5 represents hydrogen, hydroxy, halogen, C,.6-alkoxy, C,-6-alkyl, C^- alkenynyl, C2.6-alkenyl, C2.6-alkynyl or arylalkyl optionally substituted with one or more halogen, or perhalomethyl or R5 forms a bond together with R6.
In another preferred embodiment, the present invention is concerned with compounds of formula I wherein R5 represents hydrogen, halogen, C,_6-alkoxy, C,.6-alkyi, or perhalomethyl or R5 forms a bond together with R6.
In another preferred embodiment, the present invention is concerned with compounds of formula I wherein R5 represents hydrogen, halogen or R5 forms a bond together with R6.
In another preferred embodiment, the present invention is concerned with compounds of formula I wherein R5 represents hydrogen. In another preferred embodiment, the present invention is concerned with compounds of formula I wherein R6 represents hydrogen, C,.6-alkoxy, C,-6-alkyl, C4.6-alkenynyl, C2.6-alkenyl, C2. 6-alkynyl, acyl or arylalkyl optionally substituted with one or more halogen or perhalomethyl or R6 forms a bond together with R5.
In another preferred embodiment, the present invention is concerned with compounds of formula I wherein R6 represents hydrogen, halogen, C,.6-alkoxy, or R6 forms a bond together with R5.
In another preferred embodiment, the present invention is concerned with compounds of formula I wherein R6 represents hydrogen, C,.6-alkoxy, or R6 forms a bond together with R5.
In another preferred embodiment, the present invention is concerned with compounds of formula I wherein R6 represents hydrogen.
In another preferred embodiment, the present invention is concerned with compounds of formula I wherein M represents OR7, where R7 represents hydrogen, C,.6-alkyl, C4.6-alkenynyl, C2.6-alkenyl, C2.6-alkynyl, aryl, arylalkyl, Ci-e-alkoxyCLg-alkyl, C,.6-alkoxycarbonyl, aryloxycarbonyl, C,.6-alkylaminocarbonyl, arylaminocarbonyl, acyl, heterocyclyl, heteroaryl or heteroarylalkyl groups optionally substituted with one or more halogen, perhalomethyl, hydroxy, nitro or cyano.
In another preferred embodiment, the present invention is concerned with compounds of formula I wherein M represents OR7, where R7 represents hydrogen, C,.6-alkyl, C^- alkenynyl, C2.6-alkenyl, C2.6-alkynyl, aryl, arylalkyl, C,-6-alkoxyC,.6-alkyl, heterocyclyl, heteroaryl or heteroarylalkyl groups optionally substituted with one or more halogen, or perhalomethyl.
In another preferred embodiment, the present invention is concerned with compounds of for- mula I wherein M represents OR7, where R7 represents C,.6-alkyl, or M represents COYR8.
In another preferred embodiment, the present invention is concerned with compounds of formula I wherein M represents OR7, where R7 represents ethyl, or M represents COYR8. In another preferred embodiment, the present invention is concerned with compounds of formula I wherein R8 represents hydrogen, C1 6alkyl, C4 6-alkenynyl, C26-alkenyl, C2 6-alkynyl, aryl, arylalkyl, heterocyclyl, heteroaryl or heteroarylalkyl groups optionally substituted with one or more halogen, perhalomethyl, hydroxy, nitro or cyano
In another preferred embodiment, the present invention is concerned with compounds of formula I wherein R8 represents hydrogen, C, 6alkyl, C4 6-aikenynyl, C2 6-alkenyl, C2 6-alkynyl, aryl, arylalkyl, heterocyclyl, heteroaryl or heteroarylalkyl groups optionally substituted with one or more halogen, or perhalomethyl
In another preferred embodiment, the present invention is concerned with compounds of formula I wherein R8 represents hydrogen or C, 6alkyl
In another preferred embodiment, the present invention is concerned with compounds of formula I wherein R8 represents hydrogen, methyl or ethyl
In another preferred embodiment, the present invention is concerned with compounds of formula I wherein Y represents oxygen, sulphur or NR10, where R10 represents hydrogen, C, 6-alkyl, aryl, hydroxyC, 6-alkyl or arylalkyl groups or when Y is NR10, R8 and R10 may form a 5 or 6 membered nitrogen containing ring, optionally substituted with one or more C1-6-alkyl
In another preferred embodiment, the present invention is concerned with compounds of formula I wherein Y represents oxygen, or NR10, where R10 represents hydrogen, C, 6-alkyl, aryl, or arylalkyl groups, or when Y is NR10, R8 and R10 may form a 5 or 6 membered nitrogen containing ring, optionally substituted with one or more C,.6-alkyl
In another preferred embodiment, the present invention is concerned with compounds of formula I wherein Y represents oxygen
In another preferred embodiment, the present invention is concerned with compounds of formula I wherein k is an integer ranging from 1 to 2
In another preferred embodiment, the present invention is concerned with compounds of formula I wherein n and m are 1 Preferred compounds of the invention are:
2-Ethoxy-3-{4-[3-phenyl-3-(4-methylphenyl)-allyloxy]-phenyl}-propionic acid ethyl ester, 2-Ethoxy-3-{4-[3-phenyl-3-(4-methylphenyl)-allyloxy]-phenyl}-propionic acid,
3-{4-[3-(2-Chloro-phenyl)-3-phenyl-allyloxy]-phenyl}-2-ethoxy-propionic acid ethyl ester, 3-{4-[3-(2-Chloro-phenyl)-3-phenyl-allyloxy]-phenyl}-2-ethoxy-propionic acid, 3-{4-[3,3-Bis-(4-methoxy-phenyl)-allyloxy]-phenyl}-2-ethoxy-propionic acid ethyl ester, 3-{4-[3,3-Bis-(4-methoxy-phenyl)-allyloxy]-phenyl}-2-ethoxy-propionic acid, 3-{4-[3-Phenyl-3-(biphenyl-4-yl)-allyloxy]-phenyl}-2-ethoxy-propionic acid ethyl ester, 3-{4-[3-Phenyl-3-(biphenyl-4-yl)-allyloxy]-phenyl}-2-ethoxy-propionic acid, 2-Ethoxy-3-{4-[3-phenyl-3-(thiophen-2-yl)-allyloxy]-phenyl}-propionic acid ethyl ester, 2-Ethoxy-3-{4-[3-phenyl-3-(thiophen-2-yl)-allyloxy]-phenyl}-propionic acid, 2-Ethoxy-3-{4-[3-phenyl-3-(pyridin-2-yl)-allyloxy]-phenyl}-propionic acid ethyl ester, 2-Ethoxy-3-{4-[3-phenyl-3-(pyridin-2-yl)-allyloxy]-phenyl}-propionic acid, 3-[4-(3, 3-Diphenyl-propoxy)-phenyl]-2-ethoxy-propionic acid ethyl ester, 3-[4-(3,3-Diphenyl-propoxy)-phenyl]-2-ethoxy-propionic acid,
2-Ethoxy-3-{4-[3-phenyl-3-(4-methylphenyl)-propoxy]-phenyl}-propionic acid ethyl ester, 2-Ethoxy-3-{4-[3-phenyl-3-(4-methylphenyl)-propoxy]-phenyl}-propionic acid, 3-{4-[3-Phenyl-3-(biphenyl-4-yl)-propoxy]-phenyl}-2-ethoxy-propionic acid ethyl ester, 3-{4-[3-Phenyl-3-(biphenyl-4-yl)-propoxy]-phenyl}-2-ethoxy-propionic acid, 2-{4-[3,3-Bis-(4-methoxy-phenyl)-allyioxy]-benzyl}-malonic acid dimethyl ester, (E)-(2S)-2-Ethoxy-3-{4-[3-(4-furan-2-yl-phenyl)-3-phenyl-allyloxy]-phenyl}-propionic acid ethyl ester, (£)-(2S)-2-Ethoxy-3-{4-[3-(4-furan-2-yl-phenyl)-3-phenyl-allyloxy]-phenyl}-propionic acid, (£)-(2S)-3-[4-(3-Biphenyl-4-yl-3-phenyl-allyloxy)-phenyl]-2-ethoxy-propionic acid ethyl ester, (£)-(2S)-3-[4-(3-Biphenyl-4-yl-3-phenyl-allyloxy)-phenyl]-2-ethoxy-propionic acid, (£, Z)-(2S)-3-[4-(3-Biphenyl-4-yl-3-phenyl-allyloxy)-phenyl]-2-ethoxy-propionic acid ethyl ester, (E, Z)-(2S)-3-[4-(3-Biphenyl-4-yl-3-phenyl-allyloxy)-phenyl]-2-ethoxy-propionic acid,
3-{4-[3,3-Bis-(3-methyl-thiophen-2-yl)-allyloxy]-phenyl}-2-ethoxy-propionic acid ethyl ester, 3-{4-[3,3-Bis-(4-bromo-phenyl)-allyloxy]-phenyl}-2-ethoxy-propionic acid ethyl ester, 3-{4-[3,3-Bis-(4-bromo-phenyl)-allyloxy]-phenyl}-2-ethoxy-propionic acid, 2-Ethoxy-3-[4-(3-phenyl-3-pyridin-4-yl-allyloxy)-phenyl]-propionic acid ethyl ester, 2-Ethoxy-3-[4-(3-phenyl-3-pyrιdιn-4-yl-allyloxy)-phenyl]-propιonιc acιd, (E, Z)-(2S)-2-Ethoxy-3-{4-[3-(4-methoxyphenyl)-3-thιophen-2-yl-allyloxy]-phenyl}-propιonιc acid ethyl ester,
(£, Z)-(2S)-2-Ethoxy-3-{4-[3-(4-methoxyphenyl)-3-thιophen-2-yl-allyloxy]-phenyl}-propιonιc acid,
(E, Z)-(2S)-2-Ethoxy-3-[4-(3-phenyl-3-p-tolyl-allyloxy)-phenyl]-propιonιc acid ethyl ester, (£, Z)-(2S)-2-Ethoxy-3-[4-(3-phenyl-3-p-tolyl-allyloxy)-phenyl]-propιonιc acιd, (2S)-3-[4-(3,3-Dιphenyl-allyloxy)-phenyl]-2-ethoxy-propιonιc acid ethyl ester, (2S)-3-[4-(3,3-Dιphenyl-allyloxy)-phenyl]-2-ethoxy-propιonιc acιd, (Z)-(2S)-2-Ethoxy-3-{4-[3-(4-fluorophenyl)-3-phenyl-allyloxy]-phenyl}-propιonιc acid ethyl ester,
(Z)-(2S)-2-Ethoxy-3-{4-[3-(4-fluorophenyl)-3-phenyl-allyloxy]-phenyl}-propιonιc acid, (E)-(2S)-2-Ethoxy-3-{4-[3-(4-fluorophenyl)-3-phenyl-allyloxy]-phenyl}-propιonιc acid ethyl ester, (£)-(2S)-2-Ethoxy-3-{4-[3-(4-fluorophenyl)-3-phenyl-allyloxy]-phenyl}-propιonιc acid,
(2S)-3-{4-[3,3-Bιs-(4-methoxyphenyl)-allyloxy]-phenyl}-2-ethoxy-propιonιc acid ethyl ester, (2S)-3-{4-[3,3-Bιs-(4-methoxyphenyl)-allyloxy]-phenyl}-2-ethoxy-propιonιc acid, (2S)-3-[4-(3,3-Dι-p-tolyl-allyloxy)-phenyl]-2-ethoxy-propιonιc acid ethyl ester, (2S)-3-[4-(3,3-Dι-p-tolyl-allyloxy)-phenyl]-2-ethoxy-propιonιc acid, (Z)-(2S)-3-[4-(3-Bιphenyl-4-yl-3-phenyl-allyloxy)-phenyl]-2-ethoxy-propιonιc acid,
(Z)-(2S)-3-{4-[3-(4-Bromophenyl)-3-phenyl-allyloxy]-phenyl}-2-ethoxy-propιonιc acid ethyl ester,
(Z)-(2S)-3-{4-[3-(4-Bromophenyl)-3-phenyl-allyloxy]-phenyl}-2-ethoxy-propιonιc acιd, (2S)-3-[4-(3,3-Bιs-bιphenyl-4-yl-allyloxy)-phenyl]-2-ethoxy-propιonιc acid ethyl ester, (2S)-3-[4-(3,3-Bιs-bιphenyl-4-yl-allyloxy)-phenyl]-2-ethoxy-propιonιc acιd,
(2S)-3-{4-[3,3-Bιs-(4-bromophenyl)-allyloxy]-phenyl}-2-ethoxy-propιonιc acid ethyl ester, (2S)-3-{4-[3,3-Bιs-(4-bromophenyl)-allyloxy]-phenyl}-2-ethoxy-propιonιc acid, (Z)-(2S)-2-Ethoxy-3-{4-[3-(4-furan-2-yl-phenyl)-3-phenyl-allyloxy]-phenyl}-propιonιc acιd ethyl ester, (Z)-(2S)-2-Ethoxy-3-{4-[3-(4-furan-2-yl-phenyl)-3-phenyl-allyloxy]-phenyl}-propιonιc acιd, (£)-(2S)-3-{4-[3-(4-Bromophenyl)-3-phenyl-allyloxy]-phenyl}-2-ethoxy-propιonιc acid ethyl ester,
(£)-(2S)-3-{4-[3-(4-Bromophenyl)-3-phenyl-allyloxy]-phenyl}-2-ethoxy-propιonιc acιd, (2S)-3-{4-[3,3-Bιs-(4-furan-2-yl-phenyl)-allyloxy]-phenyl}-2-ethoxy-propιonιc acιd ethyl ester, (2S)-3-{4-[3,3-Bis-(4-furan-2-yl-phenyl)-allyloxy]-phenyl}-2-ethoxy-propionic acid, (E, Z)-(2S)-3-[4-(3-Biphenyl-4-yl-3-p-tolyl-allyloxy)-phenyl]-2-ethoxy-propionic acid ethyl ester, (£, Z)-(2S)-3-[4-(3-Biphenyl-4-yl-3-p-tolyl-allyloxy)-phenyl]-2-ethoxy-propionic acid,
(£, Z)-(2R)- 3-[4-(3-Biphenyl-4-yl-3-phenyl-allyloxy)-phenyl]-2-ethoxy-propionic acid ethyl ester; or a salt thereof with a pharmaceutically acceptable acid or base, or any optical isomer or mixture of optical isomers, including a racemic mixture, or any tautomeric forms.
In the above structural formulas and throughout the present specification, the following terms have the indicated meaning:
The term "C,.n-alkyl" wherein n' can be from 2 through 12, as used herein, represents a branched or straight or cyclic alkyl group having from one to the specified number of carbon atoms. Examples of such groups include, but are not limited to methyl, ethyl, n-propyl, iso- propyl, butyl, iso-butyl, sec-butyl, tert-butyl, pentyl, hexyl and the like and cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl and the like.
The terms "C2_n-alkenyl" wherein n' can be from 3 through 15, as used herein, represents an olefinically unsaturated branched or straight hydrocarbon group having from 2 to the specified number of carbon atoms and at least one double bond. Examples of such groups include, but are not limited to, vinyl, 1-propenyl, 2-propenyl, allyl, iso-proppenyl, 1 ,3-butadienyl, 1-butenyl, hexenyl, pentenyl and the like.
The terms "C2.n-alkynyl" wherein n' can be from 3 through 15, as used herein, represents an unsaturated branched or straight hydrocarbon group having from 2 to the specified number of carbon atoms and at least one triple bond. Examples of such groups include, but are not limited to, 1-propynyl, 2-propynyl, 1-butynyl, 2-butynyl, 1-pentynyl, 2-pentynyl and the like.
The terms "C4.n-alkenynyl" wherein n' can be from 5 through 15, as used herein, represent an unsaturated branched or straight hydrocarbon group having from 4 to the specified number of carbon atoms and both at least one double bond and at least one triple bond. Examples of such groups include, but are not limited to, 1-penten-4-yne, 3-penten-1-yne, 1 ,3- hexadiene-5-yne and the like. The term "C,.,2-alkoxy" as used herein, alone or in combination is intended to include those C,_ ι2-alkyl groups of the designated length in either a linear or branched or cyclic configuration linked through an ether oxygen having its free valence bond from the ether oxygen. Examples of linear alkoxy groups are methoxy, ethoxy, propoxy, butoxy, pentoxy, hexoxy and the like. Examples of branched alkoxy are isopropoxy, sec-butoxy, tert-butoxy, isopentoxy, isohexoxy and the like. Examples of cyclic alkoxy are cyclopropyloxy, cyclobutyloxy, cyclopentyloxy, cyclohexyloxy and the like.
The term "C,.,2-alkylthio" as used herein, alone or in combination, refers to a straight or branched or cyclic monovalent substituent comprising a C,.12-alkyl group linked through a divalent sulfur atom having its free valence bond from the sulfur atom and having 1 to 12 carbon atoms e.g. methylthio, ethylthio, propylthio, butylthio, pentylthio and the like. Examples of cyclic alkylthio are cyclopropylthio, cyclobutylthio, cyclopentylthio, cyclohexylthio and the like.
The term "C,.,2-alkylamino" as used herein, alone or in combination, refers to a straight or branched or cyclic monovalent substituent comprising a C,.,2-alkyl group linked through amino having a free valence bond from the nitrogen atom e.g. methylamino, ethylamino, propylamino, butylamino, pentylamino and the like. Examples of cyclic alkylamino are cyclopropylamino, cyclobutylamino, cyclopentylamino, cyclohexylamino and the like.
The term "hydroxyC ^-alkyl" as used herein, alone or in combination, refers to a C,.,2-alkyl as defined herein whereto is attached a hydroxy group, e.g. hydroxyethyl, 1-hydroxypropyl, 2-hydroxypropyl and the like.
The term "arylamino" as used herein, alone or in combination, refers to an aryl as defined herein linked through amino having a free valence bond from the nitrogen atom e.g. phenylamino, naphthylamino and the like.
The term "arylalkylamino" as used herein, alone or in combination, refers to an arylalkyl as defined herein linked through amino having a free valence bond from the nitrogen atom e.g. benzylamino, phenethylamino, 3-phenylpropylamino, 1-naphthylmethylamino, 2-(1- naphthyl)ethylamino and the like. The term "aminoC,.,2-alkyl" as used herein, alone or in combination, refers to a C,.12-alkyl as defined herein whereto is attached an amino group, e.g. aminoethyl, 1-aminopropyl, 2- aminopropyl and the like.
The term "aryloxycarbonyl" as used herein, alone or in combination, refers to an aryloxy as defined herein linked through a carbonyl having a free valence bond from the carbon atom, e.g. phenoxycarbonyl, 1-naphthyloxycarbonyl or 2-naphthyloxycarbonyl and the like.
The term "arylalkoxycarbonyl" as used herein, alone or in combination, refers to an arylalkoxy as defined herein linked through a carbonyl having a free valence bond from the carbon atom, e.g. benzyloxycarbonyl, phenethoxycarbonyl, 3-phenylpropoxycarbonyl, 1- naphthylmethoxycarbonyl, 2-(1-naphthyl)ethoxycarbonyl and the like.
The term "C,-ι2-alkoxyC,.ι2-alkyl" as used herein, alone or in combination, refers to a C,.,2- alkyl as defined herein whereto is attached a C,.,2-alkoxy as defined herein, e.g. methoxymethyl, ethoxymethyl, methoxyethyl, ethoxyethyl and the like.
The term "aryloxyC,.,2-alkyl" as used herein, alone or in combination, refers to a C,.,2-alkyl as defined herein whereto is attached an aryloxy as defined herein, e.g. phenoxymethyl, phenoxydodecyl, 1-naphthyloxyethyl, 2-naphthyloxypropyi and the like.
The term "arylalkoxyC,.12-alkyl" as used herein, alone or in combination, refers to a C,-,2-alkyl as defined herein whereto is attached an arylalkoxy as defined herein, e.g. benzyloxymethyl, phenethoxydodecyl, 3-phenylpropoxyethyl, 1-naphthylmethoxypropyl, 2-(1- naphthyl)ethoxymethyl and the like.
The term "thioC,.12-alkyl" as used herein, alone or in combination, refers to a C,.,2-alkyl as defined herein whereto is attached a group of formula -SR'" wherein R'" is hydrogen, C,.6- alkyl or aryl, e.g. thiomethyl, methylthiomethyl, phenylthioethyl and the like.
The term "C,.,2-alkoxycarbonylamino" as used herein, alone or in combination, refers to a C,_ i2-alkoxycarbonyl as defined herein linked through amino having a free valence bond from the nitrogen atom e g methoxycarbonylamino, carbethoxyamino, propoxycarbonylamino, isopropoxycarbonylammo, n-butoxycarbonylammo, tert-butoxycarbonylammo and the like
The term "aryloxycarbonylamino" as used herein, alone or in combination, refers to an aryloxycarbonyl as defined herein linked through ammo having a free valence bond from the nitrogen atom e g phenoxycarbonylamino, 1-naphthyloxycarbonylamιno or 2- naphthyloxycarbonylamino and the like
The term "arylalkoxycarbonylamino" as used herein, alone or in combination, refers to an arylalkoxycarbonyl as defined herein linked through ammo having a free valence bond from the nitrogen atom e g benzyloxycarbonylamino, phenethoxycarbonylamino, 3- phenylpropoxycarbonylamino, 1 -naphthylmethoxycarbonylamino, 2-(1 - naphthyl)ethoxycarbonylamιno and the like
The term "aryl" is intended to include aromatic rings, such as carboxylic aromatic rings selected from the group consisting of phenyl, naphthyl, (1-naphthyl or 2-naphthyl) and the like optionally substituted with halogen, ammo, hydroxy, C, 6-alkyl or C, 6-alkoxy and the like
The term "arylene" is intended to include divalent aromatic rings, such as carboxylic aromatic rings selected from the group consisting of phenylene, naphthylene and the like optionally substituted with halogen, am o, hydroxy, C, 6-alkyl or C, 6-alkoxy and the like
The term "halogen" means fluorine, chlorine, bromine or iodine
The term "perhalomethyl" means tπfluoromethyl, tπchloromethyl, tπbromomethyl or triiodomethyl
The term "C, 6-dιalkylamιno" as used herein refers to an ammo group wherein the two hydrogen atoms independently are substituted with a straight or branched, saturated hydrocarbon chain having the indicated number of carbon atoms, such as dimethylammo, N- ethyl-N-methylamino, diethylammo, dipropylamino, N-(n-butyl)-N-methylamιno, dι(n- pentyl)amιno and the like The term "acyl" as used herein refers to a monovalent substituent comprising a C,.6-alkyl group linked through a carbonyl group; such as e.g. acetyl, propionyl, butyryl, isobutyryl, pivaloyl, valeryl and the like.
The term "acyloxy" as used herein refers to acyl as defined herein linked to an oxygen atom having its free valence bond from the oxygen atom e.g. acetyloxy, propionyloxy, butyryloxy, isobutyryloxy, pivaloyloxy, valeryloxy and the like.
The term "C,.12-alkoxycarbonyl" as used herein refers to a monovalent substituent comprising a C^^-alkoxy group linked through a carbonyl group; such as e.g. methoxycarbonyl, carbethoxy, propoxycarbonyl, isopropoxycarbonyl, n-butoxycarbonyl, sec- butoxycarbonyl, tert-butoxycarbonyl, 3-methylbutoxycarbonyl, n-hexoxycarbonyl and the like.
The term "heteroaryl" as used herein, alone or in combination, refers to a monovalent substituent comprising a 5-6 membered monocyclic aromatic system or a 9-10 membered bicyclic aromatic system containing one or more heteroatoms selected from nitrogen, oxygen and sulfur, e.g. furan, thiophene, pyrrole, imidazole, pyrazole, triazole, pyridine, pyrazine, pyrimidine, pyridazine, isothiazole, isoxazole, oxazole, oxadiazole, thiadiazole, quinoline, isoquinoline, quinazoiine, quinoxaline, indole, benzimidazole, benzofuran, pteridine and purine and the like.
The term "heteroarylene" as used herein, alone or in combination, refers to a divalent group comprising a 5-6 membered monocyclic aromatic system or a 9-10 membered bicyclic aromatic system containing one or more heteroatoms selected from nitrogen, oxygen and sulfur, e.g. furan, thiophene, pyrrole, imidazole, pyrazole, triazole, pyridine, pyrazine, pyrimidine, pyridazine, isothiazole, isoxazole, oxazole, oxadiazole, thiadiazole, quinoline, isoquinoline, quinazoiine, quinoxaline, indole, benzimidazole, benzofuran, pteridine and purine and the like.
The term "heteroaryloxy" as used herein, alone or in combination, refers to a heteroaryl as defined herein linked to an oxygen atom having its free valence bond from the oxygen atom e.g. pyrrole, imidazole, pyrazole, triazole, pyridine, pyrazine, pyrimidine, pyridazine, isothiazole, isoxazole, oxazole, oxadiazole, thiadiazole, quinoline, isoquinoline, quinazoiine, quinoxaline, indole, benzimidazole, benzofuran, pteridine and purine linked to oxygen, and the like.
The term "arylalkyl" as used herein refers to a straight or branched saturated carbon chain containing from 1 to 6 carbons substituted with an aromatic carbohydride; such as benzyl, phenethyl, 3-phenylpropyl, 1-naphthylmethyl, 2-(1-naphthyl)ethyl and the like.
The term "aryloxy" as used herein refers to phenoxy, 1-naphthyloxy, 2-naphthyloxy and the like.
The term "arylalkoxy" as used herein refers to a C,.6-alkoxy group substituted with an aromatic carbohydride, such as benzyloxy, phenethoxy, 3-phenylpropoxy, 1- naphthylmethoxy, 2-(1-naphthyl)ethoxy and the like.
The term "heteroarylalkyl" as used herein refers to a straight or branched saturated carbon chain containing from 1 to 6 carbons substituted with a heteroaryl group; such as (2- furyl)methyl, (3-furyl)methyl, (2-thienyl)methyl, (3-thienyl)methyl, (2-pyridyl)methyl, 1-methyl- 1-(2-pyrimidyl)ethyl and the like.
The term "heteroarylalkoxy" as used herein refers to a heteroarylalkyl as defined herein linked to an oxygen atom having its free valence bond from the oxygen atom, e.g. (2- furyl)methyl, (3-furyl)methyl, (2-thienyl)methyl, (3-thienyl)methyl, (2-pyridyl)methyl, 1-methyl- 1-(2-pyrimidyl)ethyl linked to oxygen, and the like.
The term "acylamino" as used herein refers to an amino group wherein one of the hydrogen atoms is substituted with an acyl group, such as e.g. acetamido, propionamido, isopropylcar- bonylamino and the like.
The term "(C3-6-cycloalkyl)C,.6-alkyl" as used herein, alone or in combination, refers to a straight or branched, saturated hydrocarbon chain having 1 to 6 carbon atoms and being monosubsti- tuted with a C3-6-cycloalkyl group, the cycloalkyl group optionally being mono- or polysubsti- tuted with C,.6-alkyl, halogen, hydroxy or C,.6-alkoxy; such as e.g. cyclopropylmethyl, (1- methylcyclopropyl)methyl, 1-(cyclopropyl)ethyl, cyclopentylmethyl, cyclohexylmethyl and the like. The term "arylthio" as used herein, alone or in combination, refers to an aryl group linked through a divalent sulfur atom having its free valence bond from the sulfur atom, the aryl group optionally being mono- or polysubstituted with C,.6-alkyl, halogen, hydroxy or C,.6-alkoxy; e.g. phenylthio, (4-methylphenyl)- thio, (2-chlorophenyl)thio and the like.
The term "C,.6-alkylaminocarbonyl" as used herein refers to a monovalent substituent comprising a C,_6-monoalkylamino group linked through a carbonyl group such as e.g. methylamino- carbonyl, ethylaminocarbonyl, n-propylaminocarbonyl, isopropylaminocarbonyl, n- butylaminocarbonyl, sec-butylaminocarbonyl, isobutylaminocarbonyl, tert-butylaminocarbonyl, n-pentylaminocarbonyl, 2-methylbutylaminocarbonyl, 3-methylbutylaminocarbonyl, n- hexylaminocarbonyl, 4-methylpentylaminocarbonyl, neopentylaminocarbonyl, n- hexylaminocarbonyl and 2-2-dimethylpropylaminocarbonyl and the like.
As used herein, the phrase "heterocyclyl" means a monovalent saturated or unsaturated non aromatic group being monocyclic and containing one or more, such as from one to four carbon atom(s), and from one to four N, O or S atom(s) or a combination thereof. The phrase "heterocyclyl" includes, but is not limited to, 5-membered heterocycles having one hetero atom (e.g. pyrrolidine, pyrroline and the like); 5-membered heterocycles having two heteroa- toms in 1 ,2 or 1 ,3 positions (e.g. pyrazoline, pyrazolidine, 1 ,2-oxathiolane, imidazolidine, imi- dazoline, 4-oxazolone and the like); 5-membered heterocycles having three heteroatoms (e.g. tetrahydrofurazan and the like); 5-membered heterocycles having four heteroatoms; 6- membered heterocycles with one heteroatom (e.g. piperidine and the like); 6-membered heterocycles with two heteroatoms (e.g. piperazine, morpholine and the like); 6-membered het- erocycles with three heteroatoms; and 6-membered heterocycles with four heteroatoms, and the like.
As used herein, the phrase "a divalent heterocyclic group" means a divalent saturated or unsaturated system being monocyclic and containing one or more, such as from one to four carbon atom(s), and one to four N, O or S atom(s) or a combination thereof. The phrase a divalent heterocyclic group includes, but is not limited to, 5-membered heterocycles having one hetero atom (e.g. pyrrolidine, pyrroline and the like); 5-membered heterocycles having two heteroatoms in 1 ,2 or 1 ,3 positions (e.g. pyrazoline, pyrazolidine, 1 ,2-oxathiolane, imidazolidine, imidazoline, 4-oxazolone and the like); 5-membered heterocycles having three het- eroatoms (e.g. tetrahydrofurazan and the like); 5-membered heterocycles having four heteroatoms; 6-membered heterocycles with one heteroatom (e.g. piperidine and the like); 6- membered heterocycles with two heteroatoms (e.g. piperazine, morphoiine and the like); 6- membered heterocycles with three heteroatoms; and 6-membered heterocycles with four heteroatoms, and the like.
As used herein, the phrase "a 5-6 membered cyclic ring" means an unsaturated or saturated or aromatic system containing one or more carbon atoms and optionally from one to four N, O or S atom(s) or a combination thereof. The phrase "a 5-6 membered cyclic ring" includes, but is not limited to, e.g. cyclopentyl, cyclohexyl, phenyl, cyclohexenyl, pyrrolidinyl, pyrrolinyl, imidazolidinyl, pyrazolidinyl, pyrazolinyl, piperidyl, piperazinyl, pyrrolyl, 2H-pyrrolyl, imidazolyl, pyrazolyl, triazolyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, morpholinyl, thiomorpholinyl, isothiazolyl, isoxazolyl, oxazolyl, oxadiazolyl, thiadiazolyl, 1 ,3-dioxolanyl, 1 ,4-dioxolanyl and the like, 5-membered heterocycles having one hetero atom (e.g. thiophenes, pyrroles, furans and the like); 5-membered heterocycles having two heteroatoms in 1 ,2 or 1 ,3 positions (e.g. oxazoles, pyrazoles, imidazoles, thiazoles, purines and the like); 5-membered heterocycles having three heteroatoms (e.g. thazoles, thiadiazoles and the like); 5-membered heterocycles having four heteroatoms; 6-membered heterocycles with one heteroatom (e.g. pyridine, quinoline, isoquinoline, phenanthridine, cyclohepta[b]pyridine and the like); 6-membered heterocycles with two heteroatoms (e.g. pyridazines, cinnolines, phthalazines, pyrazines, pyrimidines, quinazolines, morpholines and the like); 6-membered heterocycles with three heteroatoms (e.g. 1 ,3,5-triazine and the like); and 6-membered heterocycles with four heteroatoms and the like.
As used herein, the phrase "a 9-10 membered bicyclic ring" means an unsaturated or saturated or aromatic system containing one or more carbon atoms and optionally from one to four N, O or S atom(s) or a combination thereof. The phrase "a 9-10 membered bicyclic ring" includes but is not limited to napthalene, quinoline, isoquinoline, indole, benzothiophene, benzofuran and the like.
Certain of the above defined terms may occur more than once in the above formula (I), and upon such occurrence each term shall be defined independently of the other. The present invention also encompasses pharmaceutically acceptable salts of the present compounds. Such salts include pharmaceutically acceptable acid addition salts, pharmaceutically acceptable base addition salts, pharmaceutically acceptable metal salts, ammonium and alkylated ammonium salts. Acid addition salts include salts of inorganic acids as well as organic acids. Representative examples of suitable inorganic acids include hydrochloric, hy- drobromic, hydroiodic, phosphoric, sulfuric, nitric acids and the like. Representative examples of suitable organic acids include formic, acetic, trichloroacetic, trifluoroacetic, propionic, benzoic, cinnamic, citric, fumaric, glycolic, lactic, maleic, malic, malonic, mandelic, oxalic, picric, pyruvic, salicylic, succinic, methanesulfonic, ethanesulfonic, tartaric, ascorbic, pamoic, bismethylene salicylic, ethanedisulfonic, gluconic, citraconic, aspartic, stearic, palmitic, EDTA, glycolic, p-aminobenzoic, glutamic, benzenesulfonic, p-toluenesulfonic acids, sulphates, nitrates, phosphates, perchlorates, borates, acetates, benzoates, hydroxynaphtho- ates, glycerophosphates, ketoglutarates and the like. Further examples of pharmaceutically acceptable inorganic or organic acid addition salts include the pharmaceutically acceptable salts listed in J. Pharm. Sci. 1977, 66, 2, which is incorporated herein by reference. Examples of metal salts include lithium, sodium, potassium, magnesium salts and the like. Examples of ammonium and alkylated ammonium salts include ammonium, methylammonium, dimethylammonium, trimethylammonium, ethylammonium, hydroxyethylammonium, diethyl- ammonium, butylammonium, tetramethylammonium salts and the like. Examples of organic bases include lysine, arginine, guanidine, diethanolamine, choline and the like.
The pharmaceutically acceptable salts are prepared by reacting the compound of formula I with 1 to 4 equivalents of a base such as sodium hydroxide, sodium methoxide, sodium hydride, potassium t-butoxide, calcium hydroxide, magnesium hydroxide and the like, in sol- vents like ether, THF, methanol, t-butanol, dioxane, isopropanol, ethanol etc. Mixture of solvents may be used. Organic bases like lysine, arginine, diethanolamine, choline, guandine and their derivatives etc. may also be used. Alternatively, acid addition salts wherever applicable are prepared by treatment with acids such as hydrochloric acid, hydrobromic acid, nitric acid, sulfuric acid, phosphoric acid, p-toluenesulphonic acid, methanesulfonic acid, ace- tic acid, citric acid, maleic acid salicylic acid, hydroxynaphthoic acid, ascorbic acid, palmitic acid, succinic acid, benzoic acid, benzenesulfonic acid, tartaric acid and the like in solvents like ethyl acetate, ether, alcohols, acetone, THF, dioxane etc. Mixture of solvents may also be used. The stereoisomers of the compounds forming part of this invention may be prepared by using reactants in their single enantiomeric form in the process wherever possible or by conducting the reaction in the presence of reagents or catalysts in their single enantiomer form or by resolving the mixture of stereoisomers by conventional methods. Some of the pre- ferred methods include use of microbial resolution, resolving the diastereomeric salts formed with chiral acids such as mandelic acid, camphorsulfonic acid, tartaric acid, lactic acid, and the like wherever applicable or chiral bases such as brucine, cinchona alkaloids and their derivatives and the like. Commonly used methods are compiled by Jaques et al in "Enanti- omers, Racemates and Resolution" (Wiley Interscience, 1981). More specifically the com- pound of formula I may be converted to a 1 :1 mixture of diastereomeric amides by treating with chiral amines, aminoacids, aminoalcohols derived from aminoacids; conventional reaction conditions may be employed to convert acid into an amide; the dia-stereomers may be separated either by fractional crystallization or chromatography and the stereoisomers of compound of formula I may be prepared by hydrolysing the pure diastereomeric amide.
Various polymorphs of compound of general formula I forming part of this invention may be prepared by crystallization of compound of formula I under different conditions. For example, using different solvents commonly used or their mixtures for recrystallization; crystallizations at different temperatures; various modes of cooling, ranging from very fast to very slow cooling during crystallizations. Polymorphs may also be obtained by heating or melting the compound followed by gradual or fast cooling. The presence of polymorphs may be determined by solid probe nmr spectroscopy, ir spectroscopy, differential scanning calorimetry, powder X-ray diffraction or such other techniques.
The invention also encompasses prodrugs of the present compounds, which on administration undergo chemical conversion by metabolic processes before becoming active pharmacological substances. In general, such prodrugs will be functional derivatives of the present compounds, which are readily convertible in vivo into the required compound of the formula (I). Conventional procedures for the selection and preparation of suitable prodrug derivatives are described, for example, in "Design of Prodrugs", ed. H. Bundgaard, Elsevier, 1985.
The invention also encompasses active metabolites of the present compounds. Furthermore, the present compounds of formula I can be utilised in the treatment and/or prevention of conditions mediated by nuclear receptors, in particular the Peroxisome Prolif- erator-Activated Receptors (PPAR).
In a further aspect, the present invention relates to a method of treating and/or preventing Type I or Type II diabetes.
In a still further aspect, the present invention relates to the use of one or more compounds of the general formula I or pharmaceutically acceptable salts thereof for the preparation of a medicament for the treatment and/or prevention of Type I or Type II diabetes.
In a still further aspect, the present compounds are useful for the treatment and/or prevention of IGT.
In a still further aspect, the present compounds are useful for the treatment and/or prevention of Type 2 diabetes.
In a still further aspect, the present compounds are useful for the delaying or prevention of the progression from IGT to Type 2 diabetes.
In a still further aspect, the present compounds are useful for the delaying or prevention of the progression from non-insulin requiring Type 2 diabetes to insulin requiring Type 2 diabetes.
In another aspect, the present compounds reduce blood glucose and triglycehde levels and are accordingly useful for the treatment and/or prevention of ailments and disorders such as diabetes and/or obesity.
In still another aspect, the present compounds are useful for the treatment and/or prophy- laxis of insulin resistance (Type 2 diabetes), impaired glucose tolerance, dyslipidemia, disorders related to Syndrome X such as hypertension, obesity, insulin resistance, hyperglycae- mia, atherosclerosis, hyperlipidemia, coronary artery disease, myocardial ischemia and other cardiovascular disorders. In still another aspect, the present compounds are effective in decreasing apoptosis in mammalian cells such as beta cells of Islets of Langerhans.
In still another aspect, the present compounds are useful for the treatment of certain renal diseases including glomerulonephritis, glomerulosclerosis, nephrotic syndrome, hypertensive nephrosclerosis.
In still another aspect, the present compounds may also be useful for improving cognitive functions in dementia, treating diabetic complications, psoriasis, polycystic ovarian syndrome (PCOS) and prevention and treatment of bone loss, e.g. osteoporosis.
The invention also relates to pharmaceutical compositions comprising, as an active ingredient, at least one compound of the formula I or any optical or geometric isomer or tautomeric form thereof including mixtures of these or a pharmaceutically acceptable salt thereof to- gether with one or more pharmaceutically acceptable carriers or diluents.
Furthermore, the invention relates to the use of compounds of the general formula I or their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts or pharmaceutically acceptable solvates thereof for the preparation of a pharmaceutical composition for the treatment and/or prevention of conditions mediated by nuclear receptors, in particular the Peroxisome Proliferator-Activated Receptors (PPAR) such as the conditions mentioned above.
The present invention also relates to a process for the preparation of the above said novel compounds, their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts or pharmaceutically acceptable solvates.
The method comprises:
a) Reacting a compound of formula (II) where A1 and A2 are as defined previously with a phosphonate ester in a Homer Emmons reaction A2 A1 0 (ID to give a compound of formula III where A1 and A2 and n are as defined previously.
Figure imgf000027_0001
whereupon a compound of formula III can be reduced with diisobutyl aluminium hydride to give a compound of formula IV where A1 and A2 and n are as defined previously. Alternatively a compound of formula IV can be prepared via reaction of a compound of formula II with (Ph3P) 3PCH2(CH2)nCH2OH.Br and BuLi in a Wittig reaction
Figure imgf000027_0002
The alcohol group in a compound of formula IV can undergo a Mitsunobo reaction with a compound of formula V, alternatively it can be converted to a suitable leaving group (mesy- loxy, halide) and react under alkylating conditions with a compound of formula V, wherein Q is OH, SH or amino, Ar, M, Y and R5-R8 are as defined previously.
Figure imgf000027_0003
to give a compound of formula I, wherein k=1 and A1, A2, Q, Ar ,M, Y, n and R5-R8 are as de- fined previously.
Figure imgf000028_0001
Ester deprotection of a compound of formula (I) can be carried out using standard hydrolysis techniques, to give a compound of formula I, wherein Y is O, k=1 and A1, A2, Q, Ar, M, n and R5-R8 are as defined previously.
Hydrogenating a compound of formula IV under palladium catalysis to give a compound of formula VI wherein A1 and A2 and n are as defined previously:
Figure imgf000028_0002
A compound of formula VI can undergo a Mitsunobo reaction with a compound of formula V to give a compound of formula I, wherein k=2 and A1, A2, Q, Ar, M, Y, n and R5-R8 are as defined previously.
Figure imgf000028_0003
Ester deprotection of a compound of formula (I) can be carried out using standard hydrolysis techniques, to give a compound of formula I, wherein Y is O, k=2 and A1, A2, Q, Ar, M, n and R5-R8 are as defined previously.
PHARMACOLOGICAL METHODS
In vitro PPAR alpha and PPAR gamma activation activity.
Principle The PPAR gene transcription activation assays were based on transient transfection into human HEK293 cells of two plasmids encoding a chimeπc test protein and a reporter protein respectively The chimeπc test protein was a fusion of the DNA binding domain (DBD) from the yeast GAL4 transcription factor to the ligand binding domain (LBD) of the human PPAR proteins The PPAR LBD harbored in addition to the ligand binding pocket also the native activation domain (activating function 2 = AF2) allowing the fusion protein to function as a PPAR ligand dependent transcription factor The GAL4 DBD will force the fusion protein to bind only to Gal4 enhancers (of which none existed in HEK293 cells) The reporter plasmid contained a Gal4 enhancer driving the expression of the firefly luciferase protein After transfection, HEK293 cells expressed the GAL4-DBD-PPAR-LBD fusion protein The fusion protein will in turn bind to the Gal4 enhancer controlling the luciferase expression, and do nothing in the absence of ligand Upon addition to the cells of a PPAR ligand, luciferase protein will be produced in amounts corresponding to the activation of the PPAR protein The amount of luciferase protein is measured by light emission after addition of the appropriate substrate
Methods
Cell culture and transfection HEK293 cells were grown in DMEM + 10% FCS, 1% PS Cells were seeded in 96-well plates the day before transfection to give a confluency of 80 % at transfection 0,8 μg DNA per well was transfected using FuGene transfection reagent according to the manufacturers instructions (Boehπnger-Mannheim) Cells were allowed to express protein for 48 h followed by addition of compound
Plasmids Human PPAR α and γ was obtained by PCR amplification using cDNA templates from liver, intestine and adipose tissue respectively Amplified cDNAs were cloned into pCR2 1 and sequenced The LBD from each isoform PPAR was generated by PCR (PPARα aa 167 - C-term, PPARγ aa 165 - C-term) and fused to GAL4-DBD by subclonmg fragments in frame into the vector pM1 generating the plasmids pMlαLBD and pMlγLBD Ensuing fusions were verified by sequencing The reporter was constructed by inserting an ohgonucleotide encoding five repeats of the Gal4 recognition sequence into the pGL2 vector (Promega) Compounds: All compounds were dissolved in DMSO and diluted 1 :1000 upon addition to the cells. Cells were treated with compound (1 :1000 in 200 μl growth medium including de- lipidated serum) for 24 h followed by luciferase assay.
Luciferase assay: Medium including test compound was aspirated and 100 μl PBS incl. 1mM Mg++ and Ca++ was added to each well. The luciferase assay was performed using the Lu- cLite kit according to the manufacturers instructions (Packard Instruments). Light emission was quantified by counting SPC mode on a Packard Instruments top-counter.
PHARMACEUTICAL COMPOSITIONS
In another aspect, the present invention includes within its scope pharmaceutical compositions comprising, as an active ingredient, at least one of the compounds of the general formula I or a pharmaceutically acceptable salt thereof together with a pharmaceutically acceptable carrier or diluent.
The present compounds may also be administered in combination with one or more further pharmacologically active substances eg., selected from antiobesity agents, antidiabetics, an- tihypertensive agents, agents for the treatment and/or prevention of complications resulting from or associated with diabetes and agents for the treatment and/or prevention of complications and disorders resulting from or associated with obesity.
Thus, in a further aspect of the invention the present compounds may be administered in combination with one or more antiobesity agents or appetite regulating agents.
Such agents may be selected from the group consisting of CART (cocaine amphetamine regulated transcript) agonists, NPY (neuropeptide Y) antagonists, MC4 (melanocortin 4) agonists, orexin antagonists, TNF (tumor necrosis factor) agonists, CRF (corticotropin releasing factor) agonists, CRF BP (corticotropin releasing factor binding protein) antagonists, urocortin agonists, β3 agonists, MSH (melanocyte-stimulating hormone) agonists, MCH (melanocyte-concentrating hormone) antagonists, CCK (cholecystokinin) agonists, serotonin re-uptake inhibitors, serotonin and noradrenaline re-uptake inhibitors, mixed serotonin and noradrenergic compounds, 5HT (serotonin) agonists, bombesm agonists, galanm antagonists, growth hormone, growth hormone releasing compounds, TRH (thyreotropm releasing hormone) agonists, UCP 2 or 3 (uncoupling protein 2 or 3) modulators, leptin agonists, DA agonists (bromocπptin, doprexm), lipase/amylase inhibitors, RXR (retmoid X receptor) modulators or TR β agonists
In one embodiment of the invention the antiobesity agent is leptin
In another embodiment the antiobesity agent is dexamphetamme or amphetamine
In another embodiment the antiobesity agent is fenfluramine or dexfenfluramine
In still another embodiment the antiobesity agent is sibutramine
In a further embodiment the antiobesity agent is orhstat
In another embodiment the antiobesity agent is mazmdol or phentermine
Suitable antidiabetics comprise insulin, GLP-1 (glucagon like peptιde-1) derivatives such as those disclosed in WO 98/08871 to Novo Nordisk A/S, which is incorporated herein by reference as well as orally active hypoglycaemic agents
The orally active hypoglycaemic agents preferably comprise sulphonylureas, biguanides, meghtinides, glucosidase inhibitors, glucagon antagonists such as those disclosed in WO 99/01423 to Novo Nordisk A/S and Agouron Pharmaceuticals, Inc , GLP-1 agonists, potassium channel openers such as those disclosed in WO 97/26265 and WO 99/03861 to Novo Nordisk A/S which are incorporated herein by reference, DPP-IV (dipeptidyl peptidase-IV) inhibitors, inhibitors of hepatic enzymes involved in stimulation of gluconeogenesis and/or glycogenolysis, glucose uptake modulators, compounds modifying the lipid metabolism such as antihyperlipidemic agents and antilipidemic agents as HMG CoA inhibitors (statins), compounds lowering food intake, RXR agonists and agents acting on the ATP-dependent potassium channel of the β-cells In one embodiment of the invention the present compounds are administered in combination with insulin.
In a further embodiment the present compounds are administered in combination with a sul- phonylurea eg. tolbutamide, glibenclamide, glipizide or glicazide.
In another embodiment the present compounds are administered in combination with a bi- guanide eg. metformin.
in yet another embodiment the present compounds are administered in combination with a meglitinide eg. repaglinide.
In a further embodiment the present compounds are administered in combination with an α-glucosidase inhibitor eg. miglitol or acarbose.
In another embodiment the present compounds are administered in combination with an agent acting on the ATP-dependent potassium channel of the β-cells eg. tolbutamide, glibenclamide, glipizide, glicazide or repaglinide.
Furthermore, the present compounds may be administered in combination with nateglinide.
In still another embodiment the present compounds are administered in combination with an antihyperlipidemic agent or antilipidemic agent eg. cholestyramine, colestipol, clofibrate, gemfibrozil, lovastatin, pravastatin, simvastatin, probucol or dextrothyroxine.
In a further embodiment the present compounds are administered in combination with more than one of the above-mentioned compounds eg. in combination with a sulphonylurea and metformin, a sulphonylurea and acarbose, repaglinide and metformin, insulin and a sulphonylurea, insulin and metformin, insulin, insulin and lovastatin, etc.
Furthermore, the present compounds may be administered in combination with one or more antihypertensive agents. Examples of antihypertensive agents are β-blockers such as aipre- nolol, atenolol, timolol, pindolol, propranolol and metoprolol, ACE (angiotensin converting enzyme) inhibitors such as benazepril, captopril, enalapril, fosinopril, lisinopril, quinap l and ramipril, calcium channel blockers such as nifedipine, felodipine, nicardipine, isradipine, ni- modipine, diltiazem and verapamil, and α-blockers such as doxazosin, urapidil, prazosin and terazosin. Further reference can be made to Remington: The Science and Practice of Pharmacy, 19th Edition, Gennaro, Ed., Mack Publishing Co., Easton, PA, 1995.
It should be understood that any suitable combination of the compounds according to the invention with one or more of the above-mentioned compounds and optionally one or more further pharmacologically active substances are considered to be within the scope of the present invention.
Pharmaceutical compositions containing a compound of the present invention may be prepared by conventional techniques, e.g. as described in Remington: The Science and Practise of Pharmacy, 19th Ed., 1995. The compositions may appear in conventional forms, for example capsules, tablets, aerosols, solutions, suspensions or topical applications.
Typical compositions include a compound of formula I or a pharmaceutically acceptable acid addition salt thereof, associated with a pharmaceutically acceptable excipient which may be a carrier or a diluent or be diluted by a carrier, or enclosed within a carrier which can be in the form of a capsule, sachet, paper or other container. In making the compositions, conventional techniques for the preparation of pharmaceutical compositions may be used. For example, the active compound will usually be mixed with a carrier, or diluted by a carrier, or enclosed within a carrier which may be in the form of a ampoule, capsule, sachet, paper, or other container. When the carrier serves as a diluent, it may be solid, semi-solid, or liquid material which acts as a vehicle, excipient, or medium for the active compound. The active compound can be adsorbed on a granular solid container for example in a sachet. Some examples of suitable carriers are water, salt solutions, alcohols, polyethylene glycols, polyhydroxyethoxylated castor oil, peanut oil, olive oil, gelatine, lactose, terra alba, sucrose, cyclodextrin, amylose, magnesium stearate, talc, gelatin, agar, pectin, acacia, stearic acid or lower alkyl ethers of cellulose, silicic acid, fatty acids, fatty acid amines, fatty acid monoglycerides and diglycerides, pentaerythritol fatty acid esters, poiyoxyethylene, hydroxymethylcelluiose and polyvinylpyrrolidone. Similarly, the carrier or diluent may include any sustained release material known in the art, such as glyceryl monostearate or giyceryl distearate, alone or mixed with a wax. The formulations may also include wetting agents, emulsifying and suspending agents, preserving agents, sweetening agents or flavouring agents. The formulations of the invention may be formulated so as to provide quick, sustained, or delayed release of the active ingredient after administration to the patient by employing procedures well known in the art.
The pharmaceutical compositions can be sterilized and mixed, if desired, with auxiliary agents, emulsifiers, salt for influencing osmotic pressure, buffers and/or colouring substances and the like, which do not deleteriously react with the active compounds.
The route of administration may be any route, which effectively transports the active com- pound to the appropriate or desired site of action, such as oral, nasal, pulmonary, transder- mal or parenteral e.g. rectal, depot, subcutaneous, intravenous, intraurethral, intramuscular, intranasal, ophthalmic solution or an ointment, the oral route being preferred.
If a solid carrier is used for oral administration, the preparation may be tabletted, placed in a hard gelatin capsule in powder or pellet form or it can be in the form of a troche or lozenge. If a liquid carrier is used, the preparation may be in the form of a syrup, emulsion, soft gelatin capsule or sterile injectable liquid such as an aqueous or non-aqueous liquid suspension or solution.
For nasal administration, the preparation may contain a compound of formula I dissolved or suspended in a liquid carrier, in particular an aqueous carrier, for aerosol application. The carrier may contain additives such as solubilizing agents, e.g. propylene glycol, surfactants, absorption enhancers such as lecithin (phosphatidylcholine) or cyclodextrin, or preservatives such as parabenes.
For parenteral application, particularly suitable are injectable solutions or suspensions, preferably aqueous solutions with the active compound dissolved in polyhydroxylated castor oil.
Tablets, dragees, or capsules having talc and/or a carbohydrate carrier or binder or the like are particularly suitable for oral application. Preferable carriers for tablets, dragees, or capsules include lactose, corn starch, and/or potato starch. A syrup or elixir can be used in cases where a sweetened vehicle can be employed.
A typical tablet which may be prepared by conventional tabletting techniques may contain: Core:
Active compound (as free compound or salt thereof) 5 mg
Colloidal silicon dioxide (Aerosil) 1.5 mg Cellulose, microcryst. (Avicel) 70 mg
Modified cellulose gum (Ac-Di-Sol) 7.5 mg
Magnesium stearate Ad.
Coating: HPMC approx. 9 mg
*Mywacett 9-40 T approx. 0.9 mg
*Acylated monoglyceride used as plasticizer for film coating.
The compounds of the invention may be administered to a mammal, especially a human in need of such treatment, prevention, elimination, alleviation or amelioration of diseases related to the regulation of blood sugar.
Such mammals include also animals, both domestic animals, e.g. household pets, and non- domestic animals such as wildlife.
The compounds of the invention are effective over a wide dosage range. For example, in the treatment of adult humans, dosages from about 0.05 to about 100 mg, preferably from about 0.1 to about 100 mg, per day may be used. A most preferable dosage is about 0.1 mg to about 70 mg per day. In choosing a regimen for patients it may frequently be necessary to begin with a dosage of from about 2 to about 70 mg per day and when the condition is under control to reduce the dosage as low as from about 0.1 to about 10 mg per day. The exact dosage will depend upon the mode of administration, on the therapy desired, form in which administered, the subject to be treated and the body weight of the subject to be treated, and the preference and experience of the physician or veterinarian in charge.
Generally, the compounds of the present invention are dispensed in unit dosage form comprising from about 0.1 to about 100 mg of active ingredient together with a pharmaceutically acceptable carrier per unit dosage. Usually, dosage forms suitable for oral, nasal, pulmonary or transdermal administration comprise from about 0.001 mg to about 100 mg, preferably from about 0.01 mg to about 50 mg of the compounds of formula I admixed with a pharmaceutically acceptable carrier or diluent.
Any novel feature or combination of features described herein is considered essential to this invention.
EXAMPLES
The process for preparing compounds of formula I, and preparations containing them, is further illustrated in the following examples, which however, are not to be construed as limiting.
The structures of the compounds are confirmed by either elemental analysis (MA) nuclear magnetic resonance (NMR) or mass spectrometry (MS). NMR shifts (d) are given in parts per million (ppm) and only selected peaks are given, mp is melting point and is given in °C.
Column chromatography was carried out using the technique described by W.C. Still et al, J.
Org. Chem. 1978, 43, 2923-2925 on Merck silica gel 60 (Art 9385). Compounds used as starting materials are either known compounds or compounds which can readily be prepared by methods known per se.
Abbrevations:
TLC: thin layer chromatography
DMSO: dimethylsulfoxide CDCI3: deutorated chloroform
DMF: N,N-dimethylformamide min: minutes h: hours
Example 1
(E,Z)-2-Ethoxy-3-{4-[3-phenyl-3-(4-methylphenyl)-allyloxy1-phenyl}-propionic acid ethyl ester To a solution of 3-phenyl-3-(4-methyl-phenyl)-prop-2-en-1-ol (150mg, 0 6mmol), tπphenyl- phosphme (195mg, 0 73mmol) and 2-ethoxy-3-(4-hydroxy-phenyl)-propιonιc acid ethyl ester (190mg, 0 79mmol) in THF at ice bath temperature was added diethylazodicarboxylate (0 11mL, 0 73mmol) and the reaction stirred 1 5h at this temperature and 16h at room tem- perature Ice water was added and the crude product isolated by a dichloromethane extraction and brine wash Concentration under reduced pressure and flash chromatography gave the title compound (300mg)
1H NMR (CDCI3, 300 MHz), δ 1 07-1 28 (6H, 2xCH3), 2 30 and 2 40 (3H, CH3), 2 90-2 93 (2H, CH2), 3 30-3 40 and 3 51-3 61 (2H, OCH2), 3 90-4 0 (1 H, CHCO2), 4 10-4 19 (2H, OCH2), 4 41-4 61 (2H, OCH2) 6 23-6 32 (1 H, CHalkene), 6 70-6 81 (2H, aryl), 7 03-7 45 (remaining H, aryl) MS calcd for C29H32O4 444 6, Found 444 2
Example 2
(E,Z)-2-Ethoxy-3-{4-r3-phenyl-3-(4-methylphenyl)-allyloxy1-phenyl)-propιonιc acid
(E,Z)-2-Ethoxy-3-{4-[3-phenyl-3-(4-methylphenyl)-allyloxy]-phenyl}-propιonιc acid ethyl ester (example 1) (80mg, 0 18mmol) was hydrolysed in 1 N NaOH (0 35mL) and ethanol (0 35mL) for 4 h at room temperature and 16h at 5°C Water (1mL) was added and the reaction mixture was neutralised with 6N HCI The crude product was extracted with dichloromethane and concentrated under reduced pressure Flash chromatography gave the title compound (48mg) .
Η NMR (CDCI3, 300 MHz), δ 1 07-1 20 (3H, CH3), 2 32 and 2 40 (3H, CH3), 2 85-3 10 (2H, CH2), 3 30-3 45 and 3 51-3 68 (2H, OCH2), 3 95-4 06 (1 H, CHCO2), 4 51 4 61 (2H, OCH2) 6 21-6 41 (1 H, CHalkene), 6 72-6 82 (2H, aryl), 7 03-7 50 (remaining H, aryl) MS calcd for C27H28O4416 5, Found 416 3
Example 3
(E, Z)-3-{4-r3-(2-Chloro-phenyl)-3-phenyl-allyloxy1-phenyl)-2-ethoxy-propιonιc acid ethyl es- ter To a solution of 3-(2-chloro-phenyl)-3-phenyl-prop-2-en-1-ol (370mg, 1.5mmol), tributyl- phosphine (0.5mL, 1.6mmol) and 2-ethoxy-3-(4-hydroxy-phenyl)-propionic acid ethyl ester (380mg, 1.6mmol) in benzene at ice bath temperature was added azodicarboxylic dipiperidide (403mg, 1.6mmol) and the reaction stirred 1 h. Work up and purification as for Example 1 gave the title compound (490mg).
Η NMR (CDCI3, 300 MHz); δ 1.07-1.30 (6H, 2xCH3), 2.90-2.95 (2H, CH2), 3.29-3.40 and 3.52-3.63 (2H, OCH2), 3.90-4.0 (1 H, CHCO2), 4.10-4.20 (2H, OCH2), 4.35-4.56 and 4.70- 4.80 (2H, OCH2), 6.00-6.08 and 6.42-6.53 (1 H, CHalkene), 6.70-6.81 (2H, aryl), 7.06-7.55 (remaining H, aryl). MS calcd for C28H29CIO4 465.0, Found 464.2.
Example 4
(E, Z)-3-{4-f3-(2-Chloro-phenyl)-3-phenyl-allyloxyl-phenyl)-2-ethoxy-propionic acid
(E, Z)-3-{4-[3-(2-Chloro-phenyl)-3-phenyl-aliyloxy]-phenyl}-2-ethoxy-propionic acid ethyl ester (example 3) (400mg, 0.86mmol) was hydrolysed in an identical manner to example 2 to give the title compound (353mg).
1H NMR (CDCI3, 300 MHz); δ 1.09-1.20 (3H, CH3), 2.85-3.10 (2H, CH2), 3.30-3.42 and 3.51- 3.65 (2H, OCH2), 3.96-4.05 (1 H, CHCO2), 4.35-4.50 and 4.70-4.74 (2H, OCH2) 6.00-6.05 and 6.42-6.49 (1 H, CHalkene), 6.71-6.82 (2H, aryl), 7.05-7.50 (remaining H, aryl). MS calcd for C26H25CIO4 436.9, Found 436.2.
Example 5
3-(4-[3,3-Bis-(4-methoxy-phenyl)-allyloxyJ-phenyl)-2-ethoxy-propionic acid ethyl ester
Reaction of 3, 3-bis(4-methoxy-phenyl)-prop-2-en-1-ol (216mg, O.δmmol), triphenyl- phosphine (240mg, 0.9mmol), 2-ethoxy-3-(4-hydroxy-phenyl)-propionic acid ethyl ester (240mg, 1.0 mmol) and diethylazodicarboxylate (0.11 mL, 0.9mmol) in an identical manner to Example 1 gave the title compound (90mg). 1H NMR (CDCI3, 300 MHz), δ 110-130 (6H, 2xCH3), 290-295 (2H, CH2), 329-339 and
352-365 (2H, OCH2), 378 (3H, OCH3), 382 (3H, OCH3), 390-399 (1H, CHCO2), 410-
4 20 (2H, OCH2), 4 51-4 59 (1 H, OCH2) 6 12-6 19 (1 H, CHalkene), 6 70-7 45 (remaining H, aryl)
MS calcd for C30H34O6 490 6, Found 488 3
Example 6
3-{4-[3,3-Bιs-(4-methoxy-phenyl)-allyloxy1-phenyl)-2-ethoxy-propιonιc acιd
3-{4-[3,3-Bιs-(4-methoxy-phenyl)-allyloxy]-phenyl}-2-ethoxy-propιonιc acid ethyl ester (example 5) (80mg, 0 16mmol) was hydrolysed in an identical manner to example 2 to give the title compound (29mg)
Η NMR (CDCI3, 300 MHz), δ 1 12-1 20 (3H, CH3), 2 87-3 09 (2H, CH2), 3 32-3 49 and 3 52- 3 63 (2H, OCH2), 3 78 (3H, OCH3), 3 82 (3H, OCH3), 3 99-4 02 (1 H, CHCO2), 4 51-4 55 (1 H, OCH2) 6 12-6 19 (1 H, CHalkene), 6 72-7 23 (remaining H, aryl) MS calcd for C28H30O6 462 5, Found 462 1
Example 7
(E, Z)-3-{4-[3-phenyl-3-(Bιphenyl-4-yl)-allyloxy]-phenyl)-2-ethoxy-propιonιc acid ethyl ester
Reaction of of 3-phenyl-3-(bιphenyl-4-yl)-prop-2-en-1-ol (250mg, 0 66mmol), tπphenyl- phosphme (195mg, 0 73mmol), 2-ethoxy-3-(4-hydroxy-phenyl)-propιonιc acid ethyl ester (190mg, 0 79 mmol) and diethylazodicarboxylate (0 11 mL, 0 79mmol) in an identical manner to Example 1 gave the title compound (180mg)
Η NMR (CDCI3, 300 MHz), δ 1 10-1 32 (6H, 2xCH3), 2 89-2 95 (2H, CH2), 3 28-3 39 and 3 52-3 63 (2H, OCH2), 3 91-3 96 (1 H, CHCO2), 4 08-4 20 (2H, OCH2), 4 51-4 62 (1 H, OCH2) 6 29-6 41 and 6 61-6 70 (1 H, CHalkene), 6 72-7 80 (2H, aryl), 7 08-7 18 (2H, aryl), 7 20-7 70 (remaining H, aryl) MS calcd for C^H^ 506 6, Found 504 2 Example 8
(E, Z)-3-{4-f3-phenyl-3-(BiDhenyl-4-yl)-allyloxyl-phenyl)-2-ethoxy-propionic acid
(E, Z)-3-{4-[3-phenyl-3-(Biphenyl-4-yl)-allyloxy]-phenyl}-2-ethoxy-propionic acid ethyl ester (example 7) (70mg, 0.13mmol) was hydrolysed in an identical manner to example 2 to give the title compound (25mg).
1H NMR (CDCI3, 300 MHz); δ 1.02-1.23 (3H, CH3), 2.83-3.12 (2H, CH2), 3.32-3.50 and 3.52- 3.63 (2H, OCH2), 3.96-4.07 (1H, CHCO2), 4.51-4.70 (1H, OCH2) 6.39-6.41 (1 H, CHalkene), 6.72-7.82 (2H, aryl), 7.01-7.65 (remaining H, aryl). MS calcd for C32H30O4 478.6, Found 478.2
Example 9
(E, Z)-2-Ethoxy-3-{4-r3-phenyl-3-(thiophen-2-yl)-allyloxy]-phenyl}-propionic acid ethyl ester
Reaction of 3-phenyl-3-(thiophen-2-yl)-prop-2-en-1-ol (320mg, 1.5mmol), tributylphosphine (0.4mL, 1.6mmol), 2-ethoxy-3-(4-hydroxy-phenyl)-propionic acid ethyl ester (380mg,
1.6mmol) and azodicarboxylic dipiperidide(403mg, 1.6mmol) in an identical manner to Example 3 gave the title compound (290mg).
1H NMR (CDCI3, 300 MHz); δ 1.08-1.32 (6H, 2xCH3), 2.90-2.99 (2H, CH2), 3.28-3.39 and 3.52-3.63 (2H, OCH2), 3.91-3.99 (1 H, CHCO2), 4.08-4.21 (2H, OCH2), 4.42-4.50 and 4.72- 4.80 (1 H, OCH2), 6.19-6.25 and 6.32-6.39 (1 H, CHalkene), 6.62-7.48 (remaining H, aryl). MS calcd for C26H28O4S 436.6, Found 436.1.
Example 10
(E, Z)-2-Ethoxy-3-{4-[3-phenyl-3-(thiophen-2-yl)-allyloxy1-phenyl}-propionic acid (E, Z)-2-Ethoxy-3-{4-[3-phenyl-3-(thiophen-2-yl)-allyloxy]-phenyl}-propionic acid ethyl ester (example 9) (200mg, 0.45mmol) was hydrolysed in an identical manner to example 2 to give the title compound (94mg).
1H NMR (CDCI3, 300 MHz); δ 1.12-1.31 (3H, CH3), 2.88-3.10 (2H, CH2), 3.28-3.48 and 3.52- 3.58 (2H, OCH2), 3.96-4.03 (1 H, CHCO2), 4.42-4.48 and 4.76-4.80 (1 H, OCH2), 6.19-6.22 and 6.32-6.39 (1 H, CHalkene), 6.65-7.48 (remaining H, aryl). MS calcd for C24H24O4S 408.5, Found 408.2.
Example 11
2-Ethoxy-3-{4-[3-phenyl-3-(pyridin-2-yl)-allyloxyl-phenyl}-propionic acid ethyl ester
Reaction of 3-phenyl-3-(pyridin-2-yl)-prop-2-en-1-ol (320mg, 1.5mmol), tributylphosphine (0.42mL, 1.6mmol), 2-ethoxy-3-(4-hydroxy-phenyl)-propionic acid ethyl ester (380mg,
1.6mmol) and azodicarboxylic dipiperidide(403mg, 1.6mmol) in an identical manner to Example 3 gave the title compound (650mg).
Η NMR (CDCI3, 300 MHz); δ 1.10-1.30 (6H, 2xCH3), 2.90-2.95 (2H, CH2), 3.28-3.39 and 3.51-3.62 (2H, OCH2), 3.90-3.95 (1 H, CHCO2), 4.05-4.20 (2H, OCH2), 4.53-4.59 (1 H,
OCH2) 6.72-6.78 (1 H, CHalkene), 6.95-7.60 (remaining H, aryl and pyridyl), 8.58-8.61 (1H, pyridyl).
MS calcd for C27H29O4N 431.5, Found 431.3.
Example 12
2-Ethoxy-3-(4-f3-phenyl-3-(pyridin-2-yl)-allyloxy1-phenyl)-propionic acid
2-Ethoxy-3-{4-[3-phenyl-3-(pyridin-2-yl)-allyloxy]-phenyl}-propionic acid ethyl ester (example 11 ) (210mg, 0.48mmol) was hydrolysed in an identical manner to example 2 to give the title compound (110mg). 1H NMR (CDCI3, 300 MHz); δ 1.10-1.18 (3H, CH3), 2.82-3.04 (2H, CH2), 3.28-3.39 and 3.51- 3.62 (2H, OCH2), 3.92-3.97 (1 H, CHCO2), 4.53-4.65 (1 H, OCH2) 6.70-6.78 (1 H, CHalkene), 6.88-7.62 (remaining H, aryl and pyridyl), 8.58-8.62 (1 H, pyridyl). MS calcd for C25H25O4N 403.5, Found 403.2.
Example 13
3-f4-(3, 3-Diphenyl-propoxy)-phenyπ-2-ethoxy-propionic acid ethyl ester
Reaction of 3, 3-diphenyl-propan-1-ol (110mg, O.δmmol), triphenylphosphine (145mg,
0.55mmol), 2-ethoxy-3-(4-hydroxy-phenyl)-propionic acid ethyl ester (140mg, 0.6 mmol) and diethylazodicarboxylate (0.09mL, 0.55mmol) in an identical manner to Example 1 gave the title compound (120mg).
1H NMR (CDCI3, 300 MHz); δ 1.10-1.29 (6H, 2xCH3), 2.44-2.55 (2H, CH2), 2.90-2.95 (2H, CH2), 3.28-3.39 and 3.51-3.62 (2H, OCH2), 3.80-3.89 (2H, CH2), 3.90-3.95 (1 H, CHCO2), 4.10-4.28 (3H, arylCH and OCH2), 6.70-6.77 (2H, aryl), 7.05-7.35 (remaining H, aryl). MS calcd for C28H32O4 432.6, Found 432.3.
Example 14
3-[4-(3,3-Diphenyl-propoxy)-phenyn-2-ethoxy-propionic acid
3-[4-(3, 3-Diphenyl-propoxy)-phenyl]-2-ethoxy-propionic acid ethyl ester (example 13) (110mg, 0.25mmol) was hydrolysed in an identical manner to example 2 to give the title compound (55mg).
Η NMR (CDCI3, 300 MHz); δ 1.10-1.19 (3H, CH3), 2.42-2.55 (2H, CH2), 2.87-3.08 (2H, CH2), 3.30-3.47 and 3.51-3.62 (2H, OCH2), 3.80-3.89 (2H, CH2), 3.98-4.03 (1 H, CHCO2), 4.10-4.25 (1 H, arylCH), 6.70-6.77 (2H, aryl), 7.05-7.35 (remaining H, aryl). MS calcd for C26H28O4 404.5, Found 404.3.
Example 15 2-Ethoxy-3-{4-[3-phenyl-3-(4-methylphenyl)-propoxy1-phenyl)-propionic acid ethyl ester
Reaction of 3-phenyl-3-(4-methylphenyl)-2-propann-1-ol (210mg, 0.88mmol), tributyl- phosphine (0.25mL, LOmmol), 2-ethoxy-3-(4-hydroxy-phenyl)-propionic acid ethyl ester (240mg, LOmmol) and azodicarboxylic dipiperidide (250mg, LOmmol) in an identical manner to Example 3 gave the title compound (160mg).
1H NMR (CDCI3, 300 MHz); δ 1.07-1.28 (6H, 2xCH3), 2.29 (3H, CH3), 2.42-2.49 (2H, CH2), 2.89-2.93 (2H, CH2), 3.25-3.40 and 3.51-3.61 (2H, OCH2), 3.88-3.85 (2H, CH2), 3.90-4.00 (1 H, CHCO2), 4.10-4.19 (3H, arylCH and OCH2), 6.69-6.73 (2H, aryl), 7.03-7.29 (remaining H, aryl). MS calcd for C29H34O4 446.6, Found 446.3.
Example 16
2-Ethoxy-3-{4-r3-phenyl-3-(4-methylphenyl)-propoxy]-phenyl)-propionic acid
2-Ethoxy-3-{4-[3-phenyl-3-(4-methylphenyl)-propoxy]-phenyl}-propionic acid ethyl ester (example 15) (130mg, 0.30mmol) was hydrolysed in an identical manner to example 2 to give the title compound (55mg).
1H NMR (CDCI3, 300 MHz); δ 1.11-1.21 (3H, CH3), 2.29 (3H, CH3), 2.42-2.53 (2H, CH2), 2.83-3.12 (2H, CH2), 3.38-3.50 and 3.51-3.63 (2H, OCH2), 3.80-3.88 (2H, CH2), 3.99-4.05 (1 H, CHCO2), 4.12-4.22 (1 H, arylCH), 6.69-6.73 (2H, aryl), 7.03-7.29 (remaining H, aryl). MS calcd for C27H30O4 418.5, Found 418.3.
Example 17
3-{4-f3-phenyl-3-(biphenyl-4-yl)-propoxy1-phenyl)-2-ethoxy-propionic acid ethyl ester
Reaction of 3-biphenyl-4-yl-3-phenyl-propan-1-ol (145mg, O.δmmol), triphenylphosphine (145mg, 0.55mmol), 2-ethoxy-3-(4-hydroxy-phenyl)-propionic acid ethyl ester (140mg, 0.6 mmol) and diethylazodicarboxylate (0.09mL, 0.55mmol) in an identical manner to Example 1 gave the title compound (230mg). 1H NMR (CDCI3, 300 MHz), δ 1 07-1 28 (6H, 2xCH3), 2 48-2 55 (2H, CH2), 2 89-2 93 (2H, CH2), 3 25-3 40 and 3 51-3 63 (2H, OCH2), 3 88-4 00 (3H, CH2 and CHCO2) 4 10-4 19 (2H, OCH2), 4 20-4 30 (1 H, CH), 6 67-6 71 (2H, aryl), 7 05-7 55 (remaining H, aryl) MS calcd for C34H36O4 508 7, Found 508 3
Example 18
3-{4-[3-phenyl-3-(bιphenyl-4-yl)-propoxy1-phenyl}-2-ethoxy-propιonιc acιd
3-{4-[3-phenyl-3-(bιphenyl-4-yl)-propoxy]-phenyl}-2-ethoxy-propιonιc acid ethyl ester (example 17) (200mg, 0 39mmol) was hydrolysed in an identical manner to example 2 to give the title compound (70mg)
1H NMR (CDCI3, 300 MHz), δ 1 07-1 20 (3H, CH3), 2 49-2 61 (2H, CH2), 2 88-3 09 (2H, CH2), 3 32-3 48 and 3 51-3 66 (2H, OCH2), 3 88-3 92 (2H, CH2) 3 95-4 05 (1 H, CHCO2), 4 20-4 30 (1 H, CH), 6 67-6 79 (2H, aryl), 7 05-7 55 (remaining H, aryl) MS calcd for C32H32O4 480 6, Found 480 3
Example 19
2-(4-f3,3-Bιs-(4-methoxy-phenyl)-allyloxy1-benzyl)-malonιc acid dimethyl ester
Under a nitrogen atmosphere, 3,3-bιs-(4-methoxy-phenyl)-prop-2-en-1-ol (500 mg, 1 95 mmol), tnbutylphosphine (424 (mg, 2 1 mmol) and 2-(4-hydroxy-benzyl)-malonιc acid dimethyl ester (464 mg, 1 95 mmol) were successively dissolved in dry benzene (50 mL) Solid azodicarboxylic dipiperidide (ADDP) (530 mg, 2 1 mmol) was added under stirring at 0°C to the solution After 10 mm, the reaction mixture was brought to room temperature and the stirring was continued for 16 h Heptane (10 mL) was added to the reaction mixture and di hydro-ADDP separated out was filtered off After evaporation of the solvent the product was purified by chromatography elutmg with heptane/ethylacetate (4 1 ) to give 150 mg (16%) of the title compound 1 H NMR (CDCI3, 300 MHz); δ 3.15 (2H, PhCH2), 3.63 (1 H, CH), 3.70 (6H, 2xCO2CH3), 3.80 (3H, PhOCH3 ), 3.83 (3H, PhOCH3), 4.55 (1 H, OCH2), 6.15 (1 H, CHalkene), 6.70-7.20 (remaining H, aryl).
Example 20
(E)-(2S)-2-Ethoxy-3-{4-[3-(4-furan-2-yl-phenyl)-3-phenyl-allyloxyl-phenyl)-propionic acid ethyl ester
Reaction of (E)-3-(4-furan-2-yl-phenyl)-3-phenyl-prop-2-en-1-ol (475 mg, 1.72 mmol), tnbutylphosphine (0.63 ml, 2.58 mmol), (2S)-2-ethoxy-3-(4-hydroxy-phenyl)-propionic acid ethyl ester (451 mg, 1.89 mmol) and azodicarboxylic dipiperidide (650 mg, 2.58 mmol) in benzene in an identical manner to example 3 gave the title compound (450 mg, 53%).
1H NMR (CDCI3, 300 MHz); δ 1.16 (3H, t), 1.21 (3H, t), 2.93 (2H, d), 3.26-3.40 (1 H, m), 3.52- 3.64 (1H, m), 3.94 (1H, t), 4.14 (2H, q), 4.58 (2H, d), 6.36 (1 H, t), 6.47 (1H, dd), 6.63 (1H, d), 6.77 (2H, dm), 7.12 (2H, dm), 7.16-7.31 (4H, m), 7.31-7.50 (4H, m), 7.58 (2H, dm).
Example 21
(£)-(2S)-2-Ethoxy-3-{4-r3-(4-furan-2-yl-phenyl)-3-phenyl-allyloxyl-phenyl)-propionic acid
(£)-(2S)-2-Ethoxy-3-{4-[3-(4-furan-2-yl-phenyl)-3-phenyl-allyloxy]-phenyl}-propionic acid ethyl ester (example 20) (440 mg, 0.89 mmol) was hydrolysed in an identical manner to example 2 to give the title compound (408 mg, 97%)
1H NMR (CDCI3, 300 MHz); δ 1.17 (3H, t), 2.93 (1 H, dd), 3.07 (1 H, dd), 3.39-3.52 (1 H, m), 3.52-3.64 (1 H, m), 4.04 (1 H, dd), 4.58 (2H, d), 6.36 (1 H, t), 6.48 (1 H, m), 6.63 (1 H, d), 6.79 (2H, dm), 7.12 (2H, dm), 7.16-7.32 (4H, m), 7.32-7.50 (4H, m), 7.59 (2H, dm), COOH too broad to be observed.
LCMS (electrospray): 491 (M+Na), 259 (100%).
Example 22 (EH2S)-3-[4-(3-Biphenyl-4-yl-3-phenyl-allyloxy)-phenvH-2-ethoxy-propionic acid ethyl ester
Reaction of (£)-3-biphenyl-4-yl-3-phenyl-prop-2-en-1-ol (1.0 g, 3.49 mmol), tributylphosphine (1.3 ml, 5.24 mmol), (2S)-2-ethoxy-3-(4-hydroxy-phenyl)-propionic acid ethyl ester (0.92 g, 3.84 mmol) and azodicarboxylic dipiperidide (1.32 g, 5.24 mmol) in benzene in an identical manner to example 3 gave the title compound (1.47 g, 83%).
Η NMR (CDCI3, 300 MHz); δ 1.16 (3H, t), 1.21 (3H, t), 2.95 (2H, d), 3.28-3.40 (1 H, m), 3.53- 3.65 (1 H, m), 3.95 (1 H, t), 4.15 (2H, q), 4.57 (2H, d), 6.39 (1 H, t), 6.78 (2H, dm), 7.12 (2H, dm), 7.20-7.48 (10H, m), 7.48-7.62 (4H, m).
Example 23
(E)-(2S)-3-[4-(3-Biphenyl-4-yl-3-phenyl-allyloxy)-phenyll-2-ethoxy-propionic acid
(£)-(2S)-3-[4-(3-Biphenyl-4-yl-3-phenyl-allyloxy)-phenyl]-2-ethoxy-propionic acid ethyl ester (example 22) (1.38 g, 2.72 mmol) was hydrolysed in an identical manner to example 2 to give the title compound (1.25 mg, 96%)
H NMR (CDCI3, 300 MHz); δ 1.17 (3H, t), 2.95 (1 H, dd), 3.06 (1 H, dd), 3.37-3.52 (1 H, m), 3.52-3.64 (1 H, m), 4.03 (1 H, dd), 4.59 (2H, d), 6.38 (1 H, t), 6.78 (2H, m), 7.12 (2H, dm), 7.20-7.49 (10H, m), 7.49-7.62 (4H, m), COOH too broad to be observed.
Example 24
(E, ZH2S)-3-f4-(3-Biphenyl-4-yl-3-phenyl-allyloxy)-phenyll-2-ethoxy-propionic acid ethyl es- ter
Reaction of (E, Z)-3-biphenyl-4-yl-3-phenyl-prop-2-en-1-ol (601 mg, 2.1 mmol), triphenyl- phosphine (606 mg, 2.31 mmol), (2S)-2-ethoxy-3-(4-hydroxy-phenyl)-propionic acid ethyl ester (601 mg, 2.52 mmol) and diethy lazodicarboxylate (402 mg, 2.31 mmol) in an identical manner to example 1 gave the title compound (400 mg, 38%). 1H NMR (CDCI3, 200 MHz); δ 1.10-1.30 (6H, m), 2.94 (2H, d), 3.25-3.45 (1 H, m), 3.50-3.65 (1 H, m), 3.96 (1 H, t), 4.16 (2H, dd), 4.55-4.68 (2H, d), 6.30-6.44 (1 H, m), 6.73-6.84 (2H, m), 7 14 (2H, dm), 7.20-7.70 (14H, m).
Example 25
(E, Z)-(2S)-3-f4-(3-Biphenyl-4-yl-3-phenyl-allyloxy)-phenyn-2-ethoxy-propionic acid
(E, Z)-(2S)-3-[4-(3-Biphenyl-4-yl-3-phenyl-allyloxy)-phenyl]-2-ethoxy-propionic acid ethyl es- ter (example 24) (400 mg, 0.79 mmol) was hydrolysed in an identical manner to example 2 to give the title compound (250 mg, 66%)
1H NMR (CDCI3, 300 MHz); δ 1.05-1.20 (3H, m), 2.94 (1 H, dd), 3.01 (1 H, dd), 3.30-3.43 (1 H, m), 3.50-3.68 (1 H, m), 4.00 (1 H, dd), 4.50-4.68 (2H, m), 6.27-6.40 (1 H, m), 6.72-6.84 (2H, m), 7.12 (2H, dm), 7.18-7.65 (14H, m), 9.85 (1 H, br s).
Example 26
3-{4-[3,3-Bis-(3-methyl-thiophen-2-yl)-allyloxy1-phenyl)-2-ethoxy-propionic acid ethyl ester
Reaction of 3,3-bis-(3-methylthiophen-2-yl)-prop-2-en-1-ol (1.0 mg, 3.99 mmol), tributyl- phosphme (0.91 g, 4.5 mmol), 2-ethoxy-3-(4-hydroxy-phenyl)-propionic acid ethyl ester (1.07 g, 4.5 mmol) and azodicarboxylic dipiperidide (1.14 g, 4.5 mmol) in an identical manner to example 3 gave the title compound (680 mg, 36%).
1H NMR (CDCI3, 200 MHz); δ 1.15 (3H, t), 1.23 (3H, t), 2.00 (3H, s), 2.08 (3H, s), 2.93 (2H, d), 3.28-3.40 (1 H, m), 3.50-3.64 (1 H, m), 3.94 (1 H, t), 4.14 (2H, dd), 4.58 (2H, d), 6.24 (1 H, t), 6.70-6.81 (3H, m), 6.88 (1 H, d), 7.04-7.15 (3H, m), 7.21-7.30 (1 H, m).
Example 27
3-{4-[3,3-Bis-(4-bromo-phenyl)-allyloxy]-phenyl}-2-ethoxy-propionic acid ethyl ester Reaction of 3,3-bis-(4-bromopheny!)-prop-2-en-1-ol (0.50 g, 1.36 mmol), triphenylphosphine (0.39 g, 1.50 mmol), 2-ethoxy-3-(4-hydroxy-phenyl)-propionic acid ethyl ester (0.39 g, 1.63 mmol) and diethy lazodicarboxylate (0.26 g, 1.51 mmol) in an identical manner to example 1 gave the title compound (450 mg, 56%).
1H NMR (CDCI3, 300 MHz); δ 1.15 (3H, t), 1.22 (3H, t), 2.94 (2H, d), 3.28-3.42 (1 H, m), 3.53- 3.65 (1 H, m), 3.96 (1 H, t), 4.16 (2H, q), 4.52 (2H, d), 6.32 (1 H, t), 6.75 (2H, dm), 7.01-7.20 (6H, m), 7.43 (2H, dm), 7.52 (2H, dm). MS (El): 586/588/590 (M+), 513/515/517, 349/351/353 (100%).
Example 28
3-{4-[3,3-Bis-(4-bromo-phenyl)-allyloxy1-phenyl}-2-ethoxy-propionic acid
3-{4-[3,3-Bis-(4-bromo-phenyl)-allyloxy]-phenyl}-2-ethoxy-propionic acid ethyl ester (example 27) (150 mg, 0.25 mmol) was hydrolysed in an identical manner to example 2 to give the title compound (135 mg, 96%)
Η NMR (CDCI3, 300 MHz); δ 1.17 (3H, t), 2.94 (1 H, dd), 3.06 (1 H, dd), 3.40-3.52 (1 H, m), 3.52-3.66 (1 H, m), 4.04 (1 H, dd), 4.51 (2H, d), 6.30 (1 H, t), 6.76 (2H, dm), 7.00-7.20 (6H, m), 7.42 (2H, dm), 7.52 (2H, dm), COOH too broad to be observed. MS (El): 558/560/562 (M+), 349/351/353, 270/272 (100%), 191.
Example 29
2-Ethoxy-3-[4-(3-phenyl-3-pyridin-4-yl-allyloxy)-phenyl1-propionic acid ethyl ester
Reaction of 3-phenyl-3-pyridin-4-yl-prop-2-en-1-ol (0.50 g, 2.37 mmol), triphenylphosphine (0.68 g, 2.61 mmol), 2-ethoxy-3-(4-hydroxy-phenyl)-propionic acid ethyl ester (0.68 g, 2.84 mmol) and diethyl azodicarboxylate (0.46 g, 2.63 mmol) in an identical manner to example 1 gave the title compound (435 mg, 43%). Η NMR (CDCI3, 200 MHz); δ 1.16 (3H, t), 1.21 (3H, t), 2.94 (2H, d), 3.25-3.43 (1 H, m), 3.50- 3.70 (1 H, m), 3.98 (1 H, t), 4.17 (2H, q), 4.52 (2H, d), 6.41 (1 H, t), 6.76 (2H, dm), 7.05-7.40 (9H, m), 8.66 (2H, dm). MS (El): 431 (M+), 194 (100%). Mp. 84-87°C
Example 30
2-Ethoxy-3-[4-(3-phenyl-3-pyridin-4-yl-allyloxy)-phenyll-propionic acid
2-Ethoxy-3-[4-(3-phenyl-3-pyridin-4-yl-allyloxy)-phenyl]-propionic acid ethyl ester (example 29) (200 mg, 0.46 mmol) was hydrolysed in an identical manner to example 2 to give the title compound (50 mg, 27%)
1H NMR (CDCI3, 300 MHz); δ 1.16 (3H, t), 2.98 (1 H, dd), 3.06 (1 H, dd), 3.33-3.49 (1 H, m), 3.60-3.75 (1 H, m), 4.03 (1 H, dd), 4.52 (2H, d), 6.46 (1 H, t), 6.78 (2H, dm), 7.09-7.40 (9H, m), 8.63 (2H, dm), 9.23 (1 H, br s).
Example 31
(E, Z)-(2S)-2-Ethoxy-3-(4-f3-(4-methoxyphenyl)-3-thiophen-2-yl-allyloxyl-phenyl)-propionic acid ethyl ester
Reaction of 3-(4-methoxyphenyl)-3-thiophen-2-yl-prop-2-en-1-ol (271 mg, 1.10 mmol), triphenylphosphine (289 mg, 1.10 mmol), (2S)-2-ethoxy-3-(4-hydroxy-phenyl)-propionic acid ethyl ester (238 mg, 1.0 mmol) and diethyl azodicarboxylate (188 mg, 1.08 mmol) in an identical manner to example 1 gave the title compound (80 mg, 17%).
Η NMR (CDCI3, 200 MHz); δ 1.10-1.28 (6H, m), 2.88-2.98 (2H, m), 3.25-3.43 (1 H, m), 3.47- 3.69 (1 H, m), 3.77-3.90 (3H, m), 3.95 (1 H, tm), 4.16 (2H, q), 4.45-4.78 (2H, m), 6.10-6.48 (1 H, m), 6.70-7.50 (11 H, m).
Example 32 (E. Z)-(2S)-2-Ethoxy-3-(4-r3-(4-methoxyphenyl)-3-thiophen-2-yl-allyloxy1-phenyl>-propionic acid
(E, Z)-(2S)-2-Ethoxy-3-{4-[3-(4-methoxyphenyl)-3-thiophen-2-yl-allyloxy]-phenyl}-propionic acid ethyl ester (example 31) (75 mg, 0.16 mmol) was hydrolysed in an identical manner to example 2 to give the title compound (40 mg, 57%)
Η NMR (CDCl3, 300 MHz); δ 1.17 (3H, t), 2.83-3.13 (2H, m), 3.27-3.50 (1 H, m), 3.50-3.70 (1 H, m), 3.77-3.88 (3H, m), 3.97-4.09 (1 H, m), 4.43-4.28 (2H, m), 6.10-6.30 (1 H, m), 6.70- 7.40 (11 H, m), COOH too broad to be observed. MS (El): 438 (M+), 229 (100%).
Example 33
(E, Z)-(2S)-2-Ethoxy-3-f4-(3-phenyl-3-p-tolyl-allyloxy)-phenvH-propionic acid ethyl ester
Reaction of (E, Z)-3-phenyl-3-tolyl-prop-2-en-1-ol (841 mg, 3.75 mmol), triphenylphosphine (1.03 g, 3.93 mmol), (2S)-2-ethoxy-3-(4-hydroxy-phenyl)-propionic acid ethyl ester (851 mg, 3.57 mmol) and diethy lazodicarboxylate (656 mg, 3.94 mmol) in an identical manner to ex- ample 1 gave the title compound (0.64 g, 40%).
1H NMR (CDCI3, 300 MHz); δ 1.14 (3H, t), 1.22 (3H, t), 2.30-2.42 (3H, m), 2.93 (2H, d), 3.26- 3.40 (1 H, m), 3.51-3.66 (1 H, m), 3.94 (1 H, t), 4.16 (2H, q), 4.49-4.63 (2H, m), 6.20-6.33 (1 H, m), 6.76 (2H, dm), 7.00-7.45 (11 H, m). MS (El): 444 (M+), 207 (100%).
Example 34
(E, Z)-(2S)-2-Ethoxy-3-f4-(3-phenyl-3-p-tolyl-allyloxy)-phenyll-propionic acid
(E, Z)-(2S)-2-Ethoxy-3-[4-(3-phenyl-3-p-tolyl-allyloxy)-phenyl]-propionic acid ethyl ester (example 33) (0.55 g, 1.24 mmol) was hydrolysed in an identical manner to example 2 to give the title compound (0.50 g, 97%) Η NMR (CDCI3, 300 MHz); δ 1.17 (3H, t), 2.24-2.41 (3H, m), 2.93 (1 H, dd), 3.04 (1 H, dd), 3.37-3.64 (2H, m), 4.03 (1 H, dd), 4.50-4.63 (2H, m), 6.20-6.32 (1 H, m), 6.78 (2H, dm), 7.00- 7.43 (11 H, m), COOH too broad to be observed. MS (El): 416 (M+), 207 (100%).
Example 35
(2S)-3-r4-(313-Diphenyl-allyloxy)-phenvn-2-ethoxy-propionic acid ethyl ester
Reaction of 3,3-diphenyl-prop-2-en-1-oI (210 mg, 1.0 mmol), tnbutylphosphine (303 mg, 1.50 mmol), (2S)-2-ethoxy-3-(4-hydroxy-phenyl)-propionic acid ethyl ester (250 mg, 1.05 mmol) and azodicarboxylic dipiperidide (378 mg, 1.50 mmol) in an identical manner to example 3 gave the title compound (290 mg, 67%).
Η NMR (CDCI3, 300 MHz); δ 1.14 (3H, t), 1.21 (3H, t), 2.92 (2H, d), 3.28-3.40 (1 H, m), 3.52- 3.65 (1 H, m), 3.94 (1 H, t), 4.14 (2H, q), 4.56 (2H, d), 6.31 (1 H, t), 6.75 (2H, dm), 7.10 (2H, dm), 7.16-7.44 (10H, m).
Example 36
(2S)-3-[4-(3,3-Diphenyl-allyloxy)-phenyll-2-ethoxy-propionic acid
(2S)-3-[4-(3,3-Diphenyl-aliyloxy)-phenyl]-2-ethoxy-propionic acid ethyl ester (example 35) (215 mg, 0.50 mmol) was hydrolysed in an identical manner to example 2 to give the title compound (180 mg, 90%)
Η NMR (CDCI3, 300 MHz); δ 1.17 (3H, t), 2.93 (1 H, dd), 3.04 (1 H, dd), 3.38-3.50 (1 H, m), 3.50-3-63 (1 H, m), 4.03 (1 H, dd), 4.58 (2H, d), 6.31 (1 H, t), 6.77 (2H, dm), 7.11 (2H, dm),
7.17-7.43 (10H, m), COOH too broad to be observed.
Example 37
(Z)-(2S)-2-Ethoxy-3-{4-r3-(4-fluorophenyl)-3-phenyl-allyloxy1-phenyl)-propionic acid ethyl es- ter Reaction of (Z)-3-(4-fluorophenyl)-3-phenyl-prop-2-en-1-ol (200 mg, 0.88 mmol), triphenylphosphine (242 mg, 0.92 mmol), (2S)-2-ethoxy-3-(4-hydroxy-phenyl)-propionic acid ethyl ester (200 mg, 0.84 mmol) and diethyl azodicarboxylate (160 mg, 0.92 mmol) in an identical manner to example 1 gave the title compound (275 mg, 73%).
1H NMR (CDCI3, 300 MHz); δ 1.15 (3H, t), 1.21 (3H, t), 2.93 (2H, d), 3.27-3.40 (1 H, m), 3.51- 3.65 (1 H, m), 3.96 (1 H, t), 4.14 (2H, q), 4.54 (2H, d), 6.33 (1 H, t), 6.76 (2H, dm), 6.95-7.40 (11 H, m). MS (El): 448 (M+), 375, 211 (100%).
Example 38
(Z)-(2S)-2-Ethoxy-3-{4-r3-(4-fluorophenyl)-3-phenyl-allyloxyl-phenyl)-propionic acid
(Z)-(2S)-2-Ethoxy-3-{4-[3-(4-fluorophenyl)-3-phenyl-allyloxy]-phenyl}-propionic acid ethyl ester (example 37) (200 mg, 0.45 mmol) was hydrolysed in an identical manner to example 2 to give the title compound (158 mg, 86%)
1H NMR (CDCI3, 200 MHz); δ 1.15 (3H, t), 2.84-3.14 (2H, m), 3.35-3.68 (2H, m), 4.04 (1 H, dd), 4.54 (2H, d), 6.32 (1 H, t), 6.77 (2H, dm), 7.00-7.40 (11 H, m), COOH too broad to be observed. MS (El): 420 (M+), 368, 317, 211 (100%).
Example 39
(E)-(2S)-2-Ethoxy-3-f4-[3-(4-fluorophenyl)-3-phenyl-allyloxy1-phenyl)-propionic acid ethyl es- ter
Reaction of (E)-3-(4-fluorophenyl)-3-phenyl-prop-2-en-1-ol (200 mg, 0.88 mmol), triphenylphosphine (242 mg, 0.92 mmol), (2S)-2-ethoxy-3-(4-hydroxy-phenyl)-propionic acid ethyl ester (200 mg, 0.84 mmol) and diethyl azodicarboxylate (160 mg, 0.92 mmol) in an identical manner to example 1 gave the title compound (320 mg, 85%). Η NMR (CDCI3, 300 MHz); δ 1.15 (3H, t), 1.21 (3H, t), 2.93 (2H, d), 3.24-3.43 (1 H, m), 3.50- 3.67 (1 H, m), 3.96 (1 H, t), 4.16 (2H, q), 4.54 (2H, d), 6.25 (1 H, t), 6.75 (2H, dm), 6.90-7.03 (2H, m), 7.03-7.30 (6H, m), 7.30-7.45 (3H, m). MS (El): 448 (M+), 375, 211 (100%).
Example 40
(E)-(2S)-2-Ethoxy-3-(4-r3-(4-fluorophenyl)-3-phenyl-allyloxy]-phenyl)-propionic acid
(£)-(2S)-2-Ethoxy-3-{4-[3-(4-fluorophenyl)-3-phenyl-allyloxy]-phenyl}-propionic acid ethyl ester (example 39) (225 mg, 0.50 mmol) was hydrolysed in an identical manner to example 2 to give the title compound (245 mg, 95%)
Η NMR (CDCI3, 200 MHz); δ 1.17 (3H, t), 2.83-3.14 (2H, m), 3.34-3.68 (2H, m), 4.02 (1H, dd), 4.53 (2H, d), 6.24 (1 H, t), 6.78 (2H, dm), 6.89-7.05 (2H, m), 7.05-7.49 (9H, m), COOH too broad to be observed. MS (El): 420 (M+), 317, 211 (100%).
Example 41
(2S)-3-(4-f3,3-Bis-(4-methoxyphenyl)-allyloxy]-phenyl)-2-ethoxy-propionic acid ethyl ester
Reaction of 3,3-bis-(4-methoxyphenyl)-prop-2-en-1-ol (1.62 g, 5.99 mmol), triphenylphosphine (2.88 g, 10.98 mmol), (2S)-2-ethoxy-3-(4-hydroxy-phenyl)-propionic acid ethyl ester (1.19 g, 4.99 mmol) and diethy lazodicarboxylate (1.92 g, 1 1.04 mmol) in an identical manner to example 1 gave the title compound (0.434 g, 17%).
1H NMR (CDCI3, 300 MHz); δ 1.15 (3H, t), 1.21 (3H, t), 2.93 (2H, d), 3.27-3.41 (1 H, m), 3.53- 3.65 (1 H, m), 3.80 (3H, s), 3.84 (3H, s), 3.95 (1 H, t), 4.15 (2H, q), 4.56 (2H, d), 6.17 (1 H, t), 6.71-6.87 (4H, m), 6.92 (2H, dm), 7.05-7.25 (6H, m).
Example 42
(2S)-3-{4-f3,3-Bis-(4-methoxyphenyl)-allyloxy1-phenyl}-2-ethoxy-propionic acid (2S)-3-{4-[3,3-Bis-(4-methoxyphenyl)-allyloxy]-phenyl}-2-ethoxy-propionic acid ethyl ester (example 41 ) (225 mg, 0.495 mmol) was hydrolysed in an identical manner to example 2 to give the title compound (150 mg, 71 %)
Η NMR (CDCI3, 300 MHz); δ 1.17 (3H, t), 2.95 (1 H, dd), 3.04 (1 H, dd), 3.38-3.50 (1 H, m), 3.52-3.66 (1 H, m), 3.80 (3H, s), 3.83 (3H, s), 4.03 (1 H, dd), 4.57 (2H, d), 6.17 (1 H, t), 6.71- 6.85 (4H, m), 6.92 (2H, dm), 7.05-7.25 (6H, m), COOH too broad to be observed.
Example 43
(2S)-3-[4-(3,3-Di-p-tolyl-allyloxy)-phenvn-2-ethoxy-propionic acid ethyl ester
Reaction of 3,3-di-(4-methylphenyl)-prop-2-en-1-ol (1.0 g, 4.20 mmol), tnbutylphosphine (1.27 g, 6.30 mmol), (2S)-2-ethoxy-3-(4-hydroxy-phenyl)-propionic acid ethyl ester (1.10 g, 4.62 mmol) and azodicarboxylic dipiperidide (1.59 g, 6.30 mmol) in an identical manner to example 3 gave the title compound (0.76 g, 39%).
H NMR (CDCI3, 300 MHz); δ 1.13 (3H, t), 1.21 (3H, t), 2.33 (3H, s), 2.38 (3H, s), 2.93 (2H, d), 3.26-3.41 (1H, m), 3.52-3.66 (1H, m), 3.95 (1H, t), 4.15 (2H, q), 4.56 (2H, d), 6.27 (1H, t), 6.75 (2H, dm), 7.00-7.21 (10H, m). MS (El): 458 (M+), 385, 221 (100%).
Example 44
(2S)-3-f4-(3,3-Di-p-tolyl-allyloxy)-phenvπ-2-ethoxy-propionic acid
(2S)-3-[4-(3,3-Di-p-tolyl-allyloxy)-phenyl]-2-ethoxy-propionic acid ethyl ester (example 43) (0.76 g, 1.66 mmol) was hydrolysed in an identical manner to example 2 to give the title compound (0.696 g, 98%).
Η NMR (CDCI3, 300 MHz); δ 1.16 (3H, t), 2.33 (3H, s), 2.38 (3H, s), 2.94 (1 H, dd), 3.05 (1 H, dd), 3.39-3.51 (1H, m), 3.51-3.65 (1H, m), 4.03 (1H, dd), 4.57 (2H, d), 6.23 (1 H, t), 6.77 (2H, dm), 7.00-7.22 (10H, m), COOH too broad to be observed. MS (El): 430 (M+), 327, 221 (100%).
Example 45
(Z)-(2S)-3-f4-(3-Biphenyl-4-yl-3-phenyl-allyloxy)-phenvn-2-ethoxy-propionic acid ethyl ester
Reaction of (Z)-3-biphenyl-4-yl-3-phenyl-prop-2-en-1-ol (171 mg, 0.60 mmol), triphenylphosphine (142 mg, 0.63 mmol), (2S)-2-ethoxy-3-(4-hydroxy-phenyi)-propionic acid ethyl ester (149 mg, 0.63 mmol) and diethyl azodicarboxylate (95 mg, 0.55 mmol) in an identical manner to example 1 gave the title compound (160 mg, 53%).
1H NMR (CDCI3, 300 MHz); δ 1.16 (3H, t), 1.21 (3H, t), 2.93 (2H, d), 3.28-3.40 (1 H, m), 3.52- 3.65 (1 H, m), 3.95 (1 H, t), 4.14 (2H, q), 4.63 (2H, d), 6.33 (1 H, t), 6.78 (2H, dm), 7.12 (2H, dm), 7.20-7.50 (10H, m), 7.55-7.68 (4H, m).
Example 46
(Z)-(2S)-3-f4-(3-Biphenyl-4-yl-3-phenyl-allyloxy)-phenyll-2-ethoxy-propionic acid
(Z)-(2S)-3-[4-(3-Biphenyl-4-yl-3-phenyl-allyloxy)-phenyl]-2-ethoxy-propionic acid ethyl ester (example 45) (0.36 g, 0.71 mmol) was hydrolysed in an identical manner to example 2 to give the title compound (0.345 g, 86%) as an orange gum containing approximately 0.6 molar equivalents of ethyl acetate.
1H NMR (CDCI3, 300 MHz); δ 1.17 (3H, t), 1.26 (1.8H, t, ethyl acetate), 2.04 (1.8H, s, ethyl acetate), 2.95 (1 H, dd), 3.06 (1 H, dd), 3.38-3.52 (1 H, m), 3.52-3.64 (1 H, m), 4.03 (1 H, dd), 4.12 (1.2H, q, ethyl acetate), 4.63 (2H, d), 6.32 (1 H, t), 6.80 (2H, dm), 7.11 (2H, dm), 7.20- 7.50 (10H, m), 7.54-7.68 (4H, m), COOH too broad to be observed. MS (El): 478 (M+), 375, 269 (100%).
Example 47
(Z)-(2S)-3-{4-r3-(4-Bromophenyl)-3-phenyl-allyloxy1-phenyl)-2-ethoxy-propionic acid ethyl ester Reaction of 3-(4-bromophenyl)-3-phenyl-prop-2-en-1-ol (145 mg, 0.50 mmol), triphenylphosphine (144 mg, 0.55 mmol), (2S)-2-ethoxy-3-(4-hydroxy-phenyl)-propionic acid ethyl ester (119 mg, 0.50 mmol) and diethyl azodicarboxylate (96 mg, 0.55 mmol) in an identical manner to example 1 gave the title compound (110 mg, 43%).
1H NMR (CDCI3, 300 MHz); δ 1.17 (3H, t), 1.21 (3H, t), 2.94 (2H, d), 3.29-3.41 (1 H, m), 3.53- 3.65 (1 H, m), 3.96 (1 H, t), 4.15 (2H, q), 4.53 (2H, d), 6.32 (1 H, t), 6.75 (2H, dm), 7.05-7.18 (4H, m), 7.18-7.38 (5H, m), 7.52 (2H, dm). MS (El): 508/510 (M+) 435/437, 393/395, 271/273, 192 (100%).
Microanalysis for C28H29BrO4 + 0.1 H2O: calculated = 65.78%C, 5.76%H; found 65.79%C, 5.91 %H.
Example 48
(Z)-(2S)-3-{4-r3-(4-Bromophenyl)-3-phenyl-allyloxyl-phenyl)-2-ethoxy-propionic acid
(Z)-(2S)-3-{4-[3-(4-Bromophenyl)-3-phenyl-allyloxy]-phenyl}-2-ethoxy-propionic acid ethyl ester (example 47) (90 mg, 0.18 mmol) was hydrolysed in an identical manner to example 2 to give the title compound (60 mg, 71%).
Η NMR (CDCI3, 300 MHz); δ 1.17 (3H, t), 2.96 (1 H, dd), 3.05 (1 H, dd), 3.39-3.51 (1 H, m), 3.51-3.64 (1 H, m), 4.03 (1 H, dd), 4.52 (2H, d), 6.32 (1 H, t), 6.75 (2H, dm), 7.02-7.18 (4H, m), 7.18-7.40 (5H, m), 7.51 (2H, dm), COOH too broad to be observed. LCMS (electrospray): 503/505 (M+Na), 498/500 (M+NH4), 271/273 (100%).
Example 49
(2S)-3-f4-(3,3-Bis-biphenyl-4-yl-allyloxy)-phenyn-2-ethoxy-propionic acid ethyl ester
Reaction of 3,3-bis-biphenyl-4-yl-prop-2-en-1-ol (363 mg, 1.0 mmol), tnbutylphosphine (303 mg, 1.5 mmol), (2S)-2-ethoxy-3-(4-hydroxy-phenyl)-propionic acid ethyl ester (262 mg, 1.1 mmol) and azodicarboxylic dipiperidide (378 mg, 1.5 mmol) in an identical manner to example 3 gave the title compound (445 mg, 76%) containing 0.8 equivalents of ethyl acetate.
H NMR (CDCI3, 300 MHz); δ 1.16 (3H, t), 1.21 (3H, t), 1.25 (2.4H, t, ethyl acetate), 2.04 (2.4H, s, ethyl acetate), 2.93 (2H, d), 3.28-3.40 (1 H, m), 3.51-3.65 (1 H, m), 3.96 (1 H, t), 4.07-4.20 ({2H, q} plus {1.6H, q, ethyl acetate}), 4.54 (2H, d), 6.40 (1 H, t), 6.80 (2H, dm), 7.03 (2H, dm), 7.27-7.70 (18H, m).
Example 50
(2S)-3-[4-(3,3-Bis-biphenyl-4-yl-allyloxy)-phenyl1-2-ethoxy-propionic acid
(2S)-3-[4-(3,3-Bis-biphenyl-4-yl-allyloxy)-phenyl]-2-ethoxy-propionic acid ethyl ester (example 49) (560 mg, 0.96 mmol) was hydrolysed in an identical manner to example 2 to give the title compound (450 mg, 84%).
H NMR (CDCI3, 300 MHz); δ 1.13 (3H, t), 2.93 (1H, dd), 3.05 (1H, dd), 3.35-3.50 (1H, m), 3.50-3.64 (1 H, m), 4.02 (1 H, dd), 4.62 (2H, d), 6.39 (1 H, t), 6.80 (2H, dm), 7.02 (2H, dm), 7.27-7.72 (18H, m), COOH too broad to be observed.
Example 51
(2S)-3-(4-[3,3-Bis-(4-bromophenyl)-allyloxy1-phenyl)-2-ethoxy-propionic acid ethyl ester
Reaction of 3,3-bis-(4-bromophenyl)-prop-2-en-1-ol (2.60 g, 7.0 mmol), tnbutylphosphine (2.52 g, 10.0 mmol), (2S)-2-ethoxy-3-(4-hydroxy-phenyl)-propionic acid ethyl ester (1.50 g, 6.3 mmol) and azodicarboxylic dipiperidide (2.02 g, 10.0 mmol) in an identical manner to example 3 gave the title compound (2.8 g, 75%).
Η NMR (CDCI3, 300 MHz); δ 1.16 (3H, t), 1.21 (3H, t), 2.93 (2H, d), 3.27-3.40 (1 H, m), 3.53- 3.65 (1 H, m), 3.94 (1 H, t), 4.15 (2H, q), 4.51 (2H, d), 6.31 (1 H, t), 6.75 (2H, dm), 7.01-7.19 (6H, m), 7.42 (2H, dm), 7.52 (2H, dm). Example 52
(2S)-3-{4-r3,3-Bis-(4-bromophenyl)-allyloxyl-phenyl)-2-ethoxy-propionic acid
(2S)-3-{4-[3,3-Bis-(4-bromophenyl)-allyloxy]-phenyl}-2-ethoxy-propionic acid ethyl ester (example 51 ) (2.8 g, 4.76 mmol) was hydrolysed in an identical manner to example 2 to give the title compound (2.3 g, 83%) which contained approximately 0.25 molar equivalents of ethyl acetate.
1H NMR (CDCI3, 300 MHz); δ 1.15 (3H, t), 1.25 (0.75H, t, ethyl acetate), 2.04 (0.75H, s, ethyl acetate), 2.93 (1 H, dd), 3.04 (1 H, dd), 3.37-3.49 (1 H, m), 3.52-3.68 (1 H, m), 4.02 (1 H, dd), 4.12 (0.5H, q, ethyl acetate), 4.50 (2H, d), 6.30 (1 H, t), 6.74 (2H, dm), 7.00-7.19 (6H, m), 7.49 (2H, dm), 7.50 (2H, dm), COOH too broad to be observed.
Example 53
(Z)-(2S)-2-Ethoxy-3-(4-f3-(4-furan-2-yl-phenyl)-3-phenyl-allyloxy1-phenyl)-propionic acid ethyl ester
Reaction of (Z)-3-(4-furan-2-yl-phenyl)-3-phenyl-prop-2-en-1-ol (300 mg, 1.09 mmol), tnbutylphosphine (0.40 ml, 1.64 mmol), (2S)-2-ethoxy-3-(4-hydroxy-phenyl)-propionic acid ethyl ester (286 mg, 1.20 mmol) and azodicarboxylic dipiperidide (413 mg, 1.64 mmol) in benzene in an identical manner to example 3 gave the title compound (260 mg, 48%).
1H NMR (CDCI3, 300 MHz); δ 1.15 (3H, t), 1.21 (3H, t), 2.93 (2H, d), 3.28-3.40 (1 H, m), 3.52- 3.65 (1 H, m), 3.94 (1 H, t), 4.14 (2H, q), 4.60 (2H, d), 6.30 (1 H, t), 6.49 (1 H, dd), 6.69 (1 H, d), 6.77 (2H, dm), 7.11 (2H, dm), 7.18-7.32 (7H, m), 7.49 (1 H, d), 7.69 (2H, dm). LCMS (electrospray): 519 (M+Na), 514 (M+NH4), 259 (100%).
Example 54
(Z)-(2S)-2-Ethoxy-3-{4-r3-(4-furan-2-yl-phenyl)-3-phenyl-allyloxy1-phenyl)-propionic acid (Z)-(2S)-2-Ethoxy-3-{4-[3-(4-furan-2-yl-phenyl)-3-phenyl-allyloxy]-phenyl}-propionic acid ethyl ester (example 53) (240 mg, 0.483 mmol) was hydrolysed in an identical manner to example 2 to give the title compound (170 mg, 75%).
1H NMR (CDCI3, 300 MHz); δ 1.15 (3H, t), 2.93 (1 H, dd), 3.05 (1 H, dd), 3.33-3.49 (1 H, m), 3.50-3.65 (1 H, m), 4.01 (1 H, dd), 4.60 (2H, d), 6.30 (1 H, t), 6.49 (1 H, dd), 6.68 (1 H, d), 6.78 (2H, dm), 7.1 1 (2H, dm), 7.15-7.36 (7H, m), 7.49 (1 H, d), 7.68 (2H, dm), COOH too broad to be observed. LCMS (electrospray): 491 (M+Na), 486 (M+NH4), 259 (100%).
Example 55
(E)-(2S)-3-{4-f3-(4-Bromophenyl)-3-phenyl-allyloxy1-phenyl)-2-ethoxy-propionic acid ethyl ester
Reaction of (E)- 3-(4-bromophenyl)-3-phenyl-prop-2-en-1-ol (289 mg, 1.0 mmol), tnbutylphosphine (0.37 ml, 1.5 mmol), (2S)-2-ethoxy-3-(4-hydroxy-phenyl)-propionic acid ethyl ester (262 mg, 1.10 mmol) and azodicarboxylic dipiperidide (378 mg, 1.5 mmol) in benzene in an identical manner to example 3 gave the title compound (460 mg, 90%).
1H NMR (CDCI3, 300 MHz); δ 1.15 (3H, t), 1.21 (3H, t), 2.92 (2H, d), 3.26-3.40 (1 H, m), 3.51- 3.65 (1 H, m), 3.94 (1 H, t), 4.15 (2H, q), 4.54 (2H, d), 6.29 (1 H, t), 6.74 (2H, dm), 7.03-7.45 (11H, m). LCMS (electrospray): 531/533 (M+Na), 271/273 (100%).
Example 56
(E)-(2S)-3-(4-f3-(4-Bromophenyl)-3-phenyl-allyloxyl-phenyl)-2-ethoxy-propionic acid
(E)-(2S)-3-{4-[3-(4-Bromophenyl)-3-phenyl-allyloxy]-phenyl}-2-ethoxy-propionic acid ethyl ester (example 55) (382 mg, 0.75 mmol) was hydrolysed in an identical manner to example 2 to give the title compound (350 mg, 97%). Η NMR (CDCI3, 300 MHz); δ 1.16 (3H, t), 2.93 (1 H, dd), 3.05 (1 H, dd), 3.38-3.50 (1 H, m), 3.50-3.63 (1 H, m), 4.03 (1 H, dd), 4.53 (2H, d), 6.30 (1 H, t), 6.75 (2H, dm), 7.03-7.45 (11 H, m), COOH too broad to be observed.
LCMS (electrospray): 503/505 (M+Na), 498/500 (M+NH4), 271/273 (100%).
Example 57
(2S)-3-{4-f3,3-Bis-(4-furan-2-yl-phenyl)-allyloxy1-phenyl)-2-ethoxy-propionic acid ethyl ester
Reaction of 3,3-bis-(4-furan-2-yl-phenyl)-prop-2-en-1-ol (460 mg, 1.34 mmol), tnbutylphosphine (0.50 ml, 2.0 mmol), (2S)-2-ethoxy-3-(4-hydroxy-phenyl)-propionic acid ethyl ester (320 mg, 1.34 mmol) and azodicarboxylic dipiperidide (504 mg, 2.0 mmol) in benzene in an identical manner to example 3 gave the title compound (541 mg, 72%).
Η NMR (CDCI3, 300 MHz); δ 1.16 (3H, t), 1.21 (3H, t), 2.93 (2H, d), 3.28-3.40 (1 H, m), 3.51- 3.64 (1 H, m), 3.94 (1 H, t), 4.14 (2H, q), 4.59 (2H, d), 6.35 (1 H, t), 6.40-6.51 (2H, m), 6.62 (1 H, d), 6.69 (1H, d), 6.77 (2H, dm), 7.13 (2H, dm), 7.20-7.33 (4H, m), 7.44 (1 H, d), 7.48 (1 H, d), 7.58 (2H, dm), 7.70 (2H, m).
Example 58
(2S)-3-{4-f3,3-Bis-(4-furan-2-yl-phenyl)-allyloxy1-phenyl)-2-ethoxy-propionic acid
(2S)-3-{4-[3,3-Bis-(4-furan-2-yl-phenyl)-allyloxy]-phenyl}-2-ethoxy-propionic acid ethyl ester (example 57) (530 mg, 0.95 mmol) was hydrolysed in an identical manner to example 2 to give the title compound (400 mg, 79%).
Η NMR (CDCI3, 300 MHz); δ 1.17 (3H, t), 2.95 (1 H, dd), 3.07 (1 H, dd), 3.40-3.52 (1 H, m), 3.52-3.63 (1 H, m), 4.05 (1 H, dd), 4.60 (2H, d), 6.35 (1 H, t), 6.44-6.51 (2H, m), 6.64 (1 H, d), 6.70 (1 H, d), 6.79 (2H, dm), 7.12 (2H, dm), 7.20-7.34 (4H, m), 7.47 (1 H, d), 7.50 (1 H, d), 7.59 (2H, dm), 7.70 (2H, dm), COOH too broad to be observed.
Example 59 (E, Z)-(2S)-3-[4-(3-Biphenyl-4-yl-3-p-tolyl-allyloxy)-phenvπ-2-ethoxy-propionic acid ethyl ester
Reaction of (E, Z)-3-biphenyl-4-yl-3-p-tolyl-prop-2-en-1-ol (300 mg, 1.0 mmol), tributyl- phosphine (0.37 ml, 1.5 mmol), (2S)-2-ethoxy-3-(4-hydroxy-phenyl)-propionic acid ethyl es- ter (262 mg, 1.10 mmol) and azodicarboxylic dipiperidide (378 mg, 1.50 mmol) in benzene in an identical manner to example 3 gave the title compound (390 mg, 76%).
1H NMR (CDCI3, 300 MHz); δ 1.10-1.25 (6H, m), 2.30-2.42 (3H, m), 2.92 (2H, d), 3.27-3.40 (1H, m), 3.50-3.65 (1 H, m), 3.94 (1 H, tm), 4.13 (2H, qm), 4.57-4.64 (2H, m), 6.23-6.38 (1H, m), 6.79 (2H, dm), 7.03-7.67 (15H, dm).
LCMS (electrospray): 543 (M+Na), 538 (M+NH4), 283 (100%).
Example 60
(E, Z)-(2S)-3-r4-(3-Biphenyl-4-yl-3-p-tolyl-allyloxy)-phenyll-2-ethoxy-propionic acid
(E, Z)-(2S)-3-[4-(3-Biphenyl-4-yl-3-p-tolyl-allyloxy)-phenyl]-2-ethoxy-propionic acid ethyl ester (example 59) (370 mg, 0.71 mmol) was hydrolysed in an identical manner to example 2 to give the title compound (310 mg, 89%).
1H NMR (CDCI3, 300 MHz); δ 1.10-1.22 (3H, m), 2.30-2.44 (3H, m), 2.93 (1 H, dd), 3.04 (1 H, dd), 3.37-3.63 (2H, m), 3.98-4.07 (1 H, m), 4.54-4.65 (2H, m), 6.25-6.38 (1 H, m), 6.79 (2H, dm), 7.02-7.67 (15H, m), COOH too broad to be observed. LCMS (electrospray): 515 (M+Na), 283 (100%).
Example 61
(E, Z)-(2R)- 3-[4-(3-Biphenyl-4-yl-3-phenyl-allyloxy)-phenvn-2-ethoxy-propionic acid ethyl es- ter
Potassium carbonate (0.25 g, 1.81 mmol) was added to a stirred solution of 4-(3-bromo-1- phenyl-prop-1-enyl)-biphenyl (0.35 g, 1.00 mmol) and (2R)-2-ethoxy-3-(4-hydroxy-phenyl)- propionic acid ethyl ester (0.215 g, 0.90 mmol) in dry acetone (20 ml), and the mixture heated to 60°C under reflux for 18 h. The resulting suspension was cooled to room tempera- ture, filtered to remove inorganic products, and the solvents evaporated The product was purified by flash column chromatography on silica gel, eluting with 15% ethyl acetate in light petroleum, to give the title compound as a colourless gum (0 40 g, 87%)
1H NMR (CDCI3, 300 MHz), δ 1 09-1 32 (6H, m), 2 93 (2H, d), 3 27-3 41 (1 H, m), 3 51-3 67 (1 H, m), 3 96 (1 H, t), 4 18-4 20 (2H, m), 4 52-4 68 (2H, m), 6 28-6 41 (1 H, m), 6 72-6 83 (2H, m), 7 12 (2H, dm), 7 18-7 69 (14H, m)

Claims

CLAIMS:
1. A compound of formula (I)
Figure imgf000063_0001
wherein A1 and A2 are independently of each other a 5-6 membered cyclic ring or a 9-10 membered bicyclic ring, optionally substituted with one or more halogen, perhalomethyl, hydroxy, nitro, cyano, formyl, or
Figure imgf000063_0002
C4.12-alkenynyl, C2.12-alkenyl, C2.12-alkynyl, C^^-alkoxy, aryl, aryloxy, arylalkyl, arylalkoxy, heterocyclyl, heteroaryl, heteroarylalkyl, heteroaryloxy, heteroarylalkoxy, acyl, acyloxy, hydroxyC,-12-alkyl, amino, acylamino, C^z-alkyl-amino, C^- dialkylamino, arylamino, arylalkylammo, aminoC^^-alkyl, C^^-alkoxycarbonyl, alkylaminocarbonyl, aryloxycarbonyl, arylalkoxycarbonyl, C^^-alkoxyC^^-alkyl, aryloxyC^^-alkyl, arylalkoxyC^^-alkyl, arylthio, CL^-alkylthio, thioCι_12-alkyl, C^2- alkoxycarbonyiamino, aryloxycarbonylamino, arylalkoxycarbonylamino, -COR1, or - SO2R2, wherein R1 and R2 independently of each other are selected from hydroxy, halogen, perhalomethyl, C^-alkoxy or amino optionally substituted with one or more C^-alkyl, perhalomethyl or aryl; optionally substituted with one or more halogen, perhalomethyl, hydroxy, nitro or cyano;
Z is C, CR3, wherein R3 is hydrogen, halogen, perhalomethyl, C,.12-alkyl, C4.12- alkenynyl, C2.12-alkenyl, C2.12-alkynyl, C,.12-alkoxy, aryloxy, arylalkoxy, heteroaryloxy, heteroarylalkoxy, acyl, acyloxy, hydroxyC^^-alkyl, C^^-alkoxyC^ alkyi, aryloxyC,. 12-alkyl, arylalkoxyC^^-alkyl, thioC^z-alkyl, -COR4, or -SO2R11, wherein R4 and R11 independently of each other are selected from hydroxy, halogen, perhalomethyl, C,. 6-alkoxy or amino optionally substituted with one or more C^-alky!, perhalomethyl or aryl optionally substituted with one or more halogen, perhalomethyl, hydroxy, nitro or cyano;
Q is O, S, NR12, wherein R12 is hydrogen, perhalomethyl, d-^-alkyl, C4.12-alkenynyl, C2-12-alkenyl, C2.12-alkynyl, aryl, arylalkyl, heterocyclyl, heteroaryl, heteroarylalkyl, acyl, hydroxyC^^-alkyl, aminoC^-alkyl, C^^-alkoxycarbonyl, aryloxycarbonyl, arylalkoxycarbonyl, C^^-alkoxyC^ alkyl, aryloxyCM^alkyl, arylalkoxyCι-12-alkyl, thioC^-alkyl, -COR13, or -SO2R14, wherein R 3 and R14 independently of each other are selected from hydroxy, perhalomethyl, C^-alkoxy or amino optionally substituted with one or more C^-alkyl, perhalomethyl or aryl optionally substituted with one or more halogen, perhalomethyl, hydroxy, nitro or cyano;
represents a single bond or a double bond;
Ar represents arylene, heteroarylene, or a divalent heterocyclic group each of which can optionally be substituted with one or more halogen, C^-alkyl, amino, hydroxy, C^-alkoxy or aryl;
R5 represents hydrogen, hydroxy, halogen, C^^-alkoxy, C^^-alkyl, C4.12-alkenynyl, C2.12- alkenyl, C2.12-alkynyl or arylalkyl; optionally substituted with one or more halogen, perhalomethyl, hydroxy, nitro or cyano or R5 forms a bond together with R6;
R6 represents hydrogen, hydroxy, halogen, C^^-alkoxy, C^^-alkyl, C4.12-alkenynyl, C2.12- alkenyl, C2.12-alkynyl, acyl or arylalkyl optionally substituted with one or more halogen, perha- lomethyl, hydroxy, nitro or cyano or R6 forms a bond together with R5;
M represents OR7, where R7 represents hydrogen, C^^-alkyl, C4.12-alkenynyl, C2.12-alkenyl, C2.12-alkynyl, aryl, arylalkyl, C^^-alkoxyC^^-alkyl, C^ralkoxycarbonyl, aryloxycarbonyl, C,. 12-alkylaminocarbonyl, arylaminocarbonyl, acyl, heterocyclyl, heteroaryl or heteroarylalkyl groups optionally substituted with one or more halogen, perhalomethyl, hydroxy, nitro or cyano or M represents COYR8; R8 represents hydrogen, C^^alkyl, C4.12-alkenynyl, C2.12-alkenyl, C2.12-alkynyl, aryl, arylalkyl, heterocyclyl, heteroaryl or heteroarylalkyl groups optionally substituted with one or more halogen, perhalomethyl, hydroxy, nitro or cyano;
Y represents oxygen, sulphur or NR10, where R10 represents hydrogen, C^^-alkyl, aryl, hy- droxyC 12-alkyl or arylalkyl groups or when Y is NR10, R8 and R10 may form a 5 or 6 membered nitrogen containing ring, optionally substituted with one or more C^-alky!;
k is an integer ranging from 1 to 2, n is an integer ranging from 0 to 3 and m is an integer ranging from 0 to 1 ;
or a salt thereof with a pharmaceutically acceptable acid or base, or any optical isomer or mixture of optical isomers, including a racemic mixture, or any tautomeric forms.
2. A compound according to claim 1 wherein A1 and A2 are independently of each other a 5-6 membered cyclic ring or a 9-10 membered bicyclic ring, optionally substituted with one or more halogen, perhalomethyl, hydroxy, C^-alky!, (C3-6- cycloalky C^e-alkyl, C4.6-alkenynyl, C2-6-alkenyl, C2.6-alkynyl, C^-alkoxy, aryl, aryloxy, arylalkyl, arylalkoxy, heterocyclyl, heteroaryl, heteroarylalkyl, heteroaryloxy, heteroarylalkoxy, acyl, hydroxyd-e-alkyl, d-e-alkyl-amino, C^-dialkylamino, arylamino, arylalkylamino, aminoC^-alkyl, C^-alkoxycarbonyl, alkylaminocarbonyl, aryloxycarbonyl, arylalkoxycarbonyl, d-e-alkoxyd-e-alkyl, aryloxyd.6-alkyl, or arylalkoxyd-e-alkyl.
3. A compound according to any one of the preceding claims wherein A1 and A2 are independently of each other a 5-6 membered cyclic ring or a 9-10 membered bicyclic ring, optionally substituted with one or more halogen, perhalomethyl, hydroxy, C^-alky!, (CM- cycloalky d-e-alkyl, C^-alkenynyl, C2.6-alkenyl, C2.6-alkynyl, d-6-alkoxy, aryl, aryloxy, arylalkyl, arylalkoxy, heterocyclyl, heteroaryl, heteroarylalkyl, heteroaryloxy, heteroarylalkoxy, acyl, hydroxyC|-6-alkyl, d.6-alkyl-amino, d.6-dialkylamino, arylamino, arylalkylamino, aminod-e- alkyl, d-6-alkoxyd.g-alkyl, aryloxyd.6-alkyl, or arylalkoxyd.6-alkyl.
4. A compound according to any one of the preceding claims wherein A1 and A2 are independently of each other a 5-6 membered cyclic ring or a 9-10 membered bicyclic ring, optionally substituted with one or more halogen, d-6-alkyl, C,-6-alkoxy or aryl.
5. A compound according to any one of the preceding claims wherein A1 and A2 are independently of each other a 5-6 membered cyclic ring optionally substituted with one or more halogen, d-6-alkyl, d.6-alkoxy, or aryl.
6. A compound according to any one of the preceding claims wherein Z is a carbon atom at the end of a double bond, or Z is CR3, wherein R3 is hydrogen, halogen, perhalomethyl, C1.12- alkyl, C4.12-alkenynyl, C2.12-alkenyl, C2.12-alkynyl, d.12-alkoxy, aryloxy, arylalkoxy, heteroaryloxy, heteroarylalkoxy, acyl, acyloxy, hydroxyd.12-alkyl, d.-^-alkoxyd.^-alkyl, aryloxyC1.12- alkyl, arylalkoxyd-12-alkyl, thiod-^-alkyl, -COR4, or -SO2R11, wherein R4 and R11 independently of each other are selected from hydroxy, halogen, perhalomethyl, d-6-alkoxy or amino optionally substituted with one or more C^-alkyl, perhalomethyl or aryl optionally substituted with one or more halogen, perhalomethyl, hydroxy, nitro or cyano.
7. A compound according to any one of the preceding claims wherein Z is a carbon atom at the end of a double bond, or Z is CR3, wherein R3 is hydrogen, halogen, perhalomethyl, d.6- alkyl, C4.6-alkenynyl, C2.6-alkenyl, C2.6-alkynyl, d-e-alkoxy, aryloxy, arylalkoxy, heteroaryloxy, heteroarylalkoxy, acyl, acyloxy, hydroxyd-6-alkyl, d-e-alkoxyd-e-alkyl, aryloxyd.6-alkyl, arylalkoxyd-e-alkyl, thiod-6-alkyl, -COR4, or -SO2R11, wherein R4 and R11 independently of each other are selected from hydroxy, halogen, perhalomethyl, d.6-alkoxy or amino optionally substituted with one or more C^-alkyl, perhalomethyl or aryl optionally substituted with one or more halogen, perhalomethyl, hydroxy, nitro or cyano.
8. A compound according to any one of the preceding claims wherein Z is a carbon atom at the end of a double bond, or Z is CR3, wherein R3 is hydrogen, halogen, perhalomethyl, Chalky!, C4.6-alkenynyl, C2.6-alkenyl, C2.6-alkynyl, d-6-alkoxy, aryloxy, arylalkoxy, heteroaryloxy, heteroarylalkoxy, d-g-alkoxyd-e-alkyl, aryloxyd.6-alkyl, or arylalkoxyd-6-alkyl.
9. A compound according to any one of the preceding claims wherein Z is a carbon atom at the end of a double bond, or Z is CR3, wherein R3 is hydrogen.
10. A compound according to any one of the preceding claims wherein Q is O, S, or NR12, wherein R12 is hydrogen, perhalomethyl, d-6-alkyl, C4.6-alkenynyl, C2.6-alkenyl, C2.6-alkynyl, aryl, arylalkyl, , heterocyclyl, heteroaryl, heteroarylalkyl, acyl, hydroxyCL e-alkyl, aminod_6-alkyl, d-6-alkoxycarbonyl, aryloxycarbonyl, arylalkoxycarbonyl, d. 6-alkoxyCve-alkyl, aryloxyd.6-alkyl, arylalkoxyd-e-alkyl, thioC^-alkyl, -COR13, or - SO2R14, wherein R13 and R14 independently of each other are selected from hydroxy, perhalomethyl, d.6-alkoxy or amino optionally substituted with one or more Chalky!, perhalomethyl or aryl optionally substituted with one or more halogen, or perhalomethyl.
11. A compound according to any one of the preceding claims wherein Q is O, S, or NR12, wherein R12 is hydrogen, perhalomethyl, d.6-alkyl, aryl, arylalkyl, heteroarylalkyl, or acyl.
12. A compound according to any one of the preceding claims wherein Q is O or S.
13. A compound according to any one of the preceding claims wherein Q is O.
14. A compound according to any one of the preceding claims wherein represents a single bond or a double bond.
15. A compound according to any one of the preceding claims wherein Ar represents arylene, heteroarylene, or a divalent heterocyclic group each of which can optionally be substituted with one or more halogen, d-6-alkyl or d_6-alkoxy.
16. A compound according to any one of the preceding claims wherein Ar represents ary- lene, or heteroarylene.
17. A compound according to any one of the preceding claims wherein Ar represents arylene.
18. A compound according to any one of the preceding claims wherein R5 represents hydrogen, hydroxy, halogen, d.6-alkoxy, C^-alkyl, C^-alkenynyl, C2.6-alkenyl, C2.6-alkynyl or arylalkyl optionally substituted with one or more halogen, or perhalomethyl or R5 forms a bond together with R6.
19. A compound according to any one of the preceding claims wherein R5 represents hydrogen, halogen, d.6-alkoxy, C^-alkyl, or perhalomethyl or R5 forms a bond together with R6.
20. A compound according to any one of the preceding claims wherein R5 represents hydrogen, halogen or R5 forms a bond together with R6.
21. A compound according to any one of the preceding claims wherein R5 represents hydrogen.
22. A compound according to any one of the preceding claims wherein R6 represents hydrogen, d-g-alkoxy, C^-alkyl, C4.6-alkenynyl, C2.6-alkenyl, C2.6-alkynyl, acyl or arylalkyl optionally substituted with one or more halogen or perhalomethyl or R6 forms a bond together with R5.
23. A compound according to any one of the preceding claims wherein R6 represents hydrogen, halogen, d-6-alkoxy, or R6 forms a bond together with R5.
24. A compound according to any one of the preceding claims wherein R6 represents hydrogen, d-6-alkoxy, or R6 forms a bond together with R5.
25. A compound according to any one of the preceding claims wherein R6 represents hydrogen.
26. A compound according to any one of the preceding claims wherein M represents OR7, where R7 represents hydrogen, d-e-alkyl, d-e-aikenynyl, C2.6-alkenyl, C2.6-alkynyl, aryl, arylalkyl, C1.6-alkoxyC1.6-alkyl, d-6-alkoxycarbonyl, aryloxycarbonyl, d-e-alkylaminocarbonyl, arylaminocarbonyl, acyl, heterocyclyl, heteroaryl or heteroarylalkyl groups optionally substituted with one or more halogen, perhalomethyl, hydroxy, nitro or cyano.
27. A compound according to any one of the preceding claims wherein M represents OR7, where R7 represents hydrogen, C,.6-alkyl, C^-alkenynyl, C2.6-alkenyl, C2.6-alkynyl, aryl, arylalkyl, d-6-alkoxyd-e-alkyl, heterocyclyl, heteroaryl or heteroarylalkyl groups optionally substituted with one or more halogen or perhalomethyl.
28. A compound according to any one of the preceding claims wherein M represents OR7, where R7 represents d-6-alkyl or M represents COYR8 where R8 is defined as in claim 1.
29. A compound according to any one of the preceding claims wherein M represents OR7, where R7 represents ethyl or M represents COYR8 where R8 is defined as in claim 1.
30. A compound according to any one of the preceding claims wherein R8 represents hydrogen, d-6alkyl, C4-6-alkenynyl, C2.6-alkenyl, C2.6-alkynyl, aryl, arylalkyl, heterocyclyl, heteroaryl or heteroarylalkyl groups optionally substituted with one or more halogen, perhalomethyl, hydroxy, nitro or cyano.
31. A compound according to any one of the preceding claims wherein R8 represents hydrogen, d-ealkyl, C4.6-alkenynyl, C2.6-alkenyl, C2.6-alkynyl, aryl, arylalkyl, heterocyclyl, heteroaryl or heteroarylalkyl groups optionally substituted with one or more halogen, or perhalomethyl.
32. A compound according to any one of the preceding claims wherein R8 represents hydrogen or d-ealkyl.
33. A compound according to any one of the preceding claims wherein R8 represents hydrogen or ethyl.
34. A compound according to any one of the preceding claims wherein Y represents oxygen, sulphur or NR10, where R10 represents hydrogen, d-6-alkyl, aryl, hydroxyd.6-alkyl or arylalkyl groups or when Y is NR10, R8 and R10 may form a 5 or 6 membered nitrogen containing ring, optionally substituted with one or more d-β-alkyl.
35. A compound according to any one of the preceding claims wherein Y represents oxygen, or NR10, where R10 represents hydrogen, d-6-alkyl, aryl, or arylalkyl groups, or when Y is NR10, R8 and R10 may form a 5 or 6 membered nitrogen containing ring, optionally substituted with one or more d-6-alkyl.
36. A compound according to any one of the preceding claims wherein Y represents oxygen.
37. A compound according to any one of the preceding claims wherein k is an integer ranging from 1 to 2.
38. A compound according to any one of the preceding claims wherein n and m are 1.
39. The compound according to claim 1 , which is
2-Ethoxy-3-{4-[3-phenyl-3-(4-methylphenyl)-allyloxy]-phenyl}-propionic acid ethyl ester, 2-Ethoxy-3-{4-[3-phenyl-3-(4-methylphenyl)-allyloxy]-phenyl}-propionic acid, 3-{4-[3-(2-Chloro-phenyl)-3-phenyl-allyloxy]-phenyl}-2-ethoxy-propionic acid ethyl ester, 3-{4-[3-(2-Chloro-phenyl)-3-phenyl-allyloxy]-phenyl}-2-ethoxy-propionic acid, 3-{4-[3,3-Bis-(4-methoxy-phenyl)-allyloxy]-phenyl}-2-ethoxy-propionic acid ethyl ester, 3-{4-[3,3-Bis-(4-methoxy-phenyl)-allyloxy]-phenyl}-2-ethoxy-propionic acid, 3-{4-[3-Phenyl-3-(biphenyl-4-yl)-allyloxy]-phenyl}-2-ethoxy-propionic acid ethyl ester, 3-{4-[3-Phenyl-3-(biphenyl-4-yl)-allyloxy]-phenyl}-2-ethoxy-propionic acid,
2-Ethoxy-3-{4-[3-phenyl-3-(thiophen-2-yl)-allyloxy]-phenyl}-propionic acid ethyl ester, 2-Ethoxy-3-{4-[3-phenyl-3-(thiophen-2-yl)-allyloxy]-phenyl}-propionic acid, 2-Ethoxy-3-{4-[3-phenyl-3-(pyridin-2-yl)-allyloxy]-phenyl}-propionic acid ethyl ester, 2-Ethoxy-3-{4-[3-phenyl-3-(pyridin-2-yl)-allyloxy]-phenyl}-propionic acid, 3-[4-(3, 3-Diphenyl-propoxy)-phenyl]-2-ethoxy-propionic acid ethyl ester, 3-[4-(3,3-Diphenyl-propoxy)-phenyl]-2-ethoxy-propionic acid,
2-Ethoxy-3-{4-[3-phenyl-3-(4-methylphenyl)-propoxy]-phenyl}-propionic acid ethyl ester, 2-Ethoxy-3-{4-[3-phenyl-3-(4-methylphenyl)-propoxy]-phenyl}-propionic acid, 3-{4-[3-Phenyl-3-(biphenyl-4-yl)-propoxy]-phenyl}-2-ethoxy-propionic acid ethyl ester, 3-{4-[3-Phenyl-3-(biphenyl-4-yl)-propoxy]-phenyl}-2-ethoxy-propionic acid,
2-{4-[3,3-Bis-(4-methoxy-phenyl)-allyloxy]-benzyl}-malonic acid dimethyl ester, (E)-(2S)-2-Ethoxy-3-{4-[3-(4-furan-2-yl-phenyl)-3-phenyl-allyloxy]-phenyl}-propionic acid ethyl ester, (E)-(2S)-2-Ethoxy-3-{4-[3-(4-furan-2-yl-phenyl)-3-phenyl-allyloxy]-phenyl}-propionic acid, (E)-(2S)-3-[4-(3-Biphenyl-4-yl-3-phenyl-allyloxy)-phenyl]-2-ethoxy-propionic acid ethyl ester, (£)-(2S)-3-[4-(3-Biphenyl-4-yl-3-phenyl-allyloxy)-phenyl]-2-ethoxy-propionic acid, (E, Z)-(2S)-3-[4-(3-Biphenyl-4-yl-3-phenyl-allyloxy)-phenyl]-2-ethoxy-propionic acid ethyl ester, (E, Z)-(2S)-3-[4-(3-Biphenyl-4-yl-3-phenyl-allyloxy)-phenyl]-2-ethoxy-propionic acid, 3-{4-[3,3-Bis-(3-methyl-thiophen-2-yl)-allyloxy]-phenyl}-2-ethoxy-propionic acid ethyl ester, 3-{4-[3,3-Bis-(4-bromo-phenyl)-allyloxy]-phenyl}-2-ethoxy-propionic acid ethyl ester, 3-{4-[3,3-Bis-(4-bromo-phenyl)-allyloxy]-phenyl}-2-ethoxy-propionic acid, 2-Ethoxy-3-[4-(3-phenyl-3-pyridin-4-yl-allyloxy)-phenyl]-propionic acid ethyl ester, 2-Ethoxy-3-[4-(3-phenyl-3-pyridin-4-yl-allyloxy)-phenyl]-propionic acid,
(E, Z)-(2S)-2-Ethoxy-3-{4-[3-(4-methoxyphenyl)-3-thiophen-2-yl-allyloxy]-phenyl}-propionic acid ethyl ester,
(E, Z)-(2S)-2-Ethoxy-3-{4-[3-(4-methoxyphenyl)-3-thiophen-2-yl-allyloxy]-phenyl}-propionic acid, (E, Z)-(2S)-2-Ethoxy-3-[4-(3-phenyl-3-p-tolyl-allyloxy)-phenyl]-propionic acid ethyl ester, (E, Z)-(2S)-2-Ethoxy-3-[4-(3-phenyl-3-p-tolyl-allyloxy)-phenyl]-propionic acid, (2S)-3-[4-(3,3-Diphenyl-allyloxy)-phenyl]-2-ethoxy-propionic acid ethyl ester, (2S)-3-[4-(3,3-Diphenyl-allyloxy)-phenyl]-2-ethoxy-propionic acid, (Z)-(2S)-2-Ethoxy-3-{4-[3-(4-fluorophenyl)-3-phenyl-allyloxy]-phenyl}-propionic acid ethyl es- ter,
(Z)-(2S)-2-Ethoxy-3-{4-[3-(4-fluorophenyl)-3-phenyl-allyloxy]-phenyl}-propionic acid, (E)-(2S)-2-Ethoxy-3-{4-[3-(4-fluorophenyl)-3-phenyl-allyloxy]-phenyl}-propionic acid ethyl ester, (E)-(2S)-2-Ethoxy-3-{4-[3-(4-fluorophenyl)-3-phenyl-allyloxy]-phenyl}-propionic acid, (2S)-3-{4-[3,3-Bis-(4-methoxyphenyl)-allyloxy]-phenyl}-2-ethoxy-propionic acid ethyl ester, (2S)-3-{4-[3,3-Bis-(4-methoxyphenyl)-allyloxy]-phenyl}-2-ethoxy-propionic acid, (2S)-3-[4-(3,3-Di-p-tolyl-allyloxy)-phenyl]-2-ethoxy-propionic acid ethyl ester, (2S)-3-[4-(3,3-Di-p-tolyl-allyloxy)-phenyl]-2-ethoxy-propionic acid, (Z)-(2S)-3-[4-(3-Biphenyl-4-yl-3-phenyl-allyloxy)-phenyl]-2-ethoxy-propionic acid, (Z)-(2S)-3-{4-[3-(4-Bromophenyl)-3-phenyl-allyloxy]-phenyl}-2-ethoxy-propionic acid ethyl ester,
(Z)-(2S)-3-{4-[3-(4-Bromophenyl)-3-phenyl-allyloxy]-phenyl}-2-ethoxy-propionic acid, (2S)-3-[4-(3,3-Bis-biphenyl-4-yl-allyloxy)-phenyl]-2-ethoxy-propionic acid ethyl ester, (2S)-3-[4-(3,3-Bis-biphenyl-4-yl-allyloxy)-phenyl]-2-ethoxy-propionic acid, (2S)-3-{4-[3,3-Bis-(4-bromophenyl)-allyloxy]-phenyl}-2-ethoxy-propionic acid ethyl ester, (2S)-3-{4-[3,3-Bis-(4-bromophenyl)-allyloxy]-phenyl}-2-ethoxy-propionic acid, (Z)-(2S)-2-Ethoxy-3-{4-[3-(4-furan-2-yl-phenyl)-3-phenyl-allyloxy]-phenyl}-propionic acid ethyl ester, (Z)-(2S)-2-Ethoxy-3-{4-[3-(4-furan-2-yl-phenyl)-3-phenyl-allyloxy]-phenyl}-propionic acid, (E)-(2S)-3-{4-[3-(4-Bromophenyl)-3-phenyl-allyloxy]-phenyl}-2-ethoxy-propionic acid ethyl ester,
(£)-(2S)-3-{4-[3-(4-Bromophenyl)-3-phenyl-allyloxy]-phenyl}-2-ethoxy-propionic acid, (2S)-3-{4-[3,3-Bis-(4-furan-2-yl-phenyl)-allyloxy]-phenyl}-2-ethoxy-propionic acid ethyl ester, (2S)-3-{4-[3,3-Bis-(4-furan-2-yl-phenyl)-aliyloxy]-phenyl}-2-ethoxy-propionic acid,
(E, Z)-(2S)-3-[4-(3-Biphenyl-4-yl-3-p-tolyl-allyloxy)-phenyl]-2-ethoxy-propionic acid ethyl ester,
(E, Z)-(2S)-3-[4-(3-Biphenyl-4-yl-3-p-tolyl-allyloxy)-phenyl]-2-ethoxy-propionic acid, (E, Z)-(2R)- 3-[4-(3-Biphenyl-4-yl-3-phenyl-allyloxy)-phenyl]-2-ethoxy-propionic acid ethyl es- ter;
or a salt thereof with a pharmaceutically acceptable acid or base, or any optical isomer or mixture of optical isomers, including a racemic mixture, or any tautomeric forms.
40. A pharmaceutical composition comprising, as an active ingredient, a compound according to any one of the preceding compound claims or a pharmaceutically acceptable salt thereof together with a pharmaceutically acceptable carrier or diluent.
41. A composition according to claim 40 in unit dosage form, comprising from about 0.05 to about 100 mg, preferably from about 0.1 to about 50 mg of the compound according to any one of the preceding compound claims or a pharmaceutically acceptable salt thereof.
42. A pharmaceutical composition useful in the treatment and/or prevention of conditions mediated by nuclear receptors, in particular the Peroxisome Proliferator-Activated Receptors (PPAR), the composition comprising, as an active ingredient, a compound according to any one of the preceding compound claims or a pharmaceutically acceptable salt thereof together with a pharmaceutically acceptable carrier or diluent.
43. A pharmaceutical composition useful in the treatment and/or prevention of diabetes and/or obesity, the composition comprising, as an active ingredient, a compound according to any one of the preceding compound claims or a pharmaceutically acceptable salt thereof together with a pharmaceutically acceptable carrier or diluent.
44. A pharmaceutical composition according to any one of the claims 40-43 for oral, nasal, transdermal, pulmonary, or parenteral administration.
45. A method for the treatment of ailments, the method comprising administering to a subject in need thereof an effective amount of a compound according to any one of the preceding compound claims or a pharmaceutically acceptable salt thereof, or of a composition according to any one of the preceding claims 40-44.
46. A method for the treatment and/or prevention of conditions mediated by nuclear receptors, in particular the Peroxisome Proliferator-Activated Receptors (PPAR), the method comprising administering to a subject in need thereof an effective amount of a compound according to any one of the preceding compound claims or a pharmaceutically acceptable salt thereof, or of a composition according to any one of the preceding claims 40-44.
47. A method for the treatment and/or prevention of diabetes and/or obesity, the method comprising administering to a subject in need thereof an effective amount of a compound according to any one of the preceding compound claims or a pharmaceutically acceptable salt thereof, or of a composition according to any one of the preceding claims 40-44.
48. The method according to claims 45, 46 or 47, wherein the effective amount of the compound according to any one of the preceding compound claims or a pharmaceutically acceptable salt or ester thereof is in the range of from about 0.05 to about 100 mg per day, preferably from about 0.1 to about 50 mg per day.
49. Use of a compound according to any one of the preceding compound claims or a pharmaceutically acceptable salt thereof for the preparation of a medicament.
50. Use of a compound according to any one of the preceding compound claims or a pharmaceutically acceptable salt thereof for the preparation of a medicament useful in the treatment and/or prevention of conditions mediated by nuclear receptors, in particular the Peroxisome Proliferator-Activated Receptors (PPAR).
51. Use of a compound according to any one of the preceding compound claims or a pharmaceutically acceptable salt thereof for the preparation of a medicament for treatment and/or prevention of diabetes and/or obesity.
PCT/DK2000/000190 1999-04-20 2000-04-17 New compounds, their preparation and use WO2000063153A1 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
KR1020017013417A KR20020005703A (en) 1999-04-20 2000-04-17 New compounds, their preparation and use
JP2000612250A JP2002542218A (en) 1999-04-20 2000-04-17 New compounds, their manufacture and use
AU39580/00A AU3958000A (en) 1999-04-20 2000-04-17 New compounds, their preparation and use
IL14578900A IL145789A0 (en) 1999-04-20 2000-04-17 Derivatives of propionic acid, their preparation and pharmaceutical compositions containing them
PL00351312A PL351312A1 (en) 1999-04-20 2000-04-17 New compounds, their preparation and use
CA002367356A CA2367356A1 (en) 1999-04-20 2000-04-17 New compounds, their preparation and use
EP00918725A EP1171414A1 (en) 1999-04-20 2000-04-17 Compounds, their preparation and use
BR0009864-7A BR0009864A (en) 1999-04-20 2000-04-17 Compound, pharmaceutical composition, methods for the treatment of diseases, for the treatment and / or prevention of conditions mediated by nuclear receptors and for the treatment and / or prevention of diabetes and / or obesity, and, use of a compound
TW089108460A TW553931B (en) 1999-04-20 2000-05-02 New compounds for use in the treatment and/or prevention of conditions mediated by nuclear receptors, their preparation and use
NO20015113A NO20015113L (en) 1999-04-20 2001-10-19 New compounds, their preparation and use

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA199900533 1999-04-20
DKPA199900533 1999-04-20

Publications (1)

Publication Number Publication Date
WO2000063153A1 true WO2000063153A1 (en) 2000-10-26

Family

ID=8094620

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DK2000/000190 WO2000063153A1 (en) 1999-04-20 2000-04-17 New compounds, their preparation and use

Country Status (16)

Country Link
EP (1) EP1171414A1 (en)
JP (1) JP2002542218A (en)
KR (1) KR20020005703A (en)
CN (1) CN1348439A (en)
AU (1) AU3958000A (en)
BR (1) BR0009864A (en)
CA (1) CA2367356A1 (en)
CZ (1) CZ20013558A3 (en)
HU (1) HUP0200807A3 (en)
IL (1) IL145789A0 (en)
NO (1) NO20015113L (en)
PL (1) PL351312A1 (en)
RU (1) RU2001131111A (en)
TW (1) TW553931B (en)
WO (1) WO2000063153A1 (en)
ZA (1) ZA200107983B (en)

Cited By (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001055085A1 (en) * 2000-01-28 2001-08-02 Novo Nordisk A/S Propionic acid derivatives and their use in the treatment of diabetes and obesity
WO2003011834A1 (en) * 2001-07-30 2003-02-13 Novo Nordisk A/S Novel vinyl n-(2-benzoylphenyl)-l-tyrosine derivatives and their use as antidiabetics etc
WO2003011807A1 (en) * 2001-07-30 2003-02-13 Novo Nordisk A/S Novel vinyl carboxylic acid derivatives and their use as antidiabetics etc.
WO2003011814A1 (en) * 2001-07-30 2003-02-13 Novo Nordisk A/S Novel vinyl n-(2-benzoylphenyl)-l-tyrosine derivatives and their use as antidiabetics etc
WO2003031432A1 (en) 2001-10-12 2003-04-17 Novo Nordisk A/S Substituted piperidines and their use for the treatment of diseases related to the histamine h3 receptor
US6555577B1 (en) 2000-01-28 2003-04-29 Novo Nordisk A/S Compounds, their preparation and use
WO2003055482A1 (en) 2001-12-21 2003-07-10 Novo Nordisk A/S Amide derivatives as gk activators
WO2004002481A1 (en) 2002-06-27 2004-01-08 Novo Nordisk A/S Aryl carbonyl derivatives as therapeutic agents
WO2004022533A1 (en) * 2002-09-05 2004-03-18 Novo Nordisk A/S Novel vinyl carboxylic acid derivatives and their therapeutical use
US6716842B2 (en) 2002-04-05 2004-04-06 Warner-Lambert Company, Llc Antidiabetic agents
WO2004037776A2 (en) 2002-10-28 2004-05-06 Novo Nordisk A/S Novel compounds and their use as prar-modulators
WO2004056740A1 (en) * 2002-12-20 2004-07-08 Novo Nordisk A/S Dicarboxylic acid derivatives as ppar-agonists
WO2004101505A1 (en) 2003-05-14 2004-11-25 Novo Nordisk A/S Novel compounds for treatment of obesity
US6869967B2 (en) 2001-07-30 2005-03-22 Novo Nordisk A/S Peroxisome proliferator-activated receptor (PPAR) active vinyl carboxylic acid derivatives
WO2005030797A2 (en) 2003-09-30 2005-04-07 Novo Nordisk A/S Melanocortin receptor agonists
WO2005105785A2 (en) 2004-05-04 2005-11-10 Novo Nordisk A/S Indole derivatives for treatment of obesity
WO2005105725A1 (en) * 2004-05-05 2005-11-10 Novo Nordisk A/S Novel compounds, their preparation and use
JP2006503881A (en) * 2002-10-28 2006-02-02 ノボ　ノルディスク　アクティーゼルスカブ Novel compounds, their preparation and use
EP1634605A2 (en) 2000-03-08 2006-03-15 Novo Nordisk A/S Treatment of dyslipidemia in a patient having type 2 diabetes
US7015345B2 (en) 2002-02-21 2006-03-21 Asahi Kasei Pharma Corporation Propionic acid derivatives
WO2006053906A1 (en) 2004-11-22 2006-05-26 Novo Nordisk A/S Soluble, stable insulin-containing formulations with a protamine salt
WO2006058923A1 (en) 2004-12-03 2006-06-08 Novo Nordisk A/S Heteroaromatic glucokinase activators
US7067530B2 (en) 2001-07-30 2006-06-27 Novo Nordisk A/S Compounds, their preparation and use
WO2006090072A1 (en) * 2005-02-24 2006-08-31 Negma-Lerads Ppar activator derivatives, preparation method thereof and use of same in therapeutics
WO2006091047A1 (en) * 2005-02-25 2006-08-31 Heonjoong Kang Thiazole derivatives as ppar delta ligands and their manufacturing process
US7129268B2 (en) * 2002-10-28 2006-10-31 Novo Nordisk A/S Peroxisome proliferator activated receptor-active arylene acetic acid derivatives
WO2007006814A1 (en) 2005-07-14 2007-01-18 Novo Nordisk A/S Urea glucokinase activators
WO2007015805A1 (en) 2005-07-20 2007-02-08 Eli Lilly And Company 1-amino linked compounds
WO2007110364A1 (en) 2006-03-28 2007-10-04 High Point Pharmaceuticals, Llc Benzothiazoles having histamine h3 receptor activity
WO2007123581A1 (en) 2005-11-17 2007-11-01 Eli Lilly And Company Glucagon receptor antagonists, preparation and therapeutic uses
WO2007137968A1 (en) 2006-05-29 2007-12-06 High Point Pharmaceuticals, Llc 3- (1, 3-benz0di0x0l-5-yl) -6- (4-cyclopropylpiperazin-1-yl) -pyridazine, its salts and solvates and its use as histamine h3 receptor antagonist
EP1911462A2 (en) 2001-01-26 2008-04-16 Schering Corporation Compositions comprising a sterol absorption inhibitor
WO2008059026A1 (en) 2006-11-15 2008-05-22 High Point Pharmaceuticals, Llc Novel 2-(2-hydroxyphenyl)benzimidazoles useful for treating obesity and diabetes
WO2008059025A1 (en) 2006-11-15 2008-05-22 High Point Pharmaceuticals, Llc Novel 2-(2-hydroxyphenyl) benzothiadiazines useful for treating obesity and diabetes
WO2008084044A1 (en) 2007-01-11 2008-07-17 Novo Nordisk A/S Urea glucokinase activators
EP2233470A1 (en) 2005-07-04 2010-09-29 High Point Pharmaceuticals, LLC Histamine H3 receptor antagonists
US7816385B2 (en) 2002-12-20 2010-10-19 High Point Pharmaceuticals, Llc Dimeric dicarboxylic acid derivatives, their preparation and use
EP2298337A2 (en) 2003-12-09 2011-03-23 Novo Nordisk A/S Regulation of food preference using GLP-1 agonists
EP2316446A1 (en) 2004-06-11 2011-05-04 Novo Nordisk A/S Counteracting drug-induced obesity using GLP-1 agonists
US7943613B2 (en) 2005-12-22 2011-05-17 High Point Pharmaceuticals, Llc Compounds, their preparation and use
WO2011104378A1 (en) 2010-02-26 2011-09-01 Novo Nordisk A/S Peptides for treatment of obesity
WO2011104379A1 (en) 2010-02-26 2011-09-01 Novo Nordisk A/S Peptides for treatment of obesity
WO2011117416A1 (en) 2010-03-26 2011-09-29 Novo Nordisk A/S Novel glucagon analogues
US8053598B2 (en) 2004-05-05 2011-11-08 High Point Pharmaceuticals, Llc Compounds, their preparation and use
WO2012027331A1 (en) 2010-08-27 2012-03-01 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
EP2444397A1 (en) 2004-01-06 2012-04-25 Novo Nordisk A/S Heteroaryl-ureas and their use as glucokinase activators
WO2012130866A1 (en) 2011-03-28 2012-10-04 Novo Nordisk A/S Novel glucagon analogues
US8541368B2 (en) 2011-09-23 2013-09-24 Novo Nordisk A/S Glucagon analogues
US9474790B2 (en) 2013-04-18 2016-10-25 Novo Nordisk A/S Stable, protracted GLP-1/glucagon receptor co-agonists for medical use
US9724322B2 (en) 2003-09-19 2017-08-08 Janssen Pharmaceutica N.V. 4-(phenoxyalkyl)thio)-phenoxyacetic acids and analogs
WO2018167194A1 (en) 2017-03-15 2018-09-20 Novo Nordisk A/S Bicyclic compounds capable of binding to melanocortin 4 receptor
US10130684B2 (en) 2011-02-03 2018-11-20 Pharmedica Ltd. Oral dissolving films for insulin administration, for treating diabetes
WO2019219714A1 (en) 2018-05-15 2019-11-21 Novo Nordisk A/S Compounds capable of binding to melanocortin 4 receptor
US10570184B2 (en) 2014-06-04 2020-02-25 Novo Nordisk A/S GLP-1/glucagon receptor co-agonists for medical use
WO2020053414A1 (en) 2018-09-14 2020-03-19 Novo Nordisk A/S Bicyclic compounds capable of acting as melanocortin 4 receptor agonists
US11267795B2 (en) 2020-07-22 2022-03-08 Reneo Pharmaceuticals, Inc. Crystalline PPAR-delta agonist
US11931365B2 (en) 2022-01-25 2024-03-19 Reneo Pharmaceuticals, Inc. Use of PPAR-delta agonists in the treatment of disease

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100491316C (en) 2002-10-28 2009-05-27 高点制药有限责任公司 Novel compounds, their preparation and use
CN107915701B (en) * 2016-10-10 2020-09-29 沈阳药科大学 PPAR alpha/gamma dual agonist and application thereof

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996004261A1 (en) * 1994-07-29 1996-02-15 Smithkline Beecham Plc Benzoxazoles and pryridine derivatives useful in the treatment of the type ii diabetes
WO1997025042A1 (en) * 1996-01-09 1997-07-17 Smithkline Beecham P.L.C. Use of an agonist of ppar-alpha and ppar-gamma for the treatment of syndrom x
WO1997031907A1 (en) * 1996-02-28 1997-09-04 Glaxo Group Limited Substituted 4-hydroxy-phenylalcanoic acid derivatives with agonist activity to ppar-gamma
WO1999008501A2 (en) * 1998-04-23 1999-02-25 Dr. Reddy's Research Foundation New heterocyclic compounds and their use in medicine, process for their preparation and pharmaceutical compositions containing them
EP0903343A1 (en) * 1997-09-19 1999-03-24 SSP Co., Ltd. Alpha-Substituted phenylpropionic acid derivative and medicine containing the same
WO1999016758A1 (en) * 1997-10-27 1999-04-08 Dr. Reddy's Research Foundation Novel heterocyclic compounds and their use in medicine, process for their preparation and pharmaceutical compositions containing them
WO1999019313A1 (en) * 1997-10-27 1999-04-22 Dr. Reddy's Research Foundation Novel tricyclic compounds and their use in medicine; process for their preparation and pharmaceutical compositions containing them
WO1999020614A1 (en) * 1998-05-27 1999-04-29 Dr. Reddy's Research Foundation Bicyclic compounds, process for their preparation and pharmaceutical compositions containing them
WO1999038850A1 (en) * 1998-01-29 1999-08-05 Dr. Reddy's Research Foundation Novel alkanoic acids and their use in medicine, process for their preparation and pharmaceutical compositions containing them

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996004261A1 (en) * 1994-07-29 1996-02-15 Smithkline Beecham Plc Benzoxazoles and pryridine derivatives useful in the treatment of the type ii diabetes
WO1996004260A1 (en) * 1994-07-29 1996-02-15 Smithkline Beecham Plc Benzoxazoles and pyridine derivatives useful in the treatment of the type ii diabetes
WO1997025042A1 (en) * 1996-01-09 1997-07-17 Smithkline Beecham P.L.C. Use of an agonist of ppar-alpha and ppar-gamma for the treatment of syndrom x
WO1997031907A1 (en) * 1996-02-28 1997-09-04 Glaxo Group Limited Substituted 4-hydroxy-phenylalcanoic acid derivatives with agonist activity to ppar-gamma
EP0903343A1 (en) * 1997-09-19 1999-03-24 SSP Co., Ltd. Alpha-Substituted phenylpropionic acid derivative and medicine containing the same
WO1999016758A1 (en) * 1997-10-27 1999-04-08 Dr. Reddy's Research Foundation Novel heterocyclic compounds and their use in medicine, process for their preparation and pharmaceutical compositions containing them
WO1999019313A1 (en) * 1997-10-27 1999-04-22 Dr. Reddy's Research Foundation Novel tricyclic compounds and their use in medicine; process for their preparation and pharmaceutical compositions containing them
WO1999038850A1 (en) * 1998-01-29 1999-08-05 Dr. Reddy's Research Foundation Novel alkanoic acids and their use in medicine, process for their preparation and pharmaceutical compositions containing them
WO1999008501A2 (en) * 1998-04-23 1999-02-25 Dr. Reddy's Research Foundation New heterocyclic compounds and their use in medicine, process for their preparation and pharmaceutical compositions containing them
WO1999020614A1 (en) * 1998-05-27 1999-04-29 Dr. Reddy's Research Foundation Bicyclic compounds, process for their preparation and pharmaceutical compositions containing them

Cited By (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001055085A1 (en) * 2000-01-28 2001-08-02 Novo Nordisk A/S Propionic acid derivatives and their use in the treatment of diabetes and obesity
US6555577B1 (en) 2000-01-28 2003-04-29 Novo Nordisk A/S Compounds, their preparation and use
US6867218B2 (en) 2000-01-28 2005-03-15 Novo Nordisk A/S Compounds, their preparation and use
EP1634605A2 (en) 2000-03-08 2006-03-15 Novo Nordisk A/S Treatment of dyslipidemia in a patient having type 2 diabetes
EP1911462A2 (en) 2001-01-26 2008-04-16 Schering Corporation Compositions comprising a sterol absorption inhibitor
WO2003011814A1 (en) * 2001-07-30 2003-02-13 Novo Nordisk A/S Novel vinyl n-(2-benzoylphenyl)-l-tyrosine derivatives and their use as antidiabetics etc
WO2003011834A1 (en) * 2001-07-30 2003-02-13 Novo Nordisk A/S Novel vinyl n-(2-benzoylphenyl)-l-tyrosine derivatives and their use as antidiabetics etc
US7067530B2 (en) 2001-07-30 2006-06-27 Novo Nordisk A/S Compounds, their preparation and use
US6869967B2 (en) 2001-07-30 2005-03-22 Novo Nordisk A/S Peroxisome proliferator-activated receptor (PPAR) active vinyl carboxylic acid derivatives
WO2003011807A1 (en) * 2001-07-30 2003-02-13 Novo Nordisk A/S Novel vinyl carboxylic acid derivatives and their use as antidiabetics etc.
EP2243776A1 (en) 2001-10-12 2010-10-27 High Point Pharmaceuticals, LLC Substituted piperidines and their use for the treatment of diseases related to the histamine H3 receptor
WO2003031432A1 (en) 2001-10-12 2003-04-17 Novo Nordisk A/S Substituted piperidines and their use for the treatment of diseases related to the histamine h3 receptor
WO2003055482A1 (en) 2001-12-21 2003-07-10 Novo Nordisk A/S Amide derivatives as gk activators
EP2305648A1 (en) 2001-12-21 2011-04-06 Novo Nordisk A/S Amide derivatives useful as glucokinase activators
US7015345B2 (en) 2002-02-21 2006-03-21 Asahi Kasei Pharma Corporation Propionic acid derivatives
US6716842B2 (en) 2002-04-05 2004-04-06 Warner-Lambert Company, Llc Antidiabetic agents
EP2471533A1 (en) 2002-06-27 2012-07-04 Novo Nordisk A/S Aryl carbonyl derivatives as therapeutic agents
WO2004002481A1 (en) 2002-06-27 2004-01-08 Novo Nordisk A/S Aryl carbonyl derivatives as therapeutic agents
WO2004022533A1 (en) * 2002-09-05 2004-03-18 Novo Nordisk A/S Novel vinyl carboxylic acid derivatives and their therapeutical use
US7091245B2 (en) 2002-09-05 2006-08-15 Novo Novdisk A/S Compounds, their preparation and use
JP2005538153A (en) * 2002-09-05 2005-12-15 ノボ　ノルディスク　アクティーゼルスカブ Novel vinyl carboxylic acid derivatives and their therapeutic use
JP2006503881A (en) * 2002-10-28 2006-02-02 ノボ　ノルディスク　アクティーゼルスカブ Novel compounds, their preparation and use
WO2004037776A2 (en) 2002-10-28 2004-05-06 Novo Nordisk A/S Novel compounds and their use as prar-modulators
WO2004037776A3 (en) * 2002-10-28 2004-06-10 Novo Nordisk As Novel compounds and their use as prar-modulators
JP2006503908A (en) * 2002-10-28 2006-02-02 ノボ・ノルデイスク・エー／エス Novel compounds, their preparation and use
JP4708184B2 (en) * 2002-10-28 2011-06-22 ハイ ポイント ファーマシューティカルズ，エルエルシー Novel compounds, their preparation and use
US7129268B2 (en) * 2002-10-28 2006-10-31 Novo Nordisk A/S Peroxisome proliferator activated receptor-active arylene acetic acid derivatives
US7816385B2 (en) 2002-12-20 2010-10-19 High Point Pharmaceuticals, Llc Dimeric dicarboxylic acid derivatives, their preparation and use
WO2004056740A1 (en) * 2002-12-20 2004-07-08 Novo Nordisk A/S Dicarboxylic acid derivatives as ppar-agonists
WO2004101505A1 (en) 2003-05-14 2004-11-25 Novo Nordisk A/S Novel compounds for treatment of obesity
US9724322B2 (en) 2003-09-19 2017-08-08 Janssen Pharmaceutica N.V. 4-(phenoxyalkyl)thio)-phenoxyacetic acids and analogs
WO2005030797A2 (en) 2003-09-30 2005-04-07 Novo Nordisk A/S Melanocortin receptor agonists
EP2298337A2 (en) 2003-12-09 2011-03-23 Novo Nordisk A/S Regulation of food preference using GLP-1 agonists
EP2444397A1 (en) 2004-01-06 2012-04-25 Novo Nordisk A/S Heteroaryl-ureas and their use as glucokinase activators
WO2005105785A2 (en) 2004-05-04 2005-11-10 Novo Nordisk A/S Indole derivatives for treatment of obesity
US8053598B2 (en) 2004-05-05 2011-11-08 High Point Pharmaceuticals, Llc Compounds, their preparation and use
WO2005105725A1 (en) * 2004-05-05 2005-11-10 Novo Nordisk A/S Novel compounds, their preparation and use
EP2316446A1 (en) 2004-06-11 2011-05-04 Novo Nordisk A/S Counteracting drug-induced obesity using GLP-1 agonists
WO2006053906A1 (en) 2004-11-22 2006-05-26 Novo Nordisk A/S Soluble, stable insulin-containing formulations with a protamine salt
WO2006058923A1 (en) 2004-12-03 2006-06-08 Novo Nordisk A/S Heteroaromatic glucokinase activators
WO2006090072A1 (en) * 2005-02-24 2006-08-31 Negma-Lerads Ppar activator derivatives, preparation method thereof and use of same in therapeutics
WO2006091047A1 (en) * 2005-02-25 2006-08-31 Heonjoong Kang Thiazole derivatives as ppar delta ligands and their manufacturing process
EP2233470A1 (en) 2005-07-04 2010-09-29 High Point Pharmaceuticals, LLC Histamine H3 receptor antagonists
EP2386554A1 (en) 2005-07-04 2011-11-16 High Point Pharmaceuticals, LLC Compounds active at the histamine H3 receptor
EP2377856A1 (en) 2005-07-14 2011-10-19 Novo Nordisk A/S Urea glucokinase activators
WO2007006814A1 (en) 2005-07-14 2007-01-18 Novo Nordisk A/S Urea glucokinase activators
WO2007015805A1 (en) 2005-07-20 2007-02-08 Eli Lilly And Company 1-amino linked compounds
WO2007123581A1 (en) 2005-11-17 2007-11-01 Eli Lilly And Company Glucagon receptor antagonists, preparation and therapeutic uses
US7943613B2 (en) 2005-12-22 2011-05-17 High Point Pharmaceuticals, Llc Compounds, their preparation and use
US10947180B2 (en) 2005-12-22 2021-03-16 Vtv Therapeutics Llc Phenoxy acetic acids and phenyl propionic acids as PPAR delta agonists
US8362016B2 (en) 2005-12-22 2013-01-29 High Point Pharmaceuticals, Llc Phenyl propionic acids as PPAR delta activators
US11420929B2 (en) 2005-12-22 2022-08-23 Vtv Therapeutics Llc Phenoxy acetic acids and phenyl propionic acids as PPAR delta agonists
US8551993B2 (en) 2005-12-22 2013-10-08 High Point Pharmaceuticals, Llc Phenoxy acetic acids as PPAR delta activators
US10471066B2 (en) 2005-12-22 2019-11-12 Vtv Therapeutics Llc Phenoxy acetic acids and phenyl propionic acids as PPAR delta agonists
US9855274B2 (en) 2005-12-22 2018-01-02 Vtv Therapeutics Llc Phenoxy acetic acids and phenyl propionic acids as PPAR delta agonists
US9663481B2 (en) 2005-12-22 2017-05-30 Vtv Therapeutics Llc Phenoxy acetic acids and phenyl propionic acids as PPARδ agonists
WO2007110364A1 (en) 2006-03-28 2007-10-04 High Point Pharmaceuticals, Llc Benzothiazoles having histamine h3 receptor activity
EP2402324A1 (en) 2006-05-29 2012-01-04 High Point Pharmaceuticals, LLC Benzodioxolylcyclopropylpiperazinylpyridazines
WO2007137968A1 (en) 2006-05-29 2007-12-06 High Point Pharmaceuticals, Llc 3- (1, 3-benz0di0x0l-5-yl) -6- (4-cyclopropylpiperazin-1-yl) -pyridazine, its salts and solvates and its use as histamine h3 receptor antagonist
WO2008059026A1 (en) 2006-11-15 2008-05-22 High Point Pharmaceuticals, Llc Novel 2-(2-hydroxyphenyl)benzimidazoles useful for treating obesity and diabetes
WO2008059025A1 (en) 2006-11-15 2008-05-22 High Point Pharmaceuticals, Llc Novel 2-(2-hydroxyphenyl) benzothiadiazines useful for treating obesity and diabetes
WO2008084044A1 (en) 2007-01-11 2008-07-17 Novo Nordisk A/S Urea glucokinase activators
WO2011104379A1 (en) 2010-02-26 2011-09-01 Novo Nordisk A/S Peptides for treatment of obesity
WO2011104378A1 (en) 2010-02-26 2011-09-01 Novo Nordisk A/S Peptides for treatment of obesity
WO2011117415A1 (en) 2010-03-26 2011-09-29 Novo Nordisk A/S Novel glucagon analogues
WO2011117416A1 (en) 2010-03-26 2011-09-29 Novo Nordisk A/S Novel glucagon analogues
WO2012027331A1 (en) 2010-08-27 2012-03-01 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
US10130684B2 (en) 2011-02-03 2018-11-20 Pharmedica Ltd. Oral dissolving films for insulin administration, for treating diabetes
WO2012130866A1 (en) 2011-03-28 2012-10-04 Novo Nordisk A/S Novel glucagon analogues
US9486505B2 (en) 2011-09-23 2016-11-08 Novo Nordisk A/S Glucagon analogues
US8541368B2 (en) 2011-09-23 2013-09-24 Novo Nordisk A/S Glucagon analogues
US9751927B2 (en) 2013-04-18 2017-09-05 Novo Nordisk A/S Stable, protracted GLP-1/glucagon receptor co-agonists for medical use
US9474790B2 (en) 2013-04-18 2016-10-25 Novo Nordisk A/S Stable, protracted GLP-1/glucagon receptor co-agonists for medical use
US10570184B2 (en) 2014-06-04 2020-02-25 Novo Nordisk A/S GLP-1/glucagon receptor co-agonists for medical use
WO2018167194A1 (en) 2017-03-15 2018-09-20 Novo Nordisk A/S Bicyclic compounds capable of binding to melanocortin 4 receptor
WO2019219714A1 (en) 2018-05-15 2019-11-21 Novo Nordisk A/S Compounds capable of binding to melanocortin 4 receptor
WO2020053414A1 (en) 2018-09-14 2020-03-19 Novo Nordisk A/S Bicyclic compounds capable of acting as melanocortin 4 receptor agonists
US11267795B2 (en) 2020-07-22 2022-03-08 Reneo Pharmaceuticals, Inc. Crystalline PPAR-delta agonist
US11713301B2 (en) 2020-07-22 2023-08-01 Reneo Pharmaceuticals, Inc. Crystalline PPARδ agonist
US11931365B2 (en) 2022-01-25 2024-03-19 Reneo Pharmaceuticals, Inc. Use of PPAR-delta agonists in the treatment of disease

Also Published As

Publication number Publication date
ZA200107983B (en) 2002-05-29
EP1171414A1 (en) 2002-01-16
CA2367356A1 (en) 2000-10-26
HUP0200807A3 (en) 2003-03-28
IL145789A0 (en) 2002-07-25
KR20020005703A (en) 2002-01-17
BR0009864A (en) 2002-01-08
NO20015113L (en) 2001-12-19
NO20015113D0 (en) 2001-10-19
HUP0200807A2 (en) 2002-07-29
AU3958000A (en) 2000-11-02
JP2002542218A (en) 2002-12-10
CN1348439A (en) 2002-05-08
CZ20013558A3 (en) 2002-05-15
TW553931B (en) 2003-09-21
RU2001131111A (en) 2003-08-10
PL351312A1 (en) 2003-04-07

Similar Documents

Publication Publication Date Title
WO2000063153A1 (en) New compounds, their preparation and use
US6569901B2 (en) Alkynyl-substituted propionic acid derivatives, their preparation and use
US6534517B2 (en) Compounds, their preparation and use
EP1171431A1 (en) Compounds, their preparation and use
EP1438283A1 (en) Dicarboxylic acid derivatives, their preparation and therapeutic use
EP1276710A1 (en) New compounds, their preparation and use
WO2003011807A1 (en) Novel vinyl carboxylic acid derivatives and their use as antidiabetics etc.
US7091245B2 (en) Compounds, their preparation and use
EP1745014B1 (en) Novel compounds, their preparation and use
US7968723B2 (en) Compounds, their preparation and use
WO2001055086A1 (en) Alkynylsubstituted propionic acid derivatives and their use against diabetes and obesity
US6869967B2 (en) Peroxisome proliferator-activated receptor (PPAR) active vinyl carboxylic acid derivatives
EP1414785A1 (en) Novel vinyl n-(2-benzoylphenyl)-l-tyrosine derivatives and their use as antidiabetics etc
US6972294B1 (en) Compounds, their preparation and use
US7067530B2 (en) Compounds, their preparation and use
US6509374B2 (en) Compounds, their preparation and use
WO2003011834A1 (en) Novel vinyl n-(2-benzoylphenyl)-l-tyrosine derivatives and their use as antidiabetics etc
US6369055B1 (en) Compounds, their preparation and use
MXPA01010609A (en) Newcompounds, their preparation and use
US20030055076A1 (en) Novel compounds, their preparation and use
AU2002316815A1 (en) Novel vinyl carboxylic acid derivatives and their use as antidiabetics etc.

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 00806561.6

Country of ref document: CN

AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2000918725

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2367356

Country of ref document: CA

Ref document number: 2367356

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: PV2001-3558

Country of ref document: CZ

Ref document number: 39580/00

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: IN/PCT/2001/1423/CHE

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 2000 612250

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: PA/a/2001/010609

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 1020017013417

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2000918725

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020017013417

Country of ref document: KR

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: PV2001-3558

Country of ref document: CZ

WWW Wipo information: withdrawn in national office

Ref document number: 1020017013417

Country of ref document: KR

WWW Wipo information: withdrawn in national office

Ref document number: 2000918725

Country of ref document: EP